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Despite the remarkable yield improvements of recombinant proteins produced in mammalian 
cells, some ―difficult-to-express‖ (DTE) proteins achieve considerably lower production titres. 
The bottlenecks are exacerbated in the case of transient gene expression (TGE) systems as 
the host cells are easily overloaded with recombinant genes, hence necessitating intensive 
cell line and process development. The aims of this thesis are to study the limitations to high 
TGE yields of DTE proteins, and subsequently investigate strategies to efficiently alleviate 
the bottlenecks. For this purpose, we used a model DTE Fc-fusion protein (Sp35:Fc; 
proprietary of Biogen Idec) expressed in Chinese hamster ovary (CHO) cells, as well as 
secreted alkaline phosphatase and green fluorescent protein for comparisons. Through 
analyses of intracellular and extracellular Sp35:Fc polypeptides, we found that post-
translational mechanisms were limiting in the cells. The saturation of Sp35:Fc expression 
coincided with the retention of folded proteins in the ER and the increase in disulphide 
bonded aggregates. Further in silico analysis via a mathematical model enabled 
identification of the relative importance of specific cellular process on Sp35:Fc productivity 
(qP). Based on these observations, three strategies aimed at improving the transient 
production of Sp35:Fc were investigated. 
The first strategy involved the evaluation of functional performance of clonally derived 
cell populations to produce Sp35:Fc. We critically assessed the key intrinsic functional traits 
of the clones, and their impact on Sp35:Fc production. The data indicate that cell lines with 
the capability to accumulate high biomass while maintaining relatively high specific growth 
rate (µ) were likely to be high producers for DTE proteins. For the second strategy, we 
utilised a novel vector system specifically beneficial for DTE proteins by incorporating ER 
stress response elements (ERSE) into the SV40 vector expressing Sp35:Fc or the UPR 
transactivator ATF6c. The ERSE-SV40 vectors acted as a synthetic "amplifier/dual activator" 
circuit, where expressed ATF6c amplified both its own and Sp35:Fc expression via activation 
of ERSE-SV40, whilst generally transactivating cellular ER capacity via endogenous ERSE. 
In the third approach, we addressed the hypothesis that specific functional proteins and 
chemical chaperones could improve ER capacity for Sp35:Fc folding reactions, increase 
secretion rate and/or relieve host cells from ER stress. We employed cell/process 
engineering by co-expressing a variety of molecular chaperones or UPR transactivators with 
Sp35:Fc, as well as a range of chemicals and hypothermic condition. We observed that 
Sp35:Fc production could be improved via two distinct modes; (i) increase in qP correlated 
to repression of µ, and (ii) stimulation of µ with general reduction in qP. In this regard, genes 
and chemicals could work synergistically to provide an optimal solution.  
 iii 
Overall, this study illustrates that effective cell line and process development for DTE 
protein production requires a synergistic combination of vector, cell and process engineering 
strategies designed to alleviate cellular bottlenecks simultaneously, enabling the host cell to 
attain both high qP and cell density. Using two clonal variants and combinations of cell and 
process engineering, the transient Sp35:Fc production yield could be increased by more 
than six-fold. Rapid, high-throughput predictive mathematical tools would be particularly 
valuable in assessing the relative/synergistic impact of different engineering interventions. 
 
Keywords: Chinese hamster ovary cells; transient gene expression; difficult-to-express 
protein; aggregation; unfolded protein response; mathematical modelling; genetic 
heterogeneity; screening; vector engineering; cell engineering; chemical chaperones. 
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-1
) 
𝑘ER ,P2 rate constant for dimer transport from the ER to the Golgi complex (h
-1
) 
𝑘ER ,P4 rate constant for tetramer transport from the ER to the Golgi complex (h
-1
) 
𝑘ER ,P6 rate constant for hexamer transport from the ER to the Golgi complex (h
-1
) 
𝑘fa  rate constant for monomer-monomer assembly (cell molecule
-1
 h
-1
) 
𝑘G,P2 rate constant for dimer transport from the Golgi to the culture medium (h
-1
) 
𝑘G,P4 rate constant for tetramer transport from the Golgi to the culture medium (h
-1
) 
𝑘G,P6 rate constant for hexamer transport from Golgi to the culture medium (h
-1
) 
𝑘ubq ,P rate constant for protein monomer ubiquitination in the ER (h
-1
) 
𝑘ubq ,P2 rate constant for protein dimer ubiquitination in the ER (h
-1
) 
𝑘ubq ,P4 rate constant for protein tetramer ubiquitination in the ER (h
-1
) 
𝑘ubq ,P6 rate constant for protein hexamer ubiquitination in the ER (h
-1
) 
 xvii 
[𝑚] intracellular mRNA concentration (mRNA cell-1) 
𝑡1/2,𝑚  half-life of mRNA molecule (h) 
𝑡1/2,[P2] time required for 50% of protein dimer to be ubiquitinated (h) 
𝑡1/2,[P4] time required for 50% of protein tetramer to be ubiquitinated (h) 
𝑡1/2,[P6] time required for 50% of protein hexamer to be ubiquitinated (h) 
𝑡1/2,[P2]ER  half-time for ER-to-Golgi transport for protein dimer (h) 
𝑡1/2,[P2]G half-time for Golgi-to-culture medium transport for protein dimer (h) 
𝑡1/2,[P4]ER  half-time for ER-to-Golgi transport for protein tetramer (h) 
𝑡1/2,[P4]G half-time for Golgi-to-culture medium transport for protein tetramer (h) 
𝑡1/2,[P6]ER  half-time for ER-to-Golgi transport for protein hexamer (h) 
𝑡1/2,[P6]G half-time for Golgi-to-culture medium transport for protein hexamer (h) 
𝑞Pdimer  specific production rate of native dimer (pg cell
-1
 h
-1
) 
𝑞Ptetramer  specific production rate of tetramer aggregate (pg cell
-1
 h
-1
) 
𝑞Phexamer  specific production rate of hexamer aggregate (pg cell
-1
 h
-1
) 
 
λP2 unit conversion factor of protein dimer (3.32×10
-7
 pg h molecule
-1
 day
-1
) 
𝜇 cell specific growth/proliferation rate (h-1) 
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This chapter provides an overview of biopharmaceuticals and their expression systems. Specific 
emphasis is given to mammalian cell culture and challenges faced in the production process. The 
objective of this chapter is to contextualise the research presented in this thesis, with regard to 
the body of literature describing transient production and difficult-to-express proteins. 
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The term biopharmaceutical may refer to therapeutic biological drugs derived from living 
cells such as antibodies, vaccines, hormones and nucleic acid-based products. Today, 
there are more than 200 approved biopharmaceuticals for use in diverse clinical settings. 
Among these, recombinant protein-based products particularly monoclonal antibodies 
(MAbs) and Fc-fusion proteins, constitute the most rapidly growing class of 
biopharmaceuticals and currently dominate the biologic drug market. In terms of market 
value, MAbs and Fc-fusion proteins together account for 54% of the US$ 140 billion global 
sales of therapeutic proteins in 2013 (Walsh, 2014). The majority of recombinant protein-
based products are used against various types of cancer while other main treatment areas 
include autoimmune diseases such as arthritis, as well as transplantation and respiratory 
disorders (Huggett, 2013; Sommerfeld and Strube, 2005). 
The number of therapeutic MAb in development has continued to increase 
tremendously over the last three decades due to the flexible and robust nature of the 
immunoglobulin molecule, as well as advances in molecular biology and technology. 
Indeed, since the approval of the first MAb product Orthoclone OKT3® in 1986, MAb 
formats have evolved from entirely murine structure to "chimeric" form and later, fully 
humanised antibodies containing human sequences. Engineered human MAbs present a 
generally improved effector function, reduced immunogenicity and increased stability 
(Johnston, 2007; Sommerfeld and Strube, 2005). Gene cloning/synthesis and recombinant 
DNA technologies allow the production of new MAbs against a virtually unlimited number 
of target antigens (Igawa et al., 2011; Tachibana et al., 1999). Today, therapeutic MAbs 
boast the most active pipeline in the recombinant biopharmaceutical industry, with six of 
the top-ten selling biologics in 2013 being MAbs (Table  1.1). 
Meanwhile, many other biologically active protein and peptide drugs have very short 
serum half-lives due to fast renal clearance that limit the therapeutic efficacy. Considerable 
efforts have been made to develop techniques to extend the half-life of these therapeutic 
proteins (Kontermann, 2011). Fc fusion technology, by which the Fc domain of IgG is 
joined to a therapeutic protein, is arguably the most effectual solution where it extends a 
protein's in vivo half-life via the neonatal Fc receptor recycling mechanism. In addition to 
the enhanced pharmacokinetics and pharmacodynamics, this technology also confers 
novel properties to the hybrid molecule such as Fc receptor and protein A bindings. With  
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Table ‎1.1: Ten global top selling therapeutic proteins in 2013 (Hugget, 2013; Walsh, 2014). 
Product 
Lead 
company 
Molecule 
type 
Production 
host 
Main treatment 
Sales 
($ billions) 
 
     
Humira® 
(adalimumab) 
AbbVie MAb CHO Arthritis 11.00 
Enbrel® 
(etanercept) 
Amgen Fc-fusion 
protein 
CHO Arthritis 8.76 
Remicade® 
(infliximab) 
Johnson & 
Johnson 
MAb Murine 
myeloma 
Arthritis 8.37 
Lantus® 
(insulin glargine) 
Sanofi Protein E. coli Diabetes 7.95 
Rituxan® 
(rituximab) 
Roche MAb CHO Arthritis, cancer 7.91 
Avastin® 
(bevacizumab) 
Roche MAb CHO Cancer 6.97 
Herceptin® 
(trastuzumab) 
Roche MAb CHO Cancer 6.91 
Neulasta® 
(pegfilgrastim) 
Amgen Protein E. coli Neutropenia/ 
leukopenia 
4.39 
Lucentis® 
(ranibizumab) 
Roche MAb E. coli Macular 
degeneration  
4.27 
Epogen® 
(epoetin alfa) 
Amgen Protein CHO Anaemia 3.35 
 
 
these advantages, Fc fusion technology is used in nine FDA-approved drugs for the 
treatment of chronic diseases including rheumatoid arthritis, platelet disorders and 
psoriasis whilst several more are awaiting approvals or in the development pipelines (Mei 
et al., 2013; Walsh, 2014). 
 
 
A new range of engineered proteins, such as fusion proteins and bispecific antibodies, 
have begun to fill the development pipelines of many biopharmaceutical companies. These 
so called next-generation biologics can be significantly more ‗‗difficult to express‘‘ (DTE) 
compared to natural protein formats―generally host cells cannot correctly fold and 
process the recombinant polypeptide where factors such as translation rate and redox 
potential can be limiting, therefore resulting in low production titres. Additionally, many 
complex proteins involve post-translational modifications (glycosylation, phosphorylation, 
etc) that are absent or vary from expression host to expression host, and the problems can 
extend to protein insolubility, degradation and aggregation, thereby affecting product 
qualities (DePalma, 2012; Hall, 2007). Artificial fusion proteins, for instance, have not 
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coevolved in which the interdomain interactions might not contribute to overall 
conformational stability or could even destabilise the confirmation (Fast et al., 2009). 
Therefore, DTE proteins require effective cell line and process development to achieve a 
good balance between drug manufacturing costs (i.e. prices) and therapeutic benefits. 
 
 
 
A wide range of hosts are available for the production of biopharmaceuticals including 
bacteria, yeast, insect, plant and mammalian cells. Prokaryotic systems, especially E. coli, 
have the advantage of low cost and high productivity compared to eukaryotic expression 
systems. However, bacterial cells are unable to carry out the post-translational 
modifications required for the biological function of many recombinant proteins (Pandhal 
and Wright, 2010). On the other hand, yeast, insect and plant cells have a limited 
capability in synthesising proteins that are similar to those naturally occurring in humans. 
For instance, yeast cells are known to provide N-linked and O-linked high-mannose-type 
glycans that could be immunogenic in humans. In this regard, mammalian cells become 
the preferential host as they have the correct molecular machinery to perform human-like 
post-translational modifications (Dasgupta et al., 2007; Durocher and Butler, 2009). 
Accordingly, more than 55% of therapeutic proteins on the market are produced 
using mammalian cells, with Chinese hamster ovary (CHO) cells being the predominant 
host (Walsh, 2014). This is reflected in Table  1.1 where seven of the ten best-selling 
biologics are produced in mammalian cells, and of those seven, six are from CHO cells. 
Similarly, CHO cells are the major host for Fc-fusion protein production—six Fc-fusion 
molecules on the market are expressed in CHO cells, while two more are expressed in 
human embryonic kidney (HEK293) cells and one in E. coli (Mei et al., 2013; Walsh, 2014). 
Nevertheless, other established mammalian cell lines such as NS0 murine myeloma and 
baby hamster kidney (BHK) cells have been, and to a certain extent, continue to be used 
to develop biologics (Estes and Melville, 2014; Wurm, 2004). 
 
 
Large scale manufacturing of therapeutic recombinant proteins involves development of 
recombinant cell lines. Principally, the generation of stably expressing cell clones consists 
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of the transfection of the cell with a gene of interest cloned into a plasmid vector, followed 
by the selection of host cells that have the recombinant gene integrated into the cell 
genome, and the characterisation of the clones for production process (Figure  1.1A; Lai et 
al., 2013). To isolate cells that have successfully integrated the transgene, a selection 
marker is used in which the gene of interest is flanked with a gene coding for a vital 
enzyme. The glutamine synthetase (GS) and dehydrofolate reductase (DHFR) systems 
are commonly used in the industry. In both systems, selection takes place in culture media 
lacking the appropriate metabolite(s), namely glutamine for GS and glycine, hypoxanthine, 
and thymidine for DHFR (Hacker et al., 2008).  
 
 
Figure ‎1.1: Stable expression and transient expression approaches to recombinant 
protein production. (A) The generation of stably expressing cell lines enables selection of 
clones with desirable production and growth characteristics for large-scale manufacturing of 
kilogram quantities. The plasmid DNA encoding for the protein of interest is randomly integrated 
in the genome of the host cell. (B) Transient gene expression represents an attractive 
alternative to stable expression in which small (gram) quantities of product can be generated in 
days rather than months. Unlike stably expressing cells, the recombinant DNA is maintained as 
an extrachromosomal unit within the cell nucleus that results in impermanent, lower productivity 
(Codamo et al., 2011; Lai et al., 2013). 
Cells surviving selection are characterised by the integration of one or several copies 
of the expression vector into a transcriptionally active region of the host cell chromosomes. 
With both GS- and DHFR-based selection, the copy number of the integrated recombinant 
DNA can be amplified by exposure of the selected cells to increasing levels of methionine 
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sulphoximine (MSX) or methotrexate (MTX), respectively, that inhibits the enzymatic 
activity of the selection marker. This approach for cell line generation relies on the 
screening of hundreds to thousands of individual cell lines for the desired phenotype with 
regard to cell growth rate and recombinant protein productivity. The rare, superior cell lines 
are also eventually evaluated for the stability of protein production over time and in the 
absence of selection marker (Hacker et al., 2008). Consequently, the generation and 
selection of stable, high-performing mammalian cell lines is regarded as a major bottleneck 
in process development for the production of biologics (Browne and Al-Rubeai, 2007).  
To shorten the overall developmental time frame for therapeutic proteins, an 
alternative approach using stable transfection pool technology is also being employed. The 
technology is similar to the stable gene expression approach except that the step of 
isolating and characterising clonal cell lines is omitted. Following selection and 
amplification, the stably transfected pools is used for bioreactor production of recombinant 
proteins, yielding gram quantities of recombinant proteins within two months post-
transfection (Ye et al., 2010). In addition to the relatively high yields, stable pools offer an 
advantage over transient expression platforms in that their production does not require 
large amounts of high-purity, endotoxin-free plasmid DNA (Bertschinger et al., 2006; 
Schmid et al., 2001). 
 
 
The vast expansion in the number of recombinant protein molecules needed both as 
therapeutic candidates and for research purposes demands a means of rapid high-
throughput production of good-quality recombinant protein in mammalian cells (Figure  1.2). 
Transient gene expression (TGE) systems are an attractive alternative for rapid production 
of research-grade protein during the early stages of drug development due to the 
substantial time and resources associated with stable cell line generation. TGE methods 
can be employed to fast track the production of multiple biologics to perform biochemical 
study and early preclinical evaluation of drug candidates (Figure  1.1B). 
TGE has been used for decades in cell biology laboratories for small-scale research 
and analytical purposes, and in the last 15 years or so the technique has been scaled-up 
for rapid supply of biopharmaceuticals. HEK293 cells were originally used for scaled up 
TGE owing to its well established system for episomal replication, whereas systems for 
episomal replication in CHO cells came later (Baldi et al., 2007; Geisse, 2009). Whilst 
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Figure ‎1.2: Research and development (R&D) process in the biopharmaceutical industry. 
The development of a new drug is a lengthy multi-stage process and costs $1.2 billion for one 
successful drug launch. A way to ease this predicament would be to reduce the time and the 
costs associated with the preclinical research by providing a rapid, high-throughput production 
platform including using transient gene expression technology. Adapted from PhRMA (2012). 
HEK293 cells are regularly used in TGE for the early preclinical stage, it is desirable to 
align the early stage production with later manufacturing stage through use of the same 
cell line. For example HEK293 cells and CHO cells are known to have different post-
translational modifications such as glycosylation, thereby reducing predictability of drug 
candidate development (Suen et al., 2010). Therefore, recent works on TGE processes 
have focused on CHO cells which is the industry's major cell line for biomanufacturing. To 
date, the highest TGE titre for HEK293 cells reported within the literature is 1.1 g/L 
(Backliwal et al., 2008), whereas more recent work using CHO cells achieved 2 g/L 
(Daramola et al., 2014). 
A plethora of transfection methods have been described within the literature, with 
electroporation, cationic lipids and cationic polymers being the most commonly employed 
(Kim and Eberwine, 2010). With respect to the former, direct physical electroporation of 
expression plasmids into the cell nucleus ensures very high transfection efficiency and 
consistency. The recent advent of MaxCyte® technology (Fratantoni et al., 2003) has 
enabled large-scale electroporation for TGE, although the relatively expensive equipment 
and reagents practically limit its use. Similarly, despite their widespread use for microscale 
research applications, cationic lipids (commonly available in proprietary formulations such 
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as Lipofectamine®) are not used for large scale TGE due to its prohibitive cost. 
Consequently, the cationic polymer polyethylenimine (PEI) is arguably the most suitable 
method for large scale TGE. The technique requires low cost with relatively high 
transfection efficacy, and is now immerging as the leading TGE method for bioproduction 
(Backliwal et al., 2008; Daramola et al., 2014; Rajendra et al., 2011; Raymond et al., 
2011). 
 
 
Heterogeneity in a clonal cell population is readily revealed by phenotypic marker 
analyses, which typically result in Gaussian distribution histograms for the abundance of a 
certain protein per cell in a population of cells (Figure  1.3). Within the histogram, the 
abundance of the protein in the cells with the highest and lowest expression level usually 
varies by 10 to 1000 orders of magnitude—disparities which could not be attributed to 
signal measurement noise (Brock et al., 2009; Chang et al., 2008). This variation in 
phenotype is often explained by genetic heterogeneity, which in turn, is thought to be 
promoted by genetic instability in cells (Huang, 2009; O'Callaghan and James, 2008). The 
term genetic, or genomic, instability refers to an increased mutation rate that alter the 
normal organisation and function of genes and chromosomes (Kuttler and Mai, 2006; 
Smith et al., 2010). In other words, the heterogeneity with respect to a given protein (or 
any other quantifiable functional parameters) between individual cells is due to alteration to 
the genes that control the protein expression in the cells. 
 
 
Figure ‎1.3: Heterogeneity in three clonal cell populations in fluorescent protein 
expression as manifested by the width of the Gaussian distributions. A cell line may also 
have two or more distinct subpopulations of cells (e.g. population A plus population B) having 
different levels of protein expression. 
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Although cell lines are generally required to maintain functional genetic stability 
throughout a period of 30–60 generations beyond the production of a manufacturer‘s 
working cell bank (Brown et al., 1992; Robinson and Chu, 2007), transformed mammalian 
cell lines are artificially immortalised cells, and thus have an inherent temperament of 
genetic instability (Barnes et al., 2006). With the exception of the study of Kaneko et al. 
(2010), it has been shown that mammalian production cell lines are genetically unstable, 
especially after long periods of cultivation and in the absence of selective agents (Derouazi 
et al., 2006; Heller-Harrison et al., 2009; Kim and Lee, 1999). CHO cells, for example, are 
known to have a very unstable karyotype due to chromosome rearrangements arising from 
homologous recombination and translocations, primarily in response to gene amplification 
(Kim et al., 2001; Yoshikawa et al., 2000). 
In the absence of selective pressure, amplified genes localised to extrachromosomal 
double minutes are often lost by disproportionate segregation at mitosis (Kaufman et al., 
1983; Wahl et al., 1982). Consequently, clonally-derived cell lines can display erratic and 
uncontrollable behaviour in culture such as variation in specific growth rate (Barnes et al., 
2006), variations in protein modifications such as N-linked glycosylation (van Berkel et al., 
2009) and loss of productivity (Heller-Harrison et al., 2009). With respect to the latter, cell 
lines may exhibit a relatively stable qP profile, gradual instability over numerous population 
doublings, or a dramatic loss of recombinant protein expression (Heller-Harrison et al., 
2009). In some cases, the instability has also been shown to be transient, with productivity 
reverting to a specific level after a period of time in culture (Merritt and Palsson, 1993). 
Nevertheless, the rapid mutation capability of a host cell provides a mechanism to enrich 
clonal populations with cells that have survival advantages and the ability to grow 
autonomously, for instance with regard to ―ease of adaptation‖ to a selective culture 
condition (O'Callaghan and James, 2008). 
 
 
 
Mammalian cell hosts, such as CHO, do not have a dedicated secretory phenotype and 
are poorly efficient to handle elevated trafficking load or complex secreted proteins (Dalton 
and Barton, 2014). At low levels of mRNA expression, cell-specific recombinant protein 
production and mRNA abundance are positively correlated. When mRNA expression is 
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high, this correlation often breaks down due to limiting translational and/or post-
translational mechanisms, including for non-engineered proteins such as immunoglobulins 
(Barnes and Dickson, 2006; Carpentier et al., 2007; Le Fourn et al., 2014) and luciferase 
(Mead et al., 2009; Takahashi et al., 2011). The limitation can also be due to saturation of 
ER export machinery as reported by Hasegawa et al. (2011) for a CHO phenotype. In this 
particular case, the IgG synthesis and oxidative folding reactions exceeded the ER 
transport rate, resulting in accumulation of export-ready IgG in the ER lumen until a 
threshold concentration was reached to nucleate crystals. 
The cellular bottlenecks are exacerbated in the case of DTE recombinant protein 
production using TGE systems as the host cells can be easily overloaded with transgenes 
and nascent recombinant polypeptides. As a result, for many recombinant proteins, 
productivity is unpredictably low, even MAb products in the same isotype/sub-class can 
display variable expression levels due to different translational and post-translational 
process rates (Pybus et al., 2014a,b). This can also be expected from artificial fusion 
proteins which have not coevolved; the two (or more) combined components are thought 
to have different folding and/or secretion requirements (Lee et al., 2007). On the other 
hand, stable transfectants capable of efficient DTE recombinant protein expression 
avoid/minimise unfolded protein response (UPR) induction by lowering the rate of 
recombinant gene transcription resulting in low stable expression system. Therefore, the 
amount of available recombinant mRNA often appeared to become the limiting event in 
stably producing cells, whereas translational and post-translational mechanisms are 
generally the bottlenecks in transient production of DTE proteins (Davies et al., 2011; 
Mason et al., 2012; O'Callaghan et al., 2010). 
 
 
The transport of secretory proteins typically consists of several stages and involves various 
molecular chaperones along the processes. In eukaryotic cells, the transport into the ER 
lumen represents the first secretion step, and for the majority of these proteins (particularly 
those with more than 100 amino acids) this transport occurs during translation―a process 
referred to as co-translational translocation (Figure  1.4). The binding of the signal-
recognition particle (SRP) to the sequence signal is thought to induce translational arrest 
to allow time for a ribosome-nascent chain complex to diffuse to the ER membrane. This 
would prevent premature folding of a secreted protein in the cytoplasm as well as enable 
the removal of the cleavage of the signal peptide, leading to the synthesis of properly 
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processed and translocated polypeptides. Moreover, the ER luminal Hsp70 and Hsp40 
chaperones, namely immunoglobulin binding protein (BiP) and Sec63, respectively, have 
been shown to play important roles during co-translational translocation in mammalian 
cells. For example, the gating of the channel in the ER membrane is performed by BiP 
(Alder et al., 2005; Schäuble et al., 2012), whereas the initial insertion of several protein 
polypeptides into the Sec61 complex has been associated with Sec63 (Lang et al., 2012).  
 
 
Figure ‎1.4: Co-translational translocation of secretory proteins into the ER. Translocation 
begins when a (signal-recognition particle) SRP binds to the signal sequence of a nascent 
polypeptide chain. The complex of SRP, nascent chain and ribosome then binds to the SRP 
receptor (consisting of α and β subunits) in the ER membrane. After SRP and its receptor 
dissociate from the nascent polypeptide chain, the signal sequence binds to the Sec61 
translocon, thus opening the translocon gate that blocks the internal channel. The signal 
sequence is inserted as a loop into the central cavity of the translocon and the polypeptide 
chain elongates. Then the signal sequence is cleaved and rapidly degraded, while the chain 
continues to elongate until translation is completed and the chain is extruded into the ER lumen. 
ER lumen molecular chaperones BiP and Sec63 are known to assist the translocation process. 
Finally, the ribosome is released, the translocon gate shuts, and the secreted protein assumes 
its tertiary conformation. Adapted from Lodish et al. (2000) and Nyathi et al. (2013). 
Furthermore, approximately two-third of therapeutic proteins and biologics candidates 
are proteins modified post-translationally by glycosylation (i.e., the attachment of 
oligosaccharide chains). This complex post-translational modification has multiple roles in 
the cell and is characterised by various glycosidic linkages, with N-linked and O-linked 
glycosylation being the most commonly observed types (Pandhal and Wright, 2010; 
Sethuraman and Stadheim, 2006). In the ER, glycosylation is performed to check the 
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status of protein folding, functioning as a quality control system to ensure that only 
correctly folded glycoproteins are exported to the Golgi complex. In the trans Golgi 
network, the sugar components can be bound by specific receptors to assist their delivery 
to the appropriate cellular destination. These sugar moieties can also potentially stabilise a 
protein (e.g. by enhancing the solubility), act as ligands for receptors on the cell surface to 
stimulate signal transduction pathways or mediate cell attachment, as well as regulate 
protein half-life (e.g. sialic acid may improve half-life) and biological activity (Walsh and 
Jefferis, 2006). 
While glycosylation is generally characterised as a post-translational process, N-
glycosylation often occurs co-translationally, in that the glycan is attached to the nascent 
polypeptide as it is being translated and translocated into the ER (Figure  1.5). N-linked 
glycans are essential in proper protein folding (90% of glycoproteins are N-glycosylated), 
in which the oligosaccharides trimming (i.e. sugar hydrolysis by glycosidases) is used to 
both monitor protein folding and specify when proteins must be degraded. The process 
involves the hydrolysis of two terminal Glc from the precursor glycan by glycosidases I and 
II, after which molecular chaperones calnexin and calreticulin bind to the nascent 
glycoprotein via the remaining Glc and assist the protein to fold. The final Glc is soon 
removed by glycosidase II, releasing the glycoprotein from the chaperones. If the protein 
fails to fold properly, glucosyltransferase transfers a Glc to the protein, and the chaperones 
again are bound to the protein to assist proper folding. This cycle of Glc removal and 
addition continues until the protein is properly folded, at which time it is not reglycosylated 
(Ellgaard et al., 2003; Roth et al., 2002). To this point, all N-linked glycoproteins have the 
same precursor glycan structure, and the glycoprotein is transported to the Golgi complex 
for further processing. 
In addition to calnexin and calreticulin, various other molecular chaperones are 
involved in building efficient protein folding machinery within the ER. As nascent 
polypeptides enter the ER in the reduced state, disulphide bonds are rapidly formed to 
stabilise the folded structure of the protein. Protein disulphide isomerase (PDI) catalyses 
the disulphide-bond formation (i.e. oxidation) between cysteine residues intra- and 
intermolecularly, thereby allowing the nascent proteins to quickly find the appropriate 
configuration in their folded state. The reoxidation of PDI is accomplished by the ER 
oxidoreductins (ERO), although the lumen of the ER also provides an oxidising 
environment and substrate glutathione. Interestingly, the reduced form of PDI is able to 
catalyse a reduction of thiol residues, which is particularly important with terminally 
misfolded proteins that must be reduced before dislocation to the cytosol for proteasomal 
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Figure ‎1.5: N-linked glycosylation in mammalian cells. Oligosaccharide chains attached 
through N-glycosidic linkages are derived from a 14-sugar precursor glycan composed of N-
acetylglucosamine (GlcNAc), mannose (Man) and glucose (Glc) that are added in sequence 
onto dolichol. The first 7 sugars (Man5GlcNAc2) are provided by sugar nucleotides (UDP- and 
GDP-sugars) in the cytoplasm and bound to dolicholpyrophosphate (dolichol-PP). After the 
intermediate is completed, the entire unit is flipped into the ER lumen, after which Man- and 
Glc-P-dolichol molecules provide the remaining 7 sugars to make the Glc3Man9GlcNAc2-PP-
dolichol precursor glycan. The oligosaccharyltransferase (OST) then transfers the sugar moiety 
(Glc3Man9GlcNAc2) to the nascent protein emerging from the Sec61 translocon, specifically the 
free amide group of the Asn (N) with sequence Asn-X-Ser/Thr. The glycan structure for all 
correctly folded glycoproteins that progress to the Golgi complex is Man9GlcNAc2. Adapted from 
Pandhal and Wright (2010). 
degradation (Anelli and Sitia, 2008; Hatahet and Ruddock, 2009). BiP, the most abundant 
ER chaperone with multi-functions, has been demonstrated to cooperate with PDI and 
calnexin in oxidative folding and refolding of glycoprotein, respectively (Mayer et al., 2000; 
Stronge et al., 2001). On the other hand, ER mannosidase (ERManI) plays a key role in 
identifying proteins that are unable to fold correctly. The hydrolysis of mannose residues 
by ERManI would remove the glycoproteins from the reglucosylation and calnexin binding 
cycles, where they would be retro-translocated into the cytosol and eventually delivered to 
ERAD via ubiquitination, a process where ubiquitin binds to lysines on the protein and acts 
as a tag for proteasomal degradation (Frenkel et al., 2003; Tsai et al., 2002). 
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Glycan processing in the Golgi complex involves both trimming and addition of 
sugars to generate diverse oligosaccharides on individual glycoproteins for different 
functions (see below). As with precursor glycan biosynthesis in the ER, this maturation 
pathway to diversify the glycans is highly ordered. The final glycan structures can be 
broadly classified into three types; (i) complex oligosaccharides (multiple sugar types), (ii) 
high-mannose oligosaccharides (multiple mannose residues), and (iii) hybrid-branches 
which consist of both complex and high mannose oligosaccharides. N-glycosylation does 
not prohibit other types of glycosylation from occurring, as O-glycosylation normally occurs 
on glycoproteins that were N-glycosylated in the ER. Unlike N-glycosylation, O-
glycosylation occurs post-translationally on Ser and Thr side chains in the Golgi complex 
and the glycans typically have much simpler oligosaccharide structures. Additionally, in O-
glycosylation the sugars are added one-at-a-time to Ser or Thr residues, which is in 
contrast to N-glycosylation in which the precursor glycan is transferred en bloc to Asn 
(Hossler et al., 2009).  
Proper glycosylation is a critical parameter for the manufacturing of glycoprotein 
therapeutics as it can affect protein stability, bioactivity, pharmacokinetics, immunogenicity 
and protein clearance in the circulation system (Walsh and Jefferis, 2006). For example, 
the clearance mechanisms for recombinant Factor VII have been associated with N-
glycosylation (Appa et al., 2010) while the removal of N-glycosylation sites on recombinant 
erythropoietin (EPO) were shown to significantly reduce its in vivo activity (Delorme et al., 
1992). Additionally, for both N-linked and O-linked oligosaccharide chains, sialic acid is 
typically the desired terminal sugar, with N-acetylneuraminic acid (Neu5Ac) and its N-
glycolylneuraminic acid (Neu5Gc) derivative being the two most common forms (Borys et 
al., 2010; Chen et al., 2011). However, Neu5Gc is not typically expressed in humans (but 
abundantly expressed in most mammals) and has been suggested to elicit human immune 
responses (Irie et al., 1998; Virki et al., 2001). In this regard, anti-NeuGc antibodies is 
detectable in 85% of healthy humans (Zhu and Hurst, 2002), whereas high Neu5Gc levels 
on a chimeric CT4-IgG fusion protein were linked with faster protein clearance profiles in 
vivo (Flesher et al., 1995). 
 
 
Protein aggregation continues to be a major complication in the development and 
manufacturing of biopharmaceuticals. The term "protein aggregation" may be referred to 
as a broad class of protein species with higher molecular weight (oligomers) than the 
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desired native or native-like protein monomer (Mahler et al., 2009; Philo, 2006). These 
protein aggregates may exhibit adverse effects such as immunogenicity, reduced or no 
biological activity, as well as production, formulation and storage problems (Wang et al., 
2010). The potential for protein aggregate formation presents at all stages of mammalian-
based biomanufacturing including during the protein folding reaction in the ER.  
Studies suggest that the poorly populated protein folding intermediates are 
precursors in protein aggregation (Figure  1.6) where these intermediates, for example, can 
have higher flexibility and expose more hydrophobic patches than the folded state. In 
contrast, unfolded (nascent polypeptide chains) and completely folded proteins do not 
aggregate easily (Wang, 2005). Under ER stress (e.g. accumulation of unfolded proteins in 
the ER), proteins can be misfolded, which can then undergo physical interaction (e.g. 
hydrophobic interaction) or cross-linking reactions that lead to formation of protein 
aggregates (Ioannou et al., 1992; Kopito, 2000; Tyedmers et al., 2010). With respect to the 
latter, the most common cross-linking reaction is the intermolecular disulphide bond 
exchange/formation, although other non-disulphide cross-linking pathways such as 
oxidation, dityrosine formation and formaldehyde-mediated cross-linking have also been 
described (Wang et al., 2010). 
 
 
Figure ‎1.6: Overview of cellular protein folding, misfolding and aggregation. After a 
polypeptide is synthesised at the ribosome, it folds through an intermediate to its native, three-
dimensional conformation. Inefficient ER-folding machinery to fold the synthesised proteins as 
they accumulate in the ER can cause ER stress and protein misfolding. The misfolded 
intermediates can be refolded to their native state via activation of UPR mechanism, or be 
degraded by ER-associated degradation (ERAD) and other cellular proteolysis systems that 
avert the accumulation of misfolded proteins. If the quality-control network is inundated (e.g. 
through increased amounts of aberrant proteins) aggregates can form. Adapted from Kopito 
(2000) and Tyedmers et al. (2010). 
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As mentioned earlier, the formation of disulphide bonds is a critical step in the 
maturation of therapeutic proteins in which they fold into their native conformation vital for 
their structure and activity (Cromwell et al., 2006; Zhang et al., 2011). However, in the case 
of MAbs, which require coordinated synthesis and folding of multiple polypeptides, in vitro 
studies have shown that the folding rate is relatively slow (Goto and Hamaguchi, 1981; 
Lilie et al., 1994), whilst comparative analyses revealed that different CHO cell lines 
(O'Callaghan et al., 2010) and different MAbs (Pybus et al., 2014a) have significantly 
different folding rates. To overcome the folding limitation, mammalian cells have a number 
of mechanisms that give them protection against protein misfolding and aggregation, 
primarily the UPR and ERAD (Dinnis and James, 2005). During the UPR, molecular 
chaperones such as BiP assist protein folding at high concentrations through binding of 
unfolded nascent polypeptides, which also helps in preventing aggregation by sheltering 
hydrophobic surfaces from forming unwanted intra- or intermolecular contacts (Kopito, 
2000). However, depending on cell lines and protein products, the capacity of these 
chaperones can become overwhelmed, resulting in decreased protein folding efficiency. In 
many cases, inefficient ER-folding machinery to fold and assemble the synthesised 
proteins as they accumulate in the ER, often result in the formation of aggregates with 
anomalous intra- and intermolecular disulphide linkages (Gomez et al., 2012; Marquardt 
and Helenius, 1992; Schröder et al., 2002).  
Accordingly, while disulphide bonds formed from the coupling of unpaired free thiols 
on cysteines are vital for the correct configuration of glycoproteins, they may also be the 
basis of protein misfolding and covalent aggregate formation. The presence of free thiols 
can also affect long-term stability of protein products where they are able to propagate 
aggregation by forming disulphide bonds during storage. This has been observed in the 
case of a lyophilised MAb stored at 30°C (Liu et al., 2005) and an Fc-fusion protein in 
liquid solution stored at ‒30°C (Wang et al., 2013). The formation of disulphide mislinkages 
may further promote physical aggregation of proteins, for example via hydrophobic 
interactions (Cabra et al., 2008; Wang et al., 2013), whereas correctly-folded disulphide-
bonded proteins with no free cysteine residues can still undergo aggregation via disulphide 
exchanges through β-elimination (Wang, 2005). 
Various approaches have been taken by manufacturers to control aggregates in 
protein-based products. Although it is technically possible to remove the aggregates at a 
later stage during downstream processing, preventing/minimising the accretion of 
aggregation-prone misfolded proteins is the first and most effectual intervention point to 
control protein aggregates (Cordoba-Rodriguez, 2008; Cromwell et al., 2006; Tyedmers et 
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al., 2010). MAbs susceptible to aggregation due to elevated free thiol can be prevented, for 
example, by adding low amounts of oxidising agent copper sulphate to the culture medium, 
which have been shown to result in a 10-fold decrease of free thiols and improved 
disulphide bond formation (Chaderjian et al., 2005). It is also evident that mutational 
changes can improve the stability of recombinant proteins which inclined to aggregate 
under stress-induced condition. In the study of Lu et al. (2008) for instance, when the 
serine residue 241 of an IgG4 produced in CHO cells was converted to proline, the hinge-
mutant antibody appeared to be more resistant to freeze-thaw-induced aggregation 
compared to its wild type. 
 
 
When the ER protein folding demand is excessive relative to the protein folding capacity, 
unfolded/misfolded proteins would accumulate in the ER, resulting in ER stress. To 
overcome ER stress, a cell activates several signalling pathways, collectively known as the 
UPR, to coordinate between the load of client proteins and the capacity of the protein 
folding machinery. The UPR promotes an adaptive cellular response to ER stress and re-
establishes homeostasis in the ER, as well as induces an apoptosis programme. Double-
stranded RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK), 
activating transcription factor 6 (ATF6) and inositol-requiring enzyme 1 (IRE1) are the 
three main sensors of unfolded proteins in the ER and are therefore key transducers of 
UPR. PERK, ATF6 and IRE1 are activated when unfolded protein levels increase and BiP 
is released from the three proteins (Figure  1.7; Chakrabarti et al., 2011; Dinnis and James, 
2005; Schröder and Kaufman, 2005). 
The main function of the PERK pathway is to modulate translation following the 
accumulation of unfolded/misfolded proteins in the ER, although it is also responsible for 
the transduction of both pro-survival and pro-apoptotic signals. Dissociation of BiP from the 
N-terminus of PERK triggers dimerisation and autophosphorylation of the protein kinase 
domain. Activated PERK phosphorylates the α-subunit of eukaryotic initiation factor 2 
(eIF2α) at Ser51, inhibiting the guanine nucleotide exchange factor eIF2B that recycles 
eIF2 to its active GTP-bound form. Lower levels of active eIF2 globally attenuates 
translation initiation as well as downregulates gene transcription (DuRose et al., 2009), 
hence reducing the influx of protein into the ER and reducing the folding load. Additionally, 
phosphorylated eIF2α paradoxically induces translation of the transcription factor ATF4 
mRNA. ATF4 upregulation stimulates the expression of pro-survival functions including  
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Figure ‎1.7: The major intracellular signalling during the UPR in mammalian cells. In 
unstressed cells, BiP binds to the lumenal domains of PERK, ATF6 and IRE1. Upon 
accumulation of unfolded/misfolded proteins in the ER lumen, PERK released from BiP 
dimerises, autophosphorylates, and phosphorylates eIF2α. eIF2α phosphorylation attenuates 
global translational initiation and paradoxically induces translation of ATF4 mRNA. ATF4 
regulates pro-survival functions such as amino acid import and ER redox control and activates 
transcription of CHOP which leads to apoptosis via downregulation of anti-apoptotic Bcl-2 
protein. CHOP also serves in a negative feedback loop ultimately reducing the phosphorylation 
of eIF2α. Secondly, ATF6 released from BiP translocates to the Golgi complex where for 
cleavage by S1 and S2 proteases to create a cytosolic domain ATF6c that travels to the 
nucleus to stimulate transcription of genes encoding ER chaperones and foldases. Similarly, 
IRE1 released from BIP dimerises to activate its kinase to initiate XBP1 mRNA splicing, yielding 
a strong transcriptional activator to further enhance transcription of chaperones and foldases. 
Additionally, key targets that need IRE1 or XBP1 pathway for induction include genes encoding 
functions in ERAD, particularly EDEM. 
amino acid import and ER redox control (Harding et al., 2003) as well as the expression of 
pro-apoptotic factors through the transcription factor C/EBP homologous protein (CHOP). 
Whilst CHOP induces apoptotic cell death by repression of B-cell lymphoma 2 (Bcl-2) 
expression (McCullough et al., 2001), it also induces a negative feedback loop involving 
the direct dephosphorylation of eIF2α by promoting the expression of growth arrest and 
DNA damage-inducible protein 34 (GADD34; Novoa et al., 2001). 
In addition to PERK, the general control non-derepressible-2 (GCN2) kinase, heme-
regulated inhibitor (HRI) kinase, and protein kinase R (PKR) can also activate this pathway 
(i.e. phosphorylation of eIF2α) independently of ER stress, and therefore this branch of the 
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UPR is termed the integrated stress response (ISR; Ron and Walter, 2007). A well-
characterised precedent for such mechanism is the eIF2α kinase GCN2. Besides inhibiting 
global rates of mRNA translation, GCN2 activation by amino acid starvation or exposure to 
oxidants and the subsequent eIF2α phosphorylation preferentially promotes the synthesis 
of ATF4 (see above). Similarly, low levels of iron lead to depletion of heme in erythroid 
cells, activating HRI autophosphorylation, which in turn phosporylates eIF2α (Han et al., 
2001). PKR participates in an antiviral defense mechanism triggered by interferon, in which 
double-stranded RNA accumulation in virus-infected cells leads to PKR 
autophosphorylation and enhanced p-eIF2α (Dey et al., 2005). 
The second branch of the UPR consists of a complex series of ATF6 translocation to 
the Golgi complex and irreversible proteolytic processing steps, eventually driving the 
upregulation of a pro-survival gene expression programme. Unlike the PERK and IRE 
kinase pathways, ATF6 activation does not involve phosphorylation but cleavage by serine 
protease site-1 (S1) and metalloprotease site-2 (S2) pr6789oteases. Cleaved ATF6 
(ATF6c), in conjunction with other basic-leucine zipper (bZIP) transcription factors and 
required co-regulators, induces a transcriptional programme that increases ER chaperone 
activity and CHOP (Kokame et al., 2001; Yoshida et al., 2000). Furthermore, ATF6c can 
enter the nucleus and bind ER stress response elements (ERSE) of X-box binding protein 
1 (XBP1) to increase its transcription which, after processing by activated IRE1α, also 
induces the expression of chaperones, foldases, lipid biosynthesis enzymes as well as 
other control elements (Yoshida et al., 2001).  
On removal of BiP, IRE1 (like PERK) homodimerises and undergoes 
autophosphorylation of the kinase domain. The endoribonuclease activity of IRE1 removes 
a 26-base pair intron from XBP1 transcripts, which generates a potent 41 kDa transcription 
factor XBP1s (Yoshida et al., 2001). XBP1s then travels to the nucleus and binds to ERSE 
and unfolded protein response elements (UPRE) of a variety of ER chaperones and ERAD 
related genes. With regard to ERAD, ER degradation-enhancing α-mannosidase-like 
(EDEM) protein is known to directly involve in recognition and targeting of unfolded and 
misfolded proteins for degradation, in which the induction is dependent on XBP1 and 
stimulated by ATF6. Since activation of ATF6 precedes XBP1 splicing, it has been 
proposed that the UPR takes place in two phases, (i) ATF6-dependent induction of ER 
chaperones to facilitate protein folding, and (ii) both protein refolding and XBP1-dependent 
induction of ERAD to degrade unfolded/misfolded proteins (Hosokawa et al., 2003; 
Yoshida et al., 2003). 
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This chapter provides an overview of cell line development and engineering strategies for the 
production of biopharmaceuticals. Specific emphasis is given to approaches utilised to improve 
or optimise the production platform, as well as computational tools to assist the development 
and engineering processes. The objective of this chapter is to contextualise the data presented in 
this thesis, with regard to their industrial applications. 
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CHO cells have the most established history of regulatory approval and thus are an 
attractive, safe option for biomanufacturing and remain the industry "workhorse" (Estes 
and Melville, 2014). Yet, the increasing demand and complexity of therapeutic proteins call 
for novel host cell types to meet the challenges of high productivity. In recent years, 
human-derived cell lines, particularly retina derived PER-C6® cells and amniocyte derived 
CAP® and CAP-T® cells, have emerged as an attractive alternative. These cell lines do 
not require amplification of the recombinant genes, thus providing enhanced stability in the 
absence of selection pressure. Additionally, their ability to confer human post-translational 
modifications reduces the potential immunogenic reactions against non-human epitopes 
(Schiedner et al., 2008; Swiech et al., 2012). The CAP-T cell line, developed for high 
transient gene expression (TGE), had been demonstrated to possess intrinsic capabilities 
to synthesise and secrete complex proteins that could not be expressed in sufficient yield 
or adequate quality in CHO and HEK293 cells (Fischer et al., 2012). PER-C6 cells are 
currently being used for production of many therapeutics in clinical trials, and with CAP 
cells they are expected to be a major production platform in the near future (Durocher and 
Butler, 2009; Swiech et al., 2012). 
 
 
Genetic heterogeneity and clonal variation are the basis of the development of mammalian 
cell production systems. Whilst randomly arising clonal genetic heterogeneity contributes 
significant negative side effects, the increased genetic instability/mutation may also grant a 
benefit by producing genetically variant cells with improved phenotypes. This form of 
mutation may be supposed to encompass the regular adaptation of cell lines to suspension 
culture (Astley and Al-Rubeai, 2008), and to serum (Sinacore et al., 2000), cholesterol and 
protein-free media (Birch et al., 1994; Hartman et al., 2007) through growth in selective 
culture conditions. In this way, it can be hypothesised that increased genetic instability is 
an inherent trait to clonally-derived cell populations and is directly linked to cell metabolism 
as well as recombinant gene expression. Therefore, from a cell line development 
perspective, it is desirable to take advantage of this natural variation to generate 
advantageous cell hosts capable of supporting biomanufacturing processes. The host cell 
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factory is a major manufacturing parameter itself, and enhancement of parental cell 
functional capacity, as well as elimination of ineffectual variants from the cell population, 
enable the selection of production process attuned cell lines.   
The maintenance of cell culture involves drastic, periodic contractions in population 
size when fresh media are inoculated during serial passage. A dilution ratio of below 0.1, 
which is a standard practice, diminishes the possibility that rare beneficial mutations are 
established (Wahl et al., 2002). In order to generate superior cell lines, desirable novel 
phenotypic traits are often selected through cloning and extensive screening, or by 
applying a suitable selective pressure. In the context of the latter approach, the genetic 
changes may characterise a developed adaptation of the overall population to a new 
surrounding condition, though in many studies it entails death of most of the cells and 
outgrowth of the surviving cells―allowing the formation of a genetically and phenotypically 
different sub-population that can tolerate that particular culture condition (Browne and Al-
Rubeai, 2011; Hartman et al., 2007). In fact, even a slight advantage in cell survival (i.e., 
higher cell proliferation rate) will allow a clonal sub-population to overgrow a culture within 
a limited number of generations (Kromenaker and Srienc, 1994; Lee et al., 1991).  
Similarly, an iterative process of extended batch culture eliminates inferior cells with 
low resistance to environmental stresses, and thus allows the selection of cells which 
exhibit improved and/or new characteristics (Browne and Al-Rubeai, 2011; Prentice et al., 
2007). Successful examples of selective strategies include the isolation of variant CHO cell 
lines with the ability to be transfected with adenovirus (Condon et al., 2003), the ability to 
survive harsh culture conditions (Keightley et al., 2004; Prentice et al., 2007), and 
improved growth rate (Prentice et al., 2007) and specific productivity (Pichler et al., 2011). 
Moreover, genetically diverse cell populations can be induced artificially, for instance by 
temporarily suspending the DNA mismatch repair mechanism, which has been shown to 
generate high-osmolarity resistant cells (Liu et al., 2010). Although such host-cell 
enhancements may also be achieved via a more direct approach of genetic engineering 
(e.g., introduction of anti-apoptotic genes, knock-out of lactate dehydrogenase gene), this 
strategy requires extensive knowledge of the genes and cellular mechanisms involved and 
proves to be largely intractable (Dietmair et al., 2011; Dinnis and James, 2005; Lim et al., 
2010).  
Nevertheless, it is also important to note that the selection of functionally superior cell 
lines and managing the consequences of cell-specific functional/genetic instability is time-
consuming and resource intensive, and with its own limitations. As mentioned earlier, all 
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inherent traits in mammalian cells may vary over time by means of point mutation, gene 
loss, etc. Consequently, the heritability of the desirable phenotypic/functional trait may be 
considered an issue; i.e. does the screened phenotypic/functional trait remain stably 
heritable over numerous sub-cultures? The rate at which genetic and its associated 
functional characteristic drift away is itself clone-specific, and therefore is likely to be the 
key parameter that needs to be evaluated.  
 
 
 
The final recombinant protein titre is a function of two culture parameters, (i) the integral of 
viable cell density, IVCD and (ii) the cell specific productivity, qP. For fed-batch 
manufacturing processes, the optimal combination is a rapid accretion of productive host 
cells to high culture density for prolonged duration (Bibila and Robinson, 1995). Indeed, 
improvements in culture conditions for recombinant protein biomanufacturing have been 
remarkable in the last three decades, leading to over 100-fold increase in product yield. In 
the late 1980s, standard batch culture production runs had a production phase of 1 week 
and a peak cell density of around 2 million cells/mL, with a product titre of 50‒100 mg/L. 
By comparison, current fed-batch production runs start with a lower cell density and last 3 
weeks with a peak cell density of over 25 million cells/mL, while the product titre can reach 
10–13 g/L (Huang et al., 2010). Much of these improvements have come from innovative 
and progressive developments of media and feeds of fed-batch operations, leading to 
more and healthier cells over a longer cultivation duration (De Jesus and Wurm, 2011). 
In addition to the media compositions, researchers also found that specific MAb 
production rate of hybridoma cells increased when the cell division rate was slowed or 
halted by either small molecule inhibitors (Suzuki and Ollis, 1990) or nutrient limitation 
during chemostat culture (Miller et al., 1988). This apparently inverse correlation between 
qP and cell growth formed the basis of a controlled proliferation strategy to enhance 
recombinant protein expression (Fussenegger et al., 1998). The logic behind this approach 
is that a cell inevitably draws energy and resources away from recombinant protein 
production in order to generate new cellular biomass during mitosis. To circumvent the 
drawback of lower cell density, a "biphasic" cell culture is often employed. According to this 
scheme, cell growth is unrestrained during the first phase to accumulate viable cell density, 
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whereas during the second phase cell cycle is arrested to allow an extended period of high 
productivity (Dinnis and James, 2005).  
Specific productivity may also be induced by increasing medium osmolarity, for 
instance through the addition of sodium chloride. Even though cell growth is depressed 
and apoptosis is induced at elevated osmolality, this can be resolved by the two-stage 
culture or by use of osmoprotectants as well as adaptation of cells to hyperosmotic 
pressure (Ryu et al., 2000). The main objective is to utilise a way of arresting cell division 
without inducing cell death and (in)directly interfere with the increase in recombinant 
protein productivity (Dinnis and James, 2005). Similarly, controlled proliferation by the use 
of lower culture temperature causes, in many cases, an increase in qP. This is particularly 
advantageous as hypothermic condition effectively extends culture longevity. However, 
several studies have shown that the enhancement effect of low temperature on 
recombinant protein production is not due to the G0/G1-phase growth arrest. Instead, the 
improvement is largely as a result of improved mRNA stability and elevated mRNA levels, 
and that a cell may still exhibit growth-associated productivity in hypothermic condition 
(Becerra et al., 2012; Fox et al., 2005; Kou et al., 2011). 
 
 
Chemical chaperones are a group of low molecular weight compounds with a common 
feature mimicking the chaperone function of molecular chaperones. These compounds are 
usually osmotically active, such as glycerol and dimethyl sulfoxide (DMSO), but other 
classes such as histone deacetylase (HDAC) inhibitors are also members of the chemical 
chaperone group. The exact mechanisms by which chemical chaperones function are not 
fully understood, but they are known to suppress ER stress, improve the folding capacity of 
ER, inhibit protein aggregation, enhance protein secretion, among others (Perlmutter, 
2002). Owing to their positive effects, various osmolytes and HDAC inhibitors are in clinical 
use/trials for folding problem-related disease (e.g. Alzheimer's disease) and cancer 
treatments (Kim and Bae, 2011; Papp and Csermely, 2006).  
In cell culture processes, chemical chaperones have been reported to grant a wide 
range of benefits as illustrated in Table  2.1. For example, HDAC inhibitors sodium 4-
phenylbutyrate (PBA), sodium butyrate (NaBu) and valproic acid (VPA) are useful in 
enhancing the production of recombinant proteins in CHO cells (Hwang et al., 2011a; Sung 
and Lee, 2005; Wulhfard et al., 2010), and at the same time are able to reduce the  
Chapter 2 
 
26 
Table ‎2.1: Examples of effects of various chemical chaperones on cell culture processes. 
Cell 
Chemical 
chaperone 
Effect Reference 
    
BHK, Neuro2a DMSO, glycerol, 
TMAO 
Reduce aggregate formation and cell 
death 
Yoshida et al. 
(2002) 
CHO Betaine Enhances cell viability and recombinant 
protein production 
Follstad and 
Potter (2006) 
CHO Betaine Suppresses protein aggregation and 
improves protein trafficking 
Roth et al. 
(2012) 
CHO, HEK293 PBA Rescues cells from ER stress and 
apoptosis from misfolded myocilin 
Yam et al. 
(2007) 
CHO DMSO Enhances hepatitis B surface antigen 
production 
Wang et al. 
(2007) 
CHO DMSO Enhances expression of various 
exogenous genes 
Liu et al. (2001) 
CHO DMSO Enhances recombinant HBsAg 
intracellular accumulation 
Ma et al. (2008) 
CHO Glycerol Enhances recombinant M-CSF 
production 
Liu and Chen 
(2007) 
CHO Glycerol Reduces protein aggregation Kim and Lee 
(1993) 
CHO 
 
Glycine betaine Protects cells in hyperosmotic culture Kim et al. 
(2000) 
CHO NaBu Enhances recombinant human 
thrombopoietin production  
Sung and Lee 
(2005) 
CHO NaBu Enhances recombinant tPA production Palermo et al. 
(1991) 
CHO NaBu Minimises Neu5Gc content of fusion 
protein 
Borys et al. 
(2010) 
CHO NaBu Enhances production and minimises 
Neu5Gc content of antibody 
Chen et al. 
(2011) 
CHO PBA, proline, 
glycerol, DMSO 
Enhance production and minimise 
aggregation of FCA1 protein  
Hwang et al. 
(2011a) 
CHO PBA Restore the functionality of misfolded 
mutant low-density lipoprotein receptor 
Tveten et al. 
(2007) 
CHO Trehalose Suppresses recombinant antibody 
aggregation  
Onitsuka et al. 
(2014) 
CHO VPA Enhances recombinant mRNA and MAb 
levels 
Wulhfard et al. 
(2010) 
COS-1, human 
neuroblastoma  
PBA Suppresses Pael receptors aggregation 
and ER stress 
Kubota et al. 
(2006) 
E. coli Arginine, sorbitol Improve recombinant protein solubility in 
cells 
Prasad et al. 
(2011) 
E. coli Proline Inhibits P39A protein aggregation Ignatova and 
Gierasch (2006) 
HEK293 PBA Reduces ER stress and prevents mutant 
HFE aggregation  
de Almeida et 
al. (2007) 
HEK293 PBA, VPA Promote assembly of functional α7 
AChRs 
Kuryatov et al. 
(2013) 
HT-1080, SW-
1353 
Glycerol, TMAO Reduces thermolabile collagen II 
mutants intracellular accumulation 
Gawron et al. 
(2010) 
Hybridoma Betaine Protects cells from hyperosmotic stress Berg et al. 
(1991) 
Mice fibroblasts PBA Rescues trafficking incompetent mutant 
α-galactosidase A 
Yam et al. 
(2007) 
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potentially immunogenic N-glycolylneuraminic acid (Neu5Gc) content of glycoproteins 
(Borys et al., 2010; Chen et al., 2011). The latter results are of particular importance as the 
chemical(s) can conveniently be employed to minimise or control Neu5Gc in the 
manufacturing processes, thereby improving product quality. 
Similarly, enhancement in productivity can also be obtained using glycerol, DMSO 
and proline, even though they are probably more recognised for their ability in 
suppressing aggregate formation (Hwang et al., 2011a; Liu and Chen, 2007; Wang et al., 
2007). On the other hand, methylamine osmolytes such as  betaine and trimethylamine N-
oxide (TMAO) are associated with a protective effect on cells, for instance against 
hyperosmotic condition (Kim et al., 2000), although betaine has also been reported to 
suppress aggregation and improve trafficking of factor VIII in CHO cells (Roth et al., 2012). 
Other chemical chaperones that have been shown to yield positive effects in cell culture 
include arginine, sorbitol (Arakawa et al., 2006) and trehalose (Onitsuka et al., 2014). 
Despite the versatility of general and specific effects, chemical chaperone treatment 
strategy is still underutilised. As low yield and aggregation have become recognised as 
critical issues in a growing number of complex and difficult-to-express proteins, the use of 
chemical chaperones is theoretically attractive because of their applicability to a broad 
range of cell culture processes. Moreover, the strategy has its practical advantage in which 
the chemical dosage can be easily and accurately titrated or applied at any time point of 
culture. 
 
 
 
Examples of constitutive promoters that are often used in mammalian expression systems 
include the human/mouse cytomegalovirus (CMV) promoter, the simian virus 40 (SV40) 
promoter and the non-viral elongation factor 1α (EF1α) promoter. As the nature/design of a 
promoter has profound effects on transgene expression level and overall productivity 
(Backliwal et al., 2008; Davies et al., 2011), developments in mammalian gene expression 
technology to increase transcriptional activity have occurred subsequently. For example, 
Running Deer and Allison (2004) cloned a Chinese hamster EF1α gene and its flanking 
sequences to generate CHEF1 vectors that had 6‒35-fold higher expression levels than 
vectors utilising the CMV or EF1α promoter. On a similar note, Chatellard et al. (2007) 
cloned an enhancer from the mouse CMV immediate early 2 region (IE2), identified as a 
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potent expression-promoting element. The IE2's unique bi-directional promoter 
architecture can be used to efficiently express multi-chain proteins, which was shown to 
result in high recombinant protein production levels. Furthermore, recent work in this 
laboratory successfully created a library of numerous synthetic promoters designed to 
precisely regulate recombinant gene expression in CHO cells over a large transcription 
range (Brown et al., 2014). 
Significant efforts have also been carried out to increase the recombinant gene copy 
number, especially in the transient gene expression (TGE) system. In the stable gene 
expression system, the transgene is inherited by the daughter cells upon mitosis, and thus 
allowing a rather constant transgene copy number in cells of succeeding generations. In 
contrast, in the TGE system the transgene copy number per cell is reduced during cell 
division, and it is therefore inevitable that the cell specific productivity decreases with 
subsequent generations. To overcome this issue, several episomal TGE systems have 
been developed that allow autonomous replication of the recombinant plasmid within 
mammalian cells. A widely used system is the Epstein-Barr virus (EBV) nuclear antigen 1 
(EBNA1), which consists of cells constitutively expressing the EBNA1 protein combined 
with an expression vector containing the EBV origin of replication (OriP) for plasmid 
retention. Other episomal systems include the SV40 large T-antigen and the Py large-T 
antigen (Epi-CHO), where the former supports the episomal amplification of plasmids 
containing the SV40 OriP, while the latter supports the amplification of plasmids containing 
the Py virus and EBV OriPs (Kunaparaju et al., 2005; Piechaczek et al., 1999).  
The ability of plasmids containing OriP to be maintained stably in antigen-positive 
cells makes such systems very efficient. For example, EBNA1 has a specific binding ability 
to the OriP, and with its ability to anchor EBV plasmid to chromosomal site, allows the 
plasmid to mediate replication and (non-random) segregation of the episome during 
division of the host cell. However, as EBNA1 is the only EBV protein necessary for plasmid 
maintenance but lacks any enzymatic activities (e.g. DNA helicase), the replication is 
mainly performed by the host cell replication apparatus (Van Craenenbroeck et al., 2000; 
Yates et al., 1985). This is consistent with studies which demonstrated that the total EBV 
chromosome did not require the replication-initiation function of OriP in latently infected 
proliferating cells. Therefore, the vital function of EBNA1 would be the maintenance 
(segregation) of the circular EBV chromosome, most likely in concurrence with the 
extrachromosomal maintenance function of OriP (Lee et al., 1999; Little et al., 1995). 
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Several investigators observed that the expression of a number of ER chaperones were 
upregulated under stressful culture conditions where recombinant protein productions were 
enhanced (Dorner et al., 1989; Mazzarella et al., 1994). More recently, functional 
proteomic profiling of MAb-producing NS0 cell lines with varying production rate revealed a 
positive relationship between qP and the relative abundance of various molecular 
chaperones and foldases including immunoglobulin binding protein (BiP), protein 
disulphide isomerase (PDI) and endoplasmin (Dinnis et al., 2006; Smales et al., 2004; 
Stansfield et al., 2007). Similarly, high-producing CHO cells (Carlage et al., 2009) and 
HEK293 cells (Jones et al., 2005) were also found to have elevated expression of BiP. 
These observations show that high-level recombinant protein production links to 
upregulation of the ER-resident proteins involved in protein folding and secretion. 
As such, the most ordinary strategy in secretion engineering to date has been one 
involving overexpression of ER chaperones like BiP and PDI (Table  2.2) which catalyses 
intra- or intermolecular disulphide bond formation. Unfortunately, while such an approach 
effectively increases heterologous protein production in insect cells (Ailor and Betenbaugh, 
1998; Hsu and Betenbaugh, 1997) and yeast (Shusta et al., 1998; Smith et al., 2004), 
genetic upregulation of discrete chaperones in mammalian cells to increase qP has not 
always been successful. For example, BiP overexpression in mammalian cells has been 
reported to generically decrease the secretion of recombinant proteins it associates with 
(Borth et al., 2005; Dorner and Kaufman, 1994; Dorner et al., 1988; Dorner et al., 1992). 
Accordingly, the reduction of the amount of endogenous BiP, rather than its 
overexpression, was found to improve secretion of proteins in CHO and BHK cells (Brown 
et al., 2011; Dorner et al., 1988). Similarly, inducible overexpression of PDI did not improve 
antibody production in hybridomas (Kitchin and Flickinger, 1995) and caused reduced 
secretion of a disulphide rich Fc-fusion protein in CHO cells (Davis et al., 2000).  
Despite previously published data, oxidation reactions catalysed by PDI that are vital 
for recombinant protein folding/assembly remain a rationale target. Certainly, specific 
reaction steps could limit the rate of folding of particular proteins (especially multimeric, 
difficult-to-express molecules) more than others. More recent reports by Mohan et al. 
(2007), Pybus et al. (2014a) and Borth et al. (2005) had specifically shown that PDI 
overexpression in CHO cells increased qP by 15‒40%, where the latter specifically 
showed that this was achieved by decreasing intracellular retention of MAb heavy chain 
polypeptides. Additionally, the active site of PDI contains disulphides that become reduced 
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Table ‎2.2: Examples for co-overexpression and down-regulation of molecular chaperones and foldases in mammalian cells. 
Host System Molecule Recombinant protein Results (titre) Reference 
BHK Stable BiP Human factor VIII 50% decrease Brown et al. (2011) 
BHK Stable BiP down-regulation Human factor VIII 2-fold increase Brown et al. (2011) 
BHK Stable BiP Procine factor VIII No effect Brown et al. (2011) 
BHK Stable BiP down-regulation Procine factor VIII 1.3-fold increase Brown et al. (2011) 
CHO Stable BiP MAb 35% decrease Borth et al. (2005) 
CHO Stable BiP M-CSF 10–50-fold increase Dorner et al. (1992) 
CHO Stable BiP Von Willebrand factor 3–4-fold increase Dorner et al. (1992) 
CHO Stable BiP Factor VIII 5–30-fold increase Dorner et al. (1992) 
CHO Stable BiP down-regulation Mutant tPA 2–3-fold increase Dorner et al. (1988) 
CHO Stable BiP Firefly luciferase Decreased secretion Dorner and Kaufman (1994) 
CHO Transient BiP MAbs 0.9–1.5-fold change Pybus et al. (2014a) 
CHO Stable BiP Antibody 2-fold increase Nishimiya et al. (2013) 
CHO Stable Calnexin and calreticulin Thrombopoietin 1.9-fold increase Chung et al. (2004) 
CHO Transient CypB MAbs 0.8–1.3-fold change Pybus et al. (2014a) 
CHO Stable SRP14 MAbs Increased secretion Le Fourn et al. (2014) 
CHO Stable ERO1Lα and XBP1s MAbs 5.3–6.2-fold increase Cain et al. (2013) 
CHO Transient ERO1L Antibody 37% increase Mohan and Lee (2010) 
CHO Transient ERO1L and PDI Antibody 55% increase Mohan and Lee (2010) 
CHO Stable PDI Thrombopoietin No effect Mohan et al. (2007) 
CHO Stable PDI Antibody 15–27% increased secretion Mohan et al. (2007) 
CHO Transient PDI MAbs 0.7–1.1-fold change Pybus et al. (2014a) 
CHO Stable PDI MAb 37% increase Borth et al. (2005) 
CHO Stable PDI Interleukin 15 No effect Davis et al. (2000) 
CHO Stable PDI TNFR:Fc Decreased secretion Davis et al. (2000) 
CHO Stable PDI MAb No effect Hayes et al. (2010) 
COS-1 Transient ERO1Lβ Antibody 1.5-fold increase Nishimiya et al. (2013) 
COS-1 Transient PDI Antibody 2-fold increase Nishimiya et al. (2013) 
Rat hepatoma Transient PDI Apolipoprotein B 37% increased secretion Grubb et al. (2012) 
Rat hepatoma Transient ERp57 Apolipoprotein B 33% decreased secretion Grubb et al. (2012) 
Rat hepatoma Transient ERp72 Apolipoprotein B 33% decreased secretion Grubb et al. (2012) 
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Table ‎2.3: Examples for co-overexpression of UPR and anti-apoptotic proteins in mammalian cells. 
Host System Molecule Recombinant protein Results (titre) Reference 
BHK Stable HBx Antibody 5.3-fold increase Jin et al. (2010) 
BHK Stable XBP1s Antibody 2.3-fold increase Jin et al. (2010) 
BHK Stable XBP1s and HBx Antibody 14-fold increase Jin et al. (2010) 
CHO Stable ATF4 Human antithrombin III 2-fold increase Ohya et al. (2008) 
CHO Stable ATF4 MAb 2.4-fold increase Haredy et al. (2013) 
CHO Transient ATF6c MAbs 0.8–1.5-fold change Pybus et al. (2014a) 
CHO Stable Bcl-2 Antibody 2–3-fold increase Kim and Lee (2000) 
CHO Transient Bcl-xL Fusion protein 70–270% increase Majors et al. (2008) 
CHO Stable Bcl-xL ErbB2 Increased expression O'Connor et al. (2009) 
CHO Stable Bcl-xL EPO No effect Kim et al. (2011b) 
CHO Stable Bcl-xL EPO 10–30% increase Han et al. (2011) 
CHO Stable Bcl-xL MAb 90% increase Chiang and Sisk (2005) 
CHO Stable 30Kc6 MAb 3.8-fold increase Wang et al. (2012) 
CHO Stable GADD34 Human antithrombin III 1.4-fold increase Omasa et al. (2008) 
CHO Transient XBP1s MAb 28% increase Codamo et al. (2011) 
CHO Stable XBP1s and ERO1Lα MAbs 5.3–6.2-fold increase Cain et al. (2013) 
CHO Transient XBP1s MAbs 0.8–1.7-fold change Pybus et al. (2014a) 
CHO Stable XBP1s SEAP 6-fold increase Tigges and Fussenegger (2006) 
CHO Stable XBP1s Secreted α-amylase 4-fold increase Tigges and Fussenegger (2006) 
CHO Stable XBP1s MAb 1.4-fold increase Becker et al. (2008) 
CHO Stable XBP1s MAb 1.4-fold increase Becker et al. (2010) 
CHO Stable XBP1s and XIAP MAb 2.1-fold increase Becker et al. (2010) 
CHO Stable XBP1s MAb No effect Ku et al. (2008) 
CHO Transient XBP1s EPO 2.5-fold increase Ku et al. (2008) 
CHO Transient XBP1s Factor VIII No effect Campos-da-Paz et al. (2008) 
COS-1 Transient CHOP (GADD153) Antibody 2-fold increase Nishimiya et al. (2013) 
HepG2 Transient XBP1s Factor VIII No effect Campos-da-Paz et al. (2008) 
NS0 Stable XBP1s MAb No effect Ku et al. (2008) 
NS0 Stable XBP1s Interferon γ No effect Ku et al. (2008) 
NS0 Transient XBP1s EPO 2-fold increase Ku et al. (2008) 
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during catalysis and their reoxidation is thought to be catalysed by the oxidoreductase 
enzyme ER oxidoreductin 1 (ERO1; Sevier and Kaiser, 2006). ERO1 overexpression 
therefore may create an altered oxidising environment suitable for MAb (or other 
disulphide-containing proteins) production within the CHO cells (Cain et al., 2013). 
 
 
Given the complexity of mammalian cellular regulation, engineering a single component of 
protein folding may not always lead to the desired results especially if the secretory 
pathway suffers from several limitations (Delic et al., 2014). A strategy that can modulate 
the secretory machinery in a more global manner holds promise to increase concentrations 
of several chaperones in a functionally meaningful ratio. Accordingly, basic leucine zipper 
(bZIP) transcription factors ATF4 (activating transcription factor 4), ATF6 (activating 
transcription factor 6) and XBP1 (X-box binding protein 1) can be more effective gene 
targets compared to particular ER chaperones (Table  2.3). XBP1 for example is a key 
regulator of the UPR where expression of the protein induced a wide spectrum of secretory 
pathway genes including BiP and PDI (Lee et al., 2003). XBP1 is also known to physically 
expanded the endoplasmic reticulum and the Golgi compartments, resulting in an increase 
in the overall production capacity (Shaffer et al., 2004; Tigges and Fussenegger, 2006). 
Several recent approaches have been described to introduce heterologous XBP1 
into mammalian host cells resulting in higher production rates of various recombinant 
protein products (Becker et al., 2008; Ku et al., 2008; Pybus et al., 2014a). It is interesting 
to note that the study of Ku et al. (2008) highlighted that overexpression of XBP1s had no 
detectable effects on EPO productivity in stable CHO cell lines but significantly enhanced 
transient production in EPO-saturated CHO cells. Pybus et al. (2014a) on the other hand 
had shown, using a panel of difficult-to-express MAbs, that the effects of XBP1s were 
more pronounced in cells with limiting folding and assembly reactions, and that no effect 
was observed with an easy-to-express (ETE) MAb. Together, these data suggest that 
overexpression of XBP1 can be more beneficial when the accumulated level of the 
nascent recombinant polypeptide exceeds the secretory capacity of host cells. 
Overexpression of UPR transcription factors AFT4 and its target CHOP and GADD34 have 
also been reported to positively affect recombinant protein production—likely by promoting 
translation through dephosphorylation of eIF2α, thereby enhancing the protein secretion 
(Nishimiya et al., 2013; Ohya et al., 2008; Omasa et al., 2008). 
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Despite the positive effects, induction of apoptosis upon transfection of the UPR-
related genes could be a drawback for this cell engineering strategy (Becker et al., 2010; 
Pybus et al., 2014a). Becker et al. (2010) overcame this issue by co-expressing the 
caspase-inhibitor x-linked inhibitor of apoptosis (XIAP) with XBP1s, resulting in both 
improved qP and CHO cell survival. Similarly, apoptosis induced by various stresses such 
as hyperosmolarity, nutrient depletion and chemicals (e.g. DMSO and butyrate) can be 
suppressed by overexpression of B-cell lymphoma 2 (Bcl-2) or its Bcl-xL counterpart, 
leading to extended culture longevity and higher recombinant protein production (Chiang 
and Sisk, 2005; Kim and Lee, 2000; Majors et al., 2008). Bcl-2 and Bcl-xL proteins, both 
commonly known to be apoptotic inhibitors, are also thought to play a vital function in 
autophagy through inhibitory interaction with Beclin-1 protein (Levine et al., 2008; 
Thorburn, 2008). 
 
 
 
Mathematical models are beneficial in elucidating biological phenomena (O'Callaghan et 
al., 2010; Stockholm et al., 2007), organising disparate information such as in the case of 
high-throughput data (Hatzimanikatis et al., 1999; Schilling et al., 1999) or rationally 
identifying optimal strategies to improve a production process (Kontoravdi et al., 2007; 
Pybus et al., 2014a). Reported models in the literature show various degrees of biological 
process and mathematical complexity, though in mammalian cell culture substantial works 
are directed towards kinetic modelling. A kinetic model is usually represented by a set of 
differential mass balance equations that are integrated over time, either to a pre-defined 
time duration or a steady state. Kinetic models therefore can account for dynamic 
behaviour and are able to represent the complex biochemistry of cells in a more complete 
way (Almquist et al., 2014). 
Conventionally cell culture models can be divided into two categories, namely, 
"unstructured" and "structured" models (Figure  2.1). The former describes culture 
dynamics encompassing cell growth/death, nutrient consumption, metabolite production 
and recombinant protein synthesis, and their dependence on various culture environmental 
factors (Jang and Barford, 2000; Pörtner et al., 1996). In contrast, the latter is based on 
single cell behaviour and attempt to explicitly describe the detailed phenomena of 
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intracellular metabolism (Bibila and Flickinger, 1991; McKinney et al., 1995). The 
unstructured and structured models can be further categorised into "unsegregated" or 
"segregated" biophases (Figure  2.1) where the latter can be applied for population balance 
modelling (Kromenaker and Srienc, 1994; Lee et al., 1991). In the recent years, several 
hybrid models for MAb production have been also developed in which the unstructured 
model of average cell population behaviour is linked to the structured synthetic model of 
MAb (Ho et al., 2006; Kontoravdi et al., 2005). 
 
 
Figure ‎2.1: Model classification for cell culture systems. The term ―structured‖ designates a 
formulation in which the cellular model is composed of multiple components (e.g. endoplasmic 
reticulum vs. Golgi complex), while the term ―segregated‖ indicates explicit accounting for the 
existence of heterogeneous cell variants within a population (e.g. producing vs. non-producing 
cells). Adapted from Bailey (1998) and Sidoli et al. (2004). 
Once a model is developed, they may be used for understanding and predicting the 
effects of adding, removing, or modifying molecular components of a mammalian cell 
factory, as well as for supporting/optimising the design of a culture process (e.g., feed 
strategies, medium formulation). With respect to the former, the analysis of fundamental 
cellular or metabolic processes and their ensuing elucidation (Karra et al., 2010; 
O'Callaghan et al., 2010) may lead to the design of more efficient cell culture systems, 
both from a bioprocess control and cell engineering perspectives. Importantly, several 
recent studies have successfully tested in silico predictions by implementing the suggested 
process engineering (Kiparissides et al., 2011; Kontoravdi et al., 2010) or cell engineering 
(Ho et al., 2012; Pybus et al., 2014a) strategies in vivo, resulting in improved recombinant 
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protein production. However, compared to chemical processes, biotechnology processes 
involve numerous reactions of the host cells with many of them being unknown or too 
complex for model application. Therefore, challenges still remain before kinetic modelling 
reaches the level of maturity to be a routine practice in the bioindustry. 
 
 
Traditionally, experiments are conducted to establish the effect of a single input factor 
upon one output response―known as one-factor-at-a-time (OFAT) method. The design-of-
experiment (DOE) technique develops models in a systematic way in order to obtain the 
maximum information from an experimental apparatus being modelled whilst minimising 
the number of experiments (i.e., time and resources) required (Franceschini and 
Macchietto, 2008). Several types of DOE methodology exist, each one has specific 
functions and benefits. Among the commonly used methodology in process development 
are factorial designs and response surface designs. The former are used for screening the 
factors affecting the responses, as well as for identifying the effects of interactions 
between the factors. On the other hand, the response surface methodology (RSM) 
consists of more advanced DOE designs aimed at mapping responses across a defined 
range of input factors (Figure  2.2). Thus, the designs capable of predicting the responses 
of a given coordinate of the design space that is not experimentally tested (Mandenius and 
Brundin, 2008). 
Despite the obvious benefits, the DOE methodology is not fully adopted in the 
bioindustry. A recent report, for example, showed that only about 5% of all biological 
assays were developed using DOE approach, even though the general anticipation was 
that considerable cost reduction (3X) could be achieved by employing DOE. The lack of 
use of the DOE method is mainly due to two reasons. Firstly, many biologists are not well 
familiarised with the technique which involves complex statistics, even with the help of 
statistical packages. Secondly, the significantly more complex biological processes 
compared to chemical processes lead to many researchers believing that DOE methods 
can lead to "illogical" biological recommendations (Comley, 2009). Nevertheless, reports 
have shown that the FDA actively encourages biopharmaceutical companies to adopt a 
DOE driven methodology towards process development and validation including in its 
Process Analytical Technology (PAT) initiative (Baseman, 2012; FDA, 2004). 
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Figure ‎2.2: Response surface methodology (RSM) for three factors with three levels 
using the Box-Behnken and central composite designs. By conducting experiments at the 
designated points, RSM allows navigation inside and around the design space to study effects 
of interactions between the factors, and identify combinations of factors for optimal response(s). 
The centre point provides the estimation of curvature and pure error and axial points that allow 
accurate modelling of the process responses. For central composite design, the distance of the 
axial points from the centre point can vary and specify the nature of the experiment.  
One common use of DOE in the production of recombinant proteins from mammalian 
cells is the optimisation of basal variables underpinning PEI-mediated transfection (Bollin 
et al., 2011; Daramola et al., 2014; Mozley et al., 2014; Thompson et al., 2012). The 
method enables the identification of optimal transfection conditions for high transfection 
efficiency and minimal polyplex cytotoxicity, and reveals that choice of host cell line is a 
critical parameter that should rationally precede the transient production platform. Other 
applications of DOE in process development include the optimisation of medium 
formulations to increase cell growth and production (Chun et al., 2003; Jiang et al., 2012; 
Kim and Lee, 2009; Sandadi et al., 2005) as well as the investigation of the combined 
effects of medium components on MAb N-glycan processing (Grainger and James, 2013). 
Such applications could further boost the multi-gram titres currently obtainable in the 
bioindustry and at the same time achieve high product qualities. Additionally, the DOE 
methodology has also been shown to be valuable in assessing scaled down culture 
systems such as cultiflask (Strnad et al., 2010) and microbioreactor (Legmann et al., 2009) 
as high-throughput tools for process development. 
 
 
Very low productivity is often associated with DTE recombinant proteins produced in 
mammalian cells. In Chapter 4, the Sp35:Fc cellular production is first studied to identify 
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the limiting processes, and the impact on the UPR and protein aggregation. The study 
provides a detailed understanding of the cellular constraints normally associated with DTE 
protein, whilst the data obtained enables the identification of rationale engineering targets 
to improve the production process. In Chapter 5, we subsequently utilise mathematical 
modelling approach to systematically and quantitatively describe the cellular kinetics and 
evaluate the relative impact of each cellular process. A model framework for Sp35:Fc 
synthesis and secretion processes is developed based on the empirical data obtained in 
Chapter 4. The in silico analysis reveals cell functions in maintaining cellular homeostasis 
and importantly predicts the relative significance of different engineering targets. 
In Chapter 6, we explore the possibility of exploiting the genetic and functional 
heterogeneity within the CHO cell population for improved Sp35:Fc production by isolating 
numerous clonal variants. The phenotypic/functional variations are characterised at 
different generations over prolonged culture, leading to the identification of several clones 
with inherent, superior characteristics for Sp35:Fc production. The data provides important 
knowledge for CHO host cell choice to express difficult to produce recombinant proteins. 
Chapter 7 describes a novel vector engineering approach specifically beneficial for DTE 
protein production. The system incorporates ER stress elements into the SV40 vector and  
manipulates endogenous and exogenous UPR transactivors. We show that the synthetic 
amplifier circuit produced a dynamic recombinant protein expression that permits rapid cell 
growth and high Sp35:Fc production in fed-batch culture.  
In order to resolve the Sp35:Fc expression bottlenecks, Chapter 8 investigates the 
effects of various cell and process engineering strategies including the co-expression of 
functional proteins and treatment of cells with chemical chaperones. The interactions 
between different strategies are also studied including using DOE methodology. Based on 
the preliminary data, we formulate integrated cell and process engineering strategies for 
fed-batch culture in which up to a six-fold increase in volumetric titre was achieved. 
Additionally, the integrated strategies are tested on two clones obtained in Chapter 6 as 
well as on the production of SEAP as a model ETE protein. In the final chapter of this 
thesis (Chapter 9), work within previous chapters is summarised as a whole, followed by a 
brief description on the prospect of future work. 
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The materials and methods used for experiments described throughout this thesis are described 
in this chapter. All materials used were of the highest purity available, unless otherwise stated.  
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The plasmid vector pCMV SEAP2-Control (Appendix A) encoding secreted alkaline 
phosphatase (SEAP) under the control of a CMV promoter was provided by Dr Nathan 
West. The plasmid was modified from pSEAP2-Control vector (Clontech, Mountain View, 
CA) which originally used SV40 promoter as described in West (2014). 
 
 
 
A CHO-S cell line was provided by Biogen Idec (Cambridge, MA). The cells were cultured 
in CD CHO medium (Life Technologies, Paisley, UK) supplemented with 8 mM L-
glutamine (Life Technologies) within Erlenmeyer shake flasks (Corning Incorporated, 
Acton, MA) maintained at 37°C under 5% CO2 and shaken at 140 rpm. Cells were seeded 
at 2×10
5
 viable cells mL
-1
 and were sub-cultured every 4 days, unless otherwise stated. 
Spent medium was removed by pelleting the cells using centrifugation at 200×g for 5 min. 
Cell culture viability and viable cell concentration were measured using a Vi-CELL™ Cell 
Viability Analyser (Vi-CELL XR; Beckman Coulter, Brea, CA) using Dulbecco's phosphate 
buffered saline (DPBS; Life Technologies) as diluent where necessary. The 
growth/proliferation rate (µ; day
-1
) and the integral of viable cell density (IVCD; cell day mL
-1
) 
were determined using Equations 3.1 and 3.2, respectively: 
µ =
ln(𝑋2/𝑋1)
Δ𝑡
                                                                                                                       (3.1) 
IVCD =  
𝑋2 + 𝑋1
2
× Δ𝑡 + IVCD2−1                                                                                (3.2) 
where X2 and X1 are the viable cell concentration at second time point and first time point, 
respectively, and t is the time. 
 
 
Cells were harvested at mid-exponential culture (day 4), centrifuged at 200×g for 5 min 
and supernatant was removed. Cell pellets were re-suspended in cold culture media 
supplemented with 10% v/v dimethyl sulfoxide (DMSO; Sigma-Aldrich, Poole, UK) to 
6.67×10
6
 cells mL
-1
 at 1.5 mL per vial. Cryovials were frozen to –80°C for 24 h before 
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transferring to cryostats containing liquid nitrogen (–196°C) for long term storage. Cells 
were brought up from liquid nitrogen storage by thawing the cells in a waterbath at 37°C 
and resuspending in warmed culture media. 
 
 
 
1% w/v agarose gel was used to visualise or separate DNA fragments of different sizes. 
Each gel block was prepared by dissolving 0.4 g of agarose into 40 mL of 1X TBE buffer 
by heating the mixture up, followed by the addition of 10 μL of ethidium bromide. After the 
gel was set, 100–500 ng of DNA was loaded into each well using 5X loading buffer (Bioline 
Reagents, London, UK) with a final volume of 10 μL. Nuclease-free water (Qiagen, 
Crawley, UK) was used as diluent where necessary and HyperLadder™ I (Bioline 
Reagents) was used as a molecular weight marker. The gels were run at a constant 
voltage of 110 V for 1.5 h and then visualised using a UV transilluminator (ImageQuant™-
RT ECL™ Imager; GE Healthcare, Amersham, UK). 
 
 
The Sp35:Fc gene was provided by Biogen Idec and inserted into pcDNA™3.1(+) vector 
(Life Technologies) at the NheI and EcoRI restriction sites. Briefly, digestion was 
performed on the GeneArt® pMA cloning plasmid containing the Sp35:Fc gene and the 
pcDNA3.1 vector at NheI and EcoRI restriction sites using the respective enzymes and 
Buffer C from Promega (Southampton, UK) according to the manufacturer's protocol. The 
Sp35:Fc gene was separated from the pMA plasmid backbone and the linearised 
pcDNA3.1 vector was separated from the small DNA fragment using gel electrophoresis. 
The Sp35:Fc gene and linearised pcDNA3.1 vector were extracted from the gel slices 
using QIAquick® Gel Extraction Kit (Qiagen) according to the manufacturer‘s protocol. The 
Sp35:Fc gene was then inserted into the linearised pcDNA3.1 vector by NheI and EcoRI 
sticky-sticky ligations using T4 DNA ligase (Promega) according to the manufacturer's 
protocol. To verify the plasmid construct (Figure 3.1), the purified product (see below) was 
subjected to single and double digests followed by gel electrophoresis prior to 
visualisation. The recombinant gene insert was confirmed by DNA sequencing using nine 
sequencing primers designed using Vector NTI® software (Life Technologies). 
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Figure ‎3.1: pcDNA3.1 plasmid vector containing the Sp35:Fc gene. The Sp35:Fc protein is 
encoded under the control of a CMV promoter. 
 
Plasmid DNA was transfected into E. coli MAX Efficiency® DH5α™ competent cells (Life 
Technologies) according to the manufacturer's instructions and successful transformants 
were selected by spreading the cells on LB agar (Fisher Scientific, Loughborough, UK) 
containing 100 µg mL
-1
 ampicillin. A single colony was picked and inoculated in 5 mL LB 
broth containing ampicillin and incubated for 8 h at 37°C and 250 rpm. Following 
amplification, the plasmid was purified using the QIAGEN® Plasmid Maxi Kit (Qiagen) 
according to the manufacturer‘s instructions and stored in TE buffer pH 8.0 (Sigma-Aldrich, 
Poole, UK) at ‒20°C. Plasmid DNA concentration (ng µL-1; Equation 3.3) was determined 
by measuring the A260 and the purity was determined via the A260/A280 ratio using a 
Biomate 3 Spectrometer (Thermo Scientific, Cramlington, UK). For accurate 
spectrophotometric DNA quantification, the A260 readings were taken in the range of 0.4 
and 0.6 absorbance unit using Nuclease-free water (Qiagen) as diluent. To control the 
purity of the DNA, only preparations with a ratio of greater than 1.8 were used. 
DNA conc.  =  50 ×  A260 × dilution factor                                                                  (3.3) 
 
 
The plasmid DNA copy number per nanogram of a given vector was determined from its 
length using the following equation; 
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Number of copies =   
amount  ng × 𝑁A
length (bp)  × 650 × 109
                                                          (3.4) 
where NA is the Avogrado's number (6.022×10
23
 molecules mol
-1
), 650 is the average 
weight of a base pair in g mol
-1
 (Dalton), and 10
9
 is unit the conversion from gram to 
nanogram. 
 
 
 
Electroporation-mediated transfection was conducted using the Amaxa® Cell Line 
Nucleofector® Kit V system (Lonza, Basel, Switzerland). Cells were seeded at 1.5×10
5
 
viable cells mL
-1
 and were sub-cultured every 2 days for 2 passages prior to transfection. 
Transient transfection was conducted at Day 2 of culture when the cell density was <1×10
6
 
cells mL
-1
. 4.5×10
6
 cells per cuvette were centrifuged at 100×g for 8 min. Cell pellets were 
resuspended in the Nucleofector solution and transfected with up to 4.6 µg plasmid DNA 
using programme U-024. Immediately after electroporation, cells were diluted in 700 µL of 
culture medium and transferred to a TubeSpin (TPP, Trasadingen, Switzerland) containing 
10 mL pre-warmed culture medium at a seeding density of 2.5×10
5
 cell mL
-1
. To scale up, 
samples from 3 cuvettes were pooled and cultured in a 125 mL Erlenmeyer flask. After 1‒2 
h of incubation at 37°C and 5% CO2, sample was taken to determine cell viability and anti-
clumping agent (Life Technologies) was added at 1:200 dilution. To determine the 
transfection efficiency, 4.5×10
6
 cells were transfected with 1–4 µg of pmaxGFP® vector 
(Lonza) using the same procedure and analysed using flow cytometry. 
 
 
Lipofectamine-mediated transfection was conducted using Lipofectamine® LTX with 
PLUS™ reagent (Life Technologies). One day before transfection, cells were sub-cultured 
at a seeding density of 3.7×10
5
 cells mL
-1
 in CD-CHO supplemented with 8 mM glutamine 
in 1 L Erlenmeyer flask. The cells were grown for 24 h to a density of 1.0×10
6
 cells mL
-1
 
and aliquots of 25 mL were added to each 125 mL Erlenmeyer flask. For each transfection, 
20 µg of plasmid DNA was diluted in 1.2 mL Opti-MEM® I Reduced Serum medium (Life 
Technologies) with 20 µL PLUS reagent, and then combined with 70 µL Lipofectamine pre-
diluted in 1.2 mL Opti-MEM® medium. The Lipofectamine/DNA mixture was allowed to 
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stand at room temperature for 5 min before being added to the culture. Anti-clumping 
agent (Life Technologies) was added 24 h post-transfection at 1:200 dilution. To determine 
the transfection efficiency, cells were transfected with pmaxGFP® vector (Lonza) using the 
same procedure and analysed using flow cytometry. 
 
 
Cells were fixed with paraformaldehyde (PFA; Sigma-Aldrich) prior to flow cytometry 
analysis. 4% w/v PFA was prepared by adding 2 g PFA to 50 mL 1X PBS (Fisher 
Scientific). An aliquot of cells to be fixed were harvested by centrifugation at 200×g for 5 
minutes and washed with 1X DPBS (Sigma-Aldrich). The cells were incubated in cold 4% 
w/v PFA solution at a concentration of 1×10
7
 cells mL
-1
 for 15 minutes. After incubation, 
the cells were then centrifuged and resuspended in cold DPBS and stored at 4°C until use 
(<2 weeks). Flow cytometry was performed using Attune® Acoustic Focusing Cytometer 
(Life Technologies). A sample of 10,000 cells was measured and negative control cells 
without GFP plasmid were used to determine cellular auto-fluorescence. Data was 
analysed using Attune® Cytometric software (Life Technologies). 
 
 
 
To determine the recombinant protein titre, 0.5 mL of culture medium was filtered through 
a 0.22 µm Costar® Spin-X® Centrifuge Tube Filter (Sigma-Aldrich) by centrifugation at 
10,000×g for 5 minutes. Sp35:Fc protein concentration was measured using FastELISA® 
Human IgG Quantification Kit (RD-Biotech, Besançon, France) whereas SEAP protein 
concentration was measured using SensoLyte® pNPP Secreted Alkaline Phosphatase 
Reporter Gene Assay Kit (AnaSpec, Fremont, CA) according to the manufacturer‘s 
instruction in both cases. A PowerWave™ XS microplate reader (Bio-Tek, Bedfordshire, 
UK) was used for absorbance measurement while KC4 3.1 software (Bio-Tek) was used to 
generate the Sp35:Fc and SEAP standard curves and interpolate the recombinant protein 
concentrations (Figure  3.2). 
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Figure ‎3.2: Example of standard curves generated using ELISA-based methods. 
Absorbance measurement was used to determine the concentration of recombinant Sp35:Fc 
fusion protein (A) and SEAP (B) in culture media. For sample concentrations above 1 µg mL
-1
, 
serial dilution was performed on the samples. 
 
The daily cell-specific productivity (qP; pg cell
-1
 day
-1
) based on viable cell number, X (cells 
mL
-1
) and volumetric titre, T (pg mL
-1
) was calculated from the titre at second time point 
and first time point using the following equation: 
𝑞P =
𝑇2 − 𝑇1
 
𝑋2 + 𝑋1
2  × Δ𝑡
                                                                                                            (3.5)     
The average qP through culture was determined from the volumetric titre and IVCD as 
follows: 
𝑞P =
𝑇2−𝑇1
IVCD2−1
                                                                                                                         (3.6)     
 
 
 
For intracellular polypeptides, 5×10
6
 cells were harvested and lysed in 500 µL of RIPA 
buffer (50 mM Tris–HCl, pH 8.0, with 150 mM sodium chloride, 1.0% Igepal CA-630 (NP-
40), 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate (Sigma-Aldrich)) and 
incubated at 4°C for 10 min. Lysates were centrifuged at 8,000×g for 10 min at 4°C, 
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supernatant fractions removed and stored short-term at 4°C. For analysis of extracellular 
polypeptides, 1 mL of 0.22 µm filtered culture supernatant was stored short-term at 4°C. 
SDS-PAGE was performed using 3–8% NuPAGE® Tris-Acetate gels (Life Technologies) 
with LDS sample buffer (Life Technologies) under reducing and non-reducing conditions, 
in which the latter contained 25 mM N-ethylmaleimidine (NEM) as an alkylating agent. For 
absolute quantification method, protein samples were resolved alongside a serial dilution 
of purified Sp35:Fc protein of known concentration at constant 150 V for 1 h. Biotinylated 
protein ladder (Cell Signaling, Danvers, MA), Novex® Sharp (Life Technologies) and 
HiMark™ marker (Life Technologies) were used for estimation of molecular weights where 
the latter was stained with SimplyBlue™ SafeStain (Life Technologies) according to the 
manufacturer's instructions. 
 
 
Resolved Sp35:Fc protein samples were transferred to nitrocellulose membranes by iBlot® 
semi-dry blotting (Life Technologies) according to manufacturer‘s instructions. Each 
membrane was washed with 20 mL 1X TBS-T for 5 min and blocked in 10 mL 5% w/v 
milk/TBS-T for 1 h at room temperature. After three washings with 15 mL 1X TBS-T (5 min 
each), the membrane was incubated overnight at 4°C with HRP-conjugated goat anti-
human IgG Fc γ fragment in 10 mL 4% w/v BSA/TBS-T solution (1:20,000; Jackson 
ImmunoResearch, West Grove, PA), followed by three washings and incubation with HRP-
conjugated anti-biotin antibody in 5% w/v milk/TBS-T solution (1:1000; Cell Signaling) for 1 
h at room temperature. Finally, the membrane was washed three times to remove 
unbound antibodies prior to quantification. 
 
 
Detected polypeptides were visualised with an Immobilon™ Western chemiluminescent 
HRP substrate according to the manufacturer's instructions (ECL; Millipore, Watford, UK) 
and chemiluminescence signals collected using a CCD camera (ImageQuant™-RT ECL™; 
GE Healthcare, Amersham, UK). Western blot images were analysed using ImageQuant 
TL image analysis software (GE Healthcare) and Sp35:Fc polypeptides were quantified by 
relative quantification method or by external calibration using the band densities (known-
concentrations) of the purified Sp35:Fc standards ran on the same gel (Figure  3.3). 
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Figure ‎3.3: Example of standard curve generated by ImageQuant TL software for external 
calibration. Band densities of purified Sp35:Fc standard at different concentrations were used 
to quantify Sp35:Fc polypeptide samples. 
 
SigmaPlot 12.0 software (Systat Software, San Jose, CA) was used for statistical analysis. 
To test for linear correlation, Pearson's product moment correlation coefficient (PPMCC) 
was used. To test for statistical significance, an unpaired, two-tailed student‘s t-test was 
used. A P value of <0.05 was considered to be significant. 
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This chapter provides a detailed understanding of the cellular constraints normally associated 
with difficult-to-express protein production, as well as broader insights to the potential 
repercussions such as formation of protein aggregates. The aims are to identify the CHO cell 
constraints in manufacturing Sp35:Fc fusion protein at elevated transgene expressions, as well 
as to study the impact of the unfolded protein response. The data obtained, in turn, enable the 
identification of engineering targets to improve the production process. 
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Major successes have been achieved in the production of recombinant therapeutic 
proteins from cultured mammalian cells, particularly with monoclonal antibodies (MAbs) 
and Fc-fusion proteins. Amplification methods to increase the recombinant DNA (rDNA) 
copy number yield efficient production of many recombinant products, with typical specific 
productivities (qP) of 10 pg/cell/day a decade ago have now increased to around 50 
pg/cell/day (Butler and Meneses-Acosta, 2012). Considerable efforts have also been 
directed to targeting rDNA to transcriptionally active sites (Nehlsen et al., 2009), and to 
include chromatin opening elements (Antoniou et al., 2003). In the case of transient 
expression systems, powerful transfection method like Nucleofection (Zeitelhofer et al., 
2007) and optimisation of transfection conditions (Mozley et al., 2014; Thompson et al., 
2012) have led to very high transfection efficiency and low toxicity, thus enabling very high 
rDNA copy number delivered per cell. Transient expressions can also be enhanced by 
using post-transcriptional regulatory elements (Mariati et al., 2012). 
Nevertheless, increased transgene copy number and transcriptional and translational 
activities do not necessarily improve the amount of secreted recombinant proteins, where 
very high rDNA copy number and/or mRNA levels have been shown not to correlate to the 
increase in protein output in both stable (Barnes et al., 2004; Schröder et al., 1999) and 
transient productions (Ku et al., 2008) as well as in vivo (Takahashi et al., 2011). 
Improvements through rDNA/mRNA strategy will ultimately reach a plateau beyond which 
no increases productivity can be achieved if no concurrent improvements in post-
translational processes are made. Moreover, such strategy can easily fail for some 
particular difficult-to-express (DTE) proteins, for which even moderate levels of protein 
expression cannot be attained. In such cases, the host cells are often incapable of 
handling the folding or processing of the recombinant proteins, thus triggering cellular 
stress responses and apoptotic effects leading to reduced cell growth and/or productivity 
(Le Fourn et al., 2014; Pybus et al., 2014a).  
The secretion of proteins by mammalian cells is a complex pathway. It involves 
translocation of nascent polypeptide from the cytosol into the endoplasmic reticulum (ER) 
where they fold with various chaperones and foldases, followed by post-translational 
modifications in the Golgi complex (e.g. glycosylation) before being transported to their 
final destination. Fundamental understanding of how mammalian cells cope with high 
levels of rDNA expression are critical to further enhance the recombinant protein titres (as 
a measure of qP), and particularly to the development of new, ever increasing difficult to 
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produce recombinant proteins. In this regard, several recent reports (e.g., Le Fourn et al., 
2014; Mason et al., 2012; Pybus et al., 2014a) have provided a detailed description of 
cellular mechanisms of MAb production, which in turn provided strategies in designing 
better expression systems during the production process. On the other hand, 
comparatively little has been done to investigate the production of Fc-fusion proteins at 
cellular level, where studies on these proteins primarily focus on the aggregation 
mechanisms (e.g., Fast et al., 2009; Shukla et al., 2007; Strand et al., 2013). 
Therefore, the mechanism for a difficult-to-express Fc-fusion protein production is 
presented here to better understand the potential cellular constraints in manufacturing this 
growing class of therapeutic proteins. In this work, we used a model Sp35:Fc fusion 
protein (proprietary of Biogen Idec, USA; Figure  4.1) to study the transient expression of 
DTE Fc-fusion protein in CHO cells. The recombinant protein was developed to provide 
means of treating diseases, disorders and injuries involving demyelination and 
dysmyelination (e.g. multiple sclerosis), by the administration of an Sp35 antagonist, 
whereas the potential advantages of the Fc fusion include solubility, in vivo stability, and 
multivalency (Mi et al., 2013). The leucine-rich repeat (LRR) motif functions by interacting 
with specific receptor complex found on neurons to constitute a functional receptor for 
myelin-derived inhibitors, which in turn suppress myelination and prevent the repair of 
damaged axons. Therefore, Sp35-derived products could have therapeutic applications for 
central nervous system injury (Mi et al., 2004; Pepinsky et al., 2014). 
 
 
Figure ‎4.1: Schematic representation of homodimeric Sp35:Fc fusion protein. Each Sp35 
molecule (also designated as LINGO-1 in the literature) consists 12 leucine-rich repeat (LRR) 
motifs flanked by N- and C-terminal capping domains, 1 immunoglobulin (Ig) domain and a 
stalk, and is fused to the Fc domain (CH2 and CH3) of an IgG1 via a non-covalent bond. The 
Fc-domain is linked via a disulphide bond in the hinge region. Adapted from Mi et al. (2004). 
The Sp35:Fc fusion protein is secreted as a homodimeric molecule comprising two 
identical polypeptide chains covalently linked through interchain disulphides in the hinge 
region, with each chain consists of a therapeutic Sp35 molecule fused to the Fc domain of 
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human IgG1 via a non-covalent bond (Figure  4.1). The recombinant protein, however, is 
particularly difficult to produce with very low productivity/titre and significant product 
aggregates. Throughout this thesis, the "monomer" for Sp35:Fc protein is defined as one 
of the two identical polypeptide chains. Each chain has 10 potential N-linked and 3 
potential O-linked glycosylation sites. Additionally, each Sp35 molecule contains 12 
cysteine amino acids that could potentially form mismatched disulphide bonds (Scott 
Estes, personal communication). 
Here we examine the impact of elevated Sp35:Fc DNA loads on the transient protein 
expression by analysing the recombinant mRNA copy number, intracellular polypeptide 
content, secreted proteins, as well as the potential repercussions of protein aggregation. 
We observe that the host cells have a very restricted cellular capability in manufacturing 
the recombinant protein even at low transgene copy numbers, and that there is a specific 
threshold level that the cells are able to process nascent polypeptides in the ER without 
significantly invokes the unfolded protein response (UPR). By elucidating the core cellular 
mechanisms responsible for differential expression at varying rDNA loads, we hope to gain 
broader insight of how CHO cells regulate DTE protein production, which can then be 
utilised to design engineering strategies for improved bioproduction process. 
 
 
 
1×10
6
 cells were harvested by centrifugation at 200×g for 5 min and cell pellets were 
immediately resuspended in 300 µL of RNAprotect® Cell Reagent (Qiagen) and stored at 
–20°C. RNA was purified using the RNeasy® Plus Mini Kit (Qiagen) and genomic DNA 
(gDNA) was eliminated by using the Ambion® TURBO DNA-free™ Kit (Applied 
Biosystems, Warrington, UK) according to the manufacturer‘s instructions in both cases. 
gDNA-free RNA was converted to cDNA in a 20 µL reaction by using the High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems) and an Applied Biosystems Veriti™ 
96-well Thermal Cycler according to the manufacturer‘s instructions. The cDNA was 
quantified by quantitative real-time polymerase chain reaction (qRT-PCR) using an Applied 
Biosystems 7500 Fast Real-Time PCR system and the calibration curve method.  
Standard curves were generated using known quantities of the linearised rDNA 
plasmids as a template (Figure  4.2; Pfaffl et al., 2002). The PCR reactions were performed 
in a final volume of 20 µL using TaqMan® Universal Master Mix II with UNG (Applied 
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Biosystems), 1 µL of cDNA, 500 nM of forward and reverse primer each and 200 nM of 
probe. Primers and probes were designed using Applied Biosystems Primer Express® 3.0 
software and TAMRA and FAM dyes were used as the quencher and reporter dyes, 
respectively. Primers and probes (Eurofins MWG Operon, Ebersberg, Germany) for 
amplification and quantification of the Sp35:Fc cDNA and SEAP cDNA were as follows: 
Sp35:Fc forward primer 5'-TGCCTGGTCAAAGGCTTCTATC-3', reverse primer 5'-
GTTCTCCGGCTGCCCATT-3' and probe 5'FAM-CCGTGGAGTGGGAGAG-3'TAM; and 
SEAP forward primer 5'-CCGCTTTAACCAGTGCAACA-3', reverse primer 5'-
CCCGATTCATCACGGAGATG-3' and probe 5'FAM-ACACGCGGCAACG-3'TAM. The 
PCR thermal cycle profile was as follows: 50°C for 2 min; 95°C for 10 min; 40 cycles of 
95°C for 15 s and 60°C for 1 min. 
 
 
Figure ‎4.2: The recombinant plasmids served as an external homologous DNA standard 
of known copy number to generate a standard curve for quantitative real-time PCR. (A) 
An example of ΔRn vs. cycle number profile for 10-fold dilution series ran in duplicate. (B) The 
corresponding standard curve generated for determination of mRNA copy numbers. 
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Sp35:Fc protein was purified from cell culture supernatant and cell lysates (prepared as 
described above) using NAb™ Protein A Spin columns (Thermo Scientific) and 
concentrated by ultrafiltration using Pierce® Concentrator 20 kDa cutoff membrane 
(Thermo Scientific) according to the manufacturer‘s instructions in both cases. Protein 
samples were denatured by heating the samples in the supplied glycoprotein denaturing 
buffer at 100°C for 10 min. 0.5–1 µg of intracellular Sp35:Fc was digested with 500–1,000 
NEB units of Endo Hf (New England Biolabs, Hitchin, UK) in 40 µL total reaction volume 
using the supplied G5 reaction buffer for 1 h at 37°C. Digestion was also performed 
without prior denaturation. RNase B and secreted Sp35:Fc protein were used as positive 
and negative control, respectively, for enzyme digestions. Samples were resolved by SDS-
PAGE under reducing conditions and subjected to immunoblotting prior to imaging and 
analysis as described Chapter 3, Section 3.6. Resolved RNase B was stained with 
SimplyBlue™ SafeStain (Life Technologies) according to the manufacturer's instructions.   
 
 
Cell lysates were prepared as described above using RIPA buffer supplemented with 10 
mM NEM and Protease Inhibitor Cocktail Set III (Merck Chemicals, Nottingham, UK). 
Ubiquitinated proteins were isolated using a Ubiquitinated Protein Enrichment Kit (Merck 
Chemicals) according to the manufacturer‘s instructions. Briefly, cell lysate protein was 
incubated with polyubiquitin affinity beads at 4°C for 4 h, washed and ubiquitinated 
proteins extracted by boiling the beads in Laemmli sample buffer (Sigma-Aldrich) for 5 min. 
After centrifugation at 10,000×g for 1 min, ubiquitinated proteins in the supernatant and a 
serial dilution of Sp35:Fc standard were resolved on non-reducing SDS-PAGE and 
subjected to immunoblotting prior to imaging and analysis (Chapter 3, Section 3.6). 
 
 
Cell lysates were prepared as described above using RIPA buffer supplemented with 
Halt™ Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific) and stored at        
–80°C. Electrophoresis was carried out on 4–12% NuPAGE Bis-Tris gels (Life 
Technologies). Resolved protein was blotted and the membrane was blocked with 5% 
BSA/TBS-T for 1 h at room temperature, washed three times with 1X TBS-T (5 min each) 
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and then probed for 1 h at room temperature with anti-BiP, PDI, eIF2α, p-eIF2α, GAPDH, 
unspliced XBP1 (all 1:2000; Cell Signaling) or unspliced XBP1 (1:1000; Abcam, 
Cambridge, UK) primary antibodies. After three washings, the membrane was incubated 
with HRP-conjugated goat anti-rabbit IgG secondary antibody (1:2000; Cell Signaling) for 1 
h at room temperature, followed by three more washings to remove unbound antibodies 
prior to imaging and analysis as described in Chapter 3, Section 3.6.3.  
 
 
 
An important prerequisite for the study was to ensure that the cells were not influenced by 
the transfection procedure per se. Transfections were therefore performed by means of the 
Nucleofector system using the same batch of cells and with the same total plasmid DNA 
load, where the latter was achieved by varying the ratio of rDNA : empty vector. The 
Nucleofector system has been shown to give very high cell viability and transfection 
efficiency and uniform plasmid uptake compared to other systems such as Lipofection (e.g. 
Davies et al., 2013; Zeitelhofer et al., 2007). Cell viabilities attained post-transfection were 
90±2% with >99% transfection efficiency as analysed by flow cytometry using GFP (Figure 
 4.3). To study the intrinsic ability of the cells to manufacture recombinant Sp35:Fc, the 
cells were transfected with varying quantities of rDNA ranging from 0 to 3 µg rDNA per 
4.5×10
6
 cells and Sp35:Fc expression levels were quantified 48 h after transfection. 
 
 
Figure ‎4.3: Determination of transfection efficiency using intracellular GFP marker and 
flow cytometry. Cells were harvested 48 h post-transfection. (A) Cell population gated for 
granularity and size. (B) The percentage of GFP-positive cells of the transfected population 
(black line) was quantified against mock-transfected negative control cells (grey line). 
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Analysis of the qP revealed that the expression of Sp35:Fc did not show a linear 
response to increasing rDNA load—at high levels of gene copy number, no further 
increase in the expression level of Sp35:Fc was observed (Figure  4.4A). To substantiate 
this saturation phenomenon, transfection was also performed using SEAP which is widely 
used to study promoter activity and gene expression as a model ETE glycosylated protein. 
Comparison of the two recombinant proteins showed a clear difference in recombinant 
protein expression in which the Sp35:Fc productivity gradually became saturated as the 
rDNA load increased, whereas SEAP productivity increased linearly to a much higher rate 
(Figure  4.4B). In both cases, the mRNA copy numbers increased proportionally to rDNA 
load (Figure  4.4C), indicating that no restriction of gene expression occurred in the system 
at the level of transcription. However, the influence of transcription efficiency, size of 
plasmid and mRNA stability can be expected to introduce some variation between the 
levels of Sp35:Fc mRNA and SEAP mRNA.  
As shown in Figure  4.4A, there was also an inverse relationship between cell specific 
growth rate (µ) and qP, with the highest Sp35:Fc-producing cells had a 28% lower µ 
compared to the non-producing mock-transfected cells. This however, was less apparent 
in the case of SEAP-producing cells even at high qP (Figure  4.4B), implying that the 
Sp35:Fc synthesis imposed a substantial metabolic burden onto the cells. For both 
Sp35:Fc and SEAP-producing cells, the analysis of cell diameter and cell protein biomass 
by image analysis and biochemical assay, respectively, showed that there were no 
significant variations in average cell size and total intracellular protein content per cell (P > 
0.05; data not shown), suggesting that there was neither change in cell morphology nor 
inhibition of cell biomass accumulation. 
 
 
Quantitative Western blot analysis was carried out to assess intracellular and extracellular 
Sp35:Fc polypeptides per unit cell at different rDNA expressions. To inhibit artefactual 
disulphide bond scrambling, protein samples (culture supernatant and cell lysates) were 
treated with the alkylating agent NEM during sample buffer preparation (Taylor et al., 
2006). Assignment of bands to particular Sp35:Fc protein species was achieved by 
comparison of the apparent molecular weight following non-reducing SDS-PAGE. Tris-
acetate gels were calibrated with HiMark and Novex Sharp molecular mass standards in 
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Figure ‎4.4: Recombinant protein production kinetics in CHO cells at different transgene 
copy numbers. (A) 4.5×10
6
 CHO-S cells were transiently co-transfected with Sp35:Fc plasmid 
DNA and empty vector at varying ratios (3 µg total plasmid DNA). Cell-specific productivity (qP) 
and growth rate (µ) were measured at 48 h after transfection while post-transfection cell viability 
was measured at 2 h after transfection. (B) Similar transfection procedure and analysis were 
performed using SEAP plasmid DNA. (C) Copies per cell of Sp35:Fc and SEAP mRNAs at 48 h 
post-transfection were determined by absolute quantification RT-PCR. Data shown is mean 
value of two biological replicates and three technical replicates. Error bars represent the 
standard deviation. 
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the 40‒500 kDa and 30‒260 kDa ranges, respectively, and biotinylated protein ladder 
(30‒200 kDa) for resultant blots. Combination of these calibrations allowed a highly 
reliable estimation of the molecular weights of very large species (Hannemann et al., 
2009). Using this approach the Sp35:Fc protein was observed to have an apparent mass 
of approximately 100 kDa per monomer and 200 kDa per native dimer under non-reducing 
conditions (Figure  4.5). Additionally, the intra- and extracellular Sp35:Fc polypeptides 
resolved were found to contain tetramer (400 kDa) and (likely) hexamer aggregates (600 
kDa). Other aggregate species were not observed, specifically trimer and pentamer, as 
well as higher oligomers (e.g., octamer). Under reduced condition, all bands were reduced 
to 100 kDa, indicating that the fully folded Sp35:Fc dimer as well as the aggregates were 
covalently bonded via intermolecular disulphide bridges. To rule out that Sp35:Fc self-
aggregated extracellularly in the culture medium, cell culture supernatant was harvested 
24 h post-transfection, incubated at 37°C for an additional 24‒48 h and immediately 
resolved by non-reducing SDS-PAGE. No increase in protein aggregates was observed 
during the additional incubation period (data not shown). 
 
 
Figure ‎4.5: Western blot analysis of extracellular and intracellular Sp35:Fc polypeptides 
at different rDNA transfections. Sp35:Fc has an apparent mass of 100 kDa per monomer and 
200 kDa per native dimer and may form 400 kDa tetramer and 600 kDa hexamer disulphide-
bonded aggregates. Other aggregate species were not detected. Culture supernatant and cell 
lysate samples were prepared 48 h post-transfection and resolved by non-reducing SDS-PAGE 
in the presence of the alkylating agent NEM to inhibit disulphide bond reduction and scrambling. 
Under reduced condition, all bands were reduced to 100 kDa monomer. The figure shows a 
representative Western blot of duplicate culture flasks analysed in triplicate. 
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The amount of each Sp35:Fc polypeptide species in Figure  4.5 was determined by 
comparing the relative band intensity obtained with anti-IgG Fc γ specific primary antibody. 
Thin 1.0 mm 3–8% polyacrylamide gels were used in this study to ensure the highest gel-
to-membrane transfer efficiency of the high molecular weight species. Western blot was 
calibrated using purified Sp35:Fc (native dimer) over a range of concentrations run on the 
same gel as an external standard. Purified Sp35:Fc was also added to non-Sp35:Fc 
producing CHO-S cell lysates as an internal standard to verify that no disulphide reduction 
or rearrangement occurred during sample processing. Under the conditions employed, no 
artefactual loss of dimer (i.e. formation of monomer from dimer) or formation of aggregates 
was observed (data not shown).  
From the quantitative Western blot analysis, the cell-specific production rate of each 
extracellular protein species was calculated using Equation 3.6 (Figure  4.6A), whilst 
analysis of the intracellular species were carried out in terms of polypeptides copies per 
unit cell (Figure  4.6B). With respect to the former, determination of qP using this method 
was highly comparable to orthogonal analysis of Sp35:Fc productivity by ELISA in Figure 
4.4A. Both the extracellular and intracellular quantification analyses (Figure  4.6A and B) 
revealed that the amount of protein aggregates per cell became significant at high rDNA 
loads. The composition of extracellular tetramer aggregate in Figure  4.6A for example rose 
from less than 0.5% w/w of the total Sp35:Fc at 0.5 µg rDNA to about 5% w/w at 3 µg 
rDNA load. There were also marked increases in the amount aggregates at 1 µg rDNA 
load which concurred with the saturation of Sp35:Fc production. 
Moreover, the 2-fold increase in cellular content of Sp35:Fc dimer between 0.5 µg 
and 1 µg rDNA loads (Figure  4.6B) yielded in only one-third increase in dimer secretion 
rate (Figure  4.6A) which implies a limited protein transport capacity. From the intracellular 
analysis (Figure  4.6B), it is also obvious that the cells differed considerably in their 
relative proportion of Sp35:Fc intermediates when transfected with different amount of 
rDNA. The amount of assembled intracellular dimer appeared to become saturated at 1–3 
µg rDNA even though the amount of nascent monomer increased linearly—indicative of 
variation between cell translation and folding/assembly processes. With regard to the 
monomer species, the amount increased from about 1.4% w/w of total intracellular 
Sp35:Fc content (at 0.25‒1 µg rDNA) to 3.8% w/w (at 3 µg rDNA) which indicates an 
accumulation of unfolded monomer polypeptides in the endoplasmic reticulum (ER).  
To quantify the relative proportion of intracellular Sp35:Fc in different parts of the 
secretory pathway, Sp35:Fc polypeptides were isolated from cell extracts using Protein A,  
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Figure ‎4.6: Elevation of recombinant gene expression does not result in linear increase 
in Sp35:Fc native dimer and promotes formation of aggregates and retention of the 
recombinant protein in the ER. (A) Cell-specific productivity (qP) was calculated from the 
level of respective Sp35:Fc species in the supernatant determined by quantitative Western 
blotting and the viable cell density. (B) Intracellular Sp35:Fc polypeptide copy numbers per cell 
determined from whole cell lysates by quantitative Western blotting. (C) The proportion of fully 
folded intracelullar (IC) Sp35:Fc species in the latter section of the secretory system decreases 
as rDNA load increases. Secreted extracellular (EC) Sp35:Fc was used as a negative control. 
Data shown is representative of duplicate culture flasks analysed in triplicate. 
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quantitated by ELISA and subjected to treatment with Endoglycosidase H (Endo H) 
enzyme. Endo H selectively cleaves N-glycan side-chains of the high-mannose form that 
present in the ER and intermediate compartment (between the ER and cis-Golgi), whereas 
glycoproteins that are transported beyond the medial Golgi generally possess N-glycans 
that are resistant to Endo H digestion. Analysis of the treated proteins by reducing SDS-
PAGE showed that the vast majority (>97%) of the fully disulphide bonded Sp35:Fc within 
the cells was associated with high-mannose N-glycans and was located in the early 
secretory compartments (ER/intermediate compartment; Figure  4.6C). These data were 
analysed in reduced condition as Endo H sensitive and resistant high molecular weight 
proteins (dimer and other oligomers) could not be separated adequately using non-
reducing SDS-PAGE. Analysis of non-reducing SDS-PAGE however showed that the 
monomer polypeptide was entirely Endo H sensitive (data not shown), implying that this 
species did not leave the early secretory pathway. 
Figure  4.6C also shows that the proportion of high mannose to complex glycans was 
greatly increased at 1 µg rDNA onwards to nearly 100%, signifying a molecular crowding in 
the ER/intermediate compartment secretory pathway and reduction in the rate of ER-to-
Golgi transport of Sp35:Fc. This molecular crowding coincided with the saturation of 
intracellular assembled dimer and marked increase in protein aggregation (Figure  4.6B), 
suggesting that the concentration of Sp35:Fc dimer within the ER might influence the 
extent to which Sp35:Fc can be found in disulphide-bonded aggregates. Combining all 
observations made above, we infer that Sp35:Fc protein production bottlenecks were due 
to the combination of (i) limited folding/assembly capacity, which in turn catalysed 
aggregate formation, and (ii) inefficient ER export rate. 
 
 
Since there were saturation of fully-folded Sp35:Fc and retention of the protein in the ER, 
as well as significant amounts of intracellular aggregates, we compared the extent of UPR 
induction in the cells with different amounts of rDNA. Perturbations of folding process (e.g. 
accumulation of nascent polypeptides) activate the UPR pathways in an attempt to 
reinstate the homeostasis between folding load imposed on the ER and its folding 
capacity. In response to ER stress, protein ER kinase (PERK) phosphorylates eIF2α which 
inhibits general protein synthesis, whilst IRE1 splices XBP1 mRNA which is then translated 
Chapter 4 
 
62 
into an active, strong transcription factor to increase the expression of molecular 
chaperones and induce the ERAD pathway. ATF6 transcription factor is also triggered 
which produces downstream targets whose functions overlap with those of IRE1 (Chapter 
1, Figure  1.7). When a set of UPR related proteins were examined by Western blotting, all 
the proteins tested were upregulated in Sp35:Fc-producing cells compared to the non-
producing as well as SEAP producing cells (Figure  4.7A). 
Firstly, the PERK pathway activation was analysed by quantifying the relative 
abundance of phosphorylated eIF2α (p-eIF2α) over total eIF2α. Cells transfected with 
Sp35:Fc DNA showed increased phosphorylation of eIF2α with the first band observed at 
0.5 µg rDNA load (Figure  4.7A). This suggests that at 0.5 µg rDNA, there was a low-level 
UPR response to cope with the increased protein folding demand. However, the cell 
growth data in Figure  4.4A also suggested that evoking a UPR might have undesirable 
impacts upon the cells―we observed a significant reduction in cell biomass production 
rate (i.e., lower µ) in the 0.5 µg rDNA transfectants when compared with those transfected 
with 0.25 µg, potentially arising from reduced global translation. Additionally, the 
progressive PERK pathway activation (Figure  4.7B) suggests a gradual translational 
attenuation of Sp35:Fc mRNA (see Chapter 5 for quantitative analysis of the translational 
kinetics). The eIF2α phosphorylation was a consequence of PERK activation due to 
intracellular stress and did not occur via the GCN2 kinase due to lack of specific media 
component (Zhang et al., 2002) as no/insignificant bands were observed at low Sp35:Fc 
DNA load and SEAP-producing cells (Figure  4.7A). 
Secondly, the IRE1 pathway activation was analysed by measurement of the 
proportion of active spliced XBP1 (XBP1s) and inactive unspliced XBP1 (XBP1u) 
abundance. Similar to p-eIF2α, cells transfected with Sp35:Fc DNA showed increased 
splicing of XBP1 with the first band observed at 0.5 µg rDNA load (Figure  4.7A), and the 
marked increase at 1 µg rDNA (Figure  4.7B) corresponds to the saturation Sp35:Fc qP 
(Figure  4.4A). Importantly, we note that the XBP1s induction was strongly correlated to the 
upregulations of BiP (see below; Pearson‘s product moment correlation coefficient,  
PPMCC r = 0.985, P < 0.0001) and PDI (see below; PPMCC r = 0.957, P < 0.001), as well 
as to the Sp35:Fc polypeptide ubiquitination targeted for ERAD (see below; PPMCC r = 
0.997, P < 0.0001). Together, these data imply that the overexpression of Sp35:Fc 
transactivated downstream UPR signalling in an attempt to restore the ER homeostasis by 
inducing chaperone synthesis and ERAD. 
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Figure ‎4.7: Measurements of UPR induction in Sp35:Fc-producing and SEAP-producing 
CHO cells. Whole cell extracts were prepared 48 h post-transfection and subjected to Western 
blotting and probed with antibodies detecting UPR-related proteins. (A) Representative 
immunoblots of PDI (57 kDa), BiP (78 kDa), phosphorylated eIF2α (p-eIF2α; 38 kDa), total 
eIF2α (38 kDa), spliced XBP1 (XBP1s; 55 kDa), unspliced XBP1 (XBP1u; 27 kDa) and GAPDH 
(37 kDa) in Sp35:Fc and SEAP-producing cells at varying rDNA loads. GAPDH was used as a 
housekeeping protein. (B) Quantitation of p-eIF2α and XBP1s levels. Expression of total eIF2α 
was detected to serve as p-eIF2α loading controls. Percent XBP1s was calculated based on its 
respective XBP1u. (C) Relative quantitation of BiP and PDI levels.   
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Furthermore, we assessed the relative abundance of BiP and PDI, known to be 
induced by the UPR (Chakrabarti et al., 2011). BiP is the major ER chaperone and the 
regulator of the activation of three arms of ER stress transducers (PERK, IRE1 and ATF6) 
whereas PDI is an ER-based enzyme that catalyses the formation of disulphide bonds in 
secretory proteins. BiP was found to be highly expressed in the cells transfected with 
Sp35:Fc DNA compared to SEAP DNA, and was 3.6-fold more abundant in cells 
transfected with 3 µg Sp35:Fc DNA than in mock-transfected control cells (Figure  4.7A and 
C). The rapid increase from 1 µg rDNA (Figure  4.7C) coincided with the saturation in fully-
assembled Sp35:Fc and increase in aggregates (Figure  4.6B). On the other hand, 
immunoblot analysis of PDI showed a slight expression saturation at high Sp35:Fc DNA 
load, with only up to a 2.1-fold increase at 3 µg rDNA (Figure  4.7A and C). This data 
suggests that PDI could potentially be a limiting factor that was responsible for the reduced 
Sp35:Fc folding/assembly activity.  
The degradation of a protein via the ubiquitin-proteasome pathway involves the 
tagging of the protein substrate by covalent attachment of ubiquitin molecules, followed by 
degradation of the ubiquitinated protein to small peptides by the 26S proteasome complex 
(Lecker et al., 2006). Therefore, we tested if the Sp35:Fc overexpression resulted in the 
appearance of tagged Sp35:Fc protein targeted for degradation. Sp35:Fc protein 
associated with ubiquitin was examined by specific affinity adsorption of ubiquitinated 
proteins and blotting the immunoprecipitates with anti-IgG Fc γ fragment antibody (Figure 
 4.8 inset). This analysis demonstrated that both unfolded monomer and fully assembled 
Sp35:Fc were targeted for degradation, although the former was only apparent at 1–3 µg 
rDNA loads (Figure  4.8).  
As no Sp35:Fc monomer polypeptides were visualised at 0.25 and 0.5 µg rDNA 
loads even when higher concentration sample was used (data not shown), we assumed 
that the rate of Sp35:Fc degradation at these rDNA loads were negligible. In contrast, 
although no ubiquitinated Sp35:Fc aggregates were observed, it was likely that the 
aggregates were still targeted for degradation but below the detection level as the 
proportions of the high molecular weight aggregates were very small (<5%). Additionally, 
as Sp35:Fc monomer did not leave the early secretory compartment as tested by Endo H, 
the proteins targeted for degradation via the ubiquitin pathway is thought to be transported 
from the ER back into cytoplasm via ERAD retro-translocation mechanism and degraded 
by the proteasome (Ron and Walter, 2007). 
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Figure ‎4.8: Overexpression of Sp35:Fc in CHO cells led to ER-associated degradation. 
Whole cell extracts were prepared 48 h post-transfection and Sp35:Fc polypeptides targeted for 
degradation were determined by ubiquitin pull-down and immunoblotting using anti-human IgG 
Fc fragment antibody. The insert shows a representative Western blot showing the observed 
trend in Sp35:Fc polypeptide ubiquitination. Data shown is representative of two biological and 
two technical replicates. Error bars represent the standard deviation. 
 
Mammalian cells, particularly CHO cells, have proven to be invaluable for stable, high-
productions of recombinant therapeutic proteins which require various co- and post-
translational modification reactions for folding, function, stability and/or subcellular 
targeting (Walsh, 2010). However, generation of recombinantly produced Fc-fusion 
derivatives can be problematic in which the production is often limited at a post-
translational level. The main cause for that is thought to lie in the different and partially 
incompatible folding and secretion requirements of protein of interest and Fc domain 
entities in mammalian cells (Haas et al., 2012; Lee et al., 2007). To engineer mammalian 
cells to better manufacture Fc-fusion proteins or other DTE proteins with high specific 
productivity, it is essential to identify the rate-limiting step(s) in the protein production at 
elevated gene expression levels.  
Advancements in gene expression technology have successfully increased 
recombinant DNA copy number and transcriptional activity in mammalian expression 
systems (Kalwy et al., 2006). However, in practical terms cell-specific production rate can 
only be proportional to recombinant mRNA abundance to a limited extent as observed with 
many (easy-to-express) recombinant proteins including SEAP (Carpentier et al., 2007), 
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antithrombin III (Schröder et al., 1999) and MAb (Barnes et al., 2004). Similarly, our 
preliminary data showed the linear increase in SEAP qP observed in this study quickly 
broke down when the cells were transfected with more than 3 µg rDNA (Figure  4.9A), 
although we note that the significant decrease in cell viability could also contributed to the 
plateau. Importantly, we found that this constraint was exacerbated in the case of DTE 
Sp35:Fc protein where increasing expression of using multiple gene copies did not 
correspondingly result in improved specific productivity even at low rDNA loads. Although 
a linear relationship between the amount of Sp35:Fc mRNA (Figure  4.4C) and the amount 
of intracellular nascent Sp35:Fc monomer (Figure  4.6B) exists and extends over the whole 
range of gene expression level, further analysis via mathematical approach in Chapter 5 
revealed that this linear relationship is essentially preserved by the translational 
attenuation mechanism. 
 
 
Figure ‎4.9: Recombinant protein productions including ETE proteins display “Michaelis-
Menten kinetics” with saturation of qP at a certain point. (A) Overexpression of SEAP 
above 3 µg rDNA in this study would rapidly saturate the SEAP productivity, although this could 
(partly) be due to the decreases in cell viability post-transfection and µ (due to higher total DNA 
loads). (B) The TGE diagnostic assay utilised in this study is analogous to the Michaelis-
Menten model of enzyme kinetics, where a cell‘s (cf. enzyme‘s) specific productivity (cf. 
reaction rate) is measured at varying substrate (recombinant gene) concentrations. 
The TGE diagnostic assay presented in this work can be considered analogous to 
the Michaelis-Menten model of enzyme kinetics (Figure  4.9), where qP (cf. reaction rate) is 
measured at varying rDNA (substrate) amounts. We anticipate that different recombinant 
proteins synthesised using the same cell line (cf. enzyme) would have different 
characteristic kinetics profiles. The gradient of initial linear phase at low rDNA load, where 
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qP is proportional to recombinant gene (or mRNA) amount, allows comparison of the 
intrinsic ease (cf. an enzyme‘s Km for a substrate) of expression of a given product (e.g. 
translation and secretion). If a saturation phase is evident as in the case of Sp35:Fc, then 
cellular synthetic processes inflicts a finite constraint, therefore limiting the cellular capacity 
of the cell (cf. enzyme Vmax). Importantly, the other primary output parameter (cell specific 
growth rate) identifies feedback mechanisms that may fundamentally limit the level of 
transient and stable expression of the recombinant protein. With respect to the stable 
expression, only stable clones with (undesirably) low transcriptional output would 
proliferate rapid enough to persist competitively in stable transfectant pools. 
Sp35:Fc is a relatively large and structurally complex glycoprotein. Elevation of 
expression level overloads the folding/assembly capacity of the host cells and triggers 
aggregation and accumulation of the recombinant protein in the ER. With respect to the 
former, studies have shown that the rate of multimeric MAb folding and assembly is 
relatively slow (Goto and Hamaguchi, 1981; Lilie et al., 1994) as well as protein and cell 
line specific (O'Callaghan et al., 2010; Pybus et al., 2014a). It is therefore not surprising 
that the folding/assembly process of an Fc-fusion protein easily becomes a production 
bottleneck for which the protein comprise two distinct protein groups (i.e., a therapeutic 
protein and the Fc domain) and require coordinated assembly of two polypeptide chains. 
Intracellular aggregation, especially disulphide-bonded, is also a common feature of Fc-
fusion proteins (Fast et al., 2009; Lee et al., 2007; Strand et al., 2013) where the aberrant 
covalent bonds can be caused by thiol-mediated disulphide shuffling or disulphide bond 
formation between free thiol groups. Since separate work is needed to further elucidate the 
Sp35:Fc aggregation pathway, we can only speculate that the Sp35:Fc tetramer and 
hexamer formations were due to aggregation of misfolded proteins that escape the cellular 
quality-control mechanisms, which is common in eukaryotic systems (Dobson, 2003). The 
ubiquitination of fully-folded protein was a good indicator that misfolded fully-assembled 
Sp35:Fc dimer was present in the ER (Chakrabarti et al., 2011). Moreover, we did not 
observe any trimer and pentamer aggregates, suggesting that the aggregation process 
was an interaction between (mis)folded, assembled Sp35:Fc proteins. 
Folding and assembly reactions in the ER require a considerable cellular energy and 
involve the concerted action of a variety of molecular chaperones and foldases (Dobson, 
2003). With regard to the latter, specific reaction steps may restrict the folding rate of 
particular proteins more than others. For example, oxidation reactions catalysed by PDI, a 
folding enzyme that catalyses the formation and breakage of disulphide bonds between 
thiol groups, is one the main cell engineering targets. As the PDI abundance in our system 
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did not correspond to the increase of nascent monomer polypeptide at high rDNA loads, 
overexpression of PDI may improve the qP (via improved folding) and possibly curb the 
rate of aggregation. To achieve efficient protein folding in the ER, PDI must be rapidly re-
oxidized, a mechanism that is largely accomplished by ER oxidoreductin-1-like α 
(ERO1Lα) and its ERO1Lβ homologue. The latter is of physiological interest because it is 
induced by the UPR to regulate oxidative protein folding under ER stress where it can 
form, besides ERO1Lβ-PDI dimers, homodimers and mixed heterodimers with ERO1Lα 
(Dias-Gunasekara et al., 2005; Pagani et al., 2000). Therefore, the overexpression of 
ERO1 can also potentially create an altered oxidising environment suitable for Sp35:Fc 
folding (Mezghrani et al., 2001). 
However, there was a negative correlation between the PDI abundance and rate of 
ER-to-Golgi transport of Sp35:Fc where the rate decreases at higher level of PDI. This 
data is very similar to data reported on the influence of PDI on retention of TNFR:Fc fusion 
protein in the ER (Davis et al., 2000), although the retention could also be due to the 
abnormal disulphide-linked oligomerisation (Lobito et al., 2006). Indeed, the outcomes of 
several attempts to improve the rate of recombinant protein production by overexpressing 
PDI in mammalian cells have been mixed and inconclusive (Borth et al., 2005; Davis et al., 
2000; Hayes et al., 2010; Kitchin and Flickinger, 1995). Other genetic upregulations of 
discrete chaperones in mammalian cell hosts to improve qP have also not been 
particularly successful. For example, BiP overexpression in CHO cells has been reported 
to generically decrease the secretion of recombinant proteins it associates with (Dorner 
and Kaufman, 1994; Dorner et al., 1988; Dorner et al., 1992). Therefore, cell engineering 
strategy for improved Sp35:Fc production likely requires engineering of multiple targets, 
either by co-expressing two or more molecular chaperones, or a specific transcription 
factor such as XBP1 that can simultaneously up-regulate a range of secretory pathway 
genes (Lee et al., 2003). 
It is noteworthy that protein folding and glycosylation are interconnected, where the 
latter acts as a quality control mechanism and aids protein folding. For example, the 
glycocomponent of interferon-γ has been implicated in facilitating folding and dimerisation 
of the protein (Sareneva et al., 1994). Therefore we also hypothesise that the limitation in 
Sp35:Fc folding/assembly was due to improper glycosylation. This is particularly pertinent 
given the level of glycosylation of Sp35:Fc, where inability of the cells to properly 
glycosylate any of the sites could leave the polypeptides susceptible to misfolding and 
aggregation. In this regard, the distribution of glycan structures (microheterogeneity) can 
be regulated by modulating culture conditions including nutrient content, temperature, pH, 
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oxygen and ammonia (Butler, 2006). Moreover, it was feasible that the inefficiency of the 
Sp35:Fc protein folding occurred further upstream, i.e. during translocation. Proper 
processing of complex, DTE proteins may necessitate an extended translational arrest if 
the kinetics of ER docking is slow. Particular combinations of IgG variable domain and 
signal sequences, or possibly complex compositions of fusion protein, could create 
unfavourable structures of nascent polypeptides that in turn lead to improper functioning of 
the SRP complex or lack of signal sequence removal (Le Fourn et al., 2014). To improve 
ER docking and the translocation of DTE MAb polypeptides, Le Fourn et al. (2014) 
modulated the translation arrest kinetic via overexpression of exogenous SRP14 
component, which eventually restored the efficiency of signal sequence processing. 
A further consideration is that the glycans may play a role in upholding the folded 
structure by minimising the conformational freedom of the polypeptide backbone (Petrescu 
et al., 2004). However, like N-glycosylation, disulphide bond formation is co-translational in 
the ER and may interfere with the accessibility of some amino acids for glycan transfer. 
This may result in variable occupancy of a specific site, leading to macroheterogeneity of 
glycoforms (Allen et al., 1995). Reduction in cell growth rate (by lowering culture 
temperature, addition of butyrate, etc) has been demonstrated to alter the levels of site 
occupancy in tissue plasminogen activator and interferon-γ (Andersen et al., 2000; Nyberg 
et al., 1999). This is also consistent with the notion that the glycosylation efficiency (and 
therefore protein folding) improves at a reduced rate of protein translation. N-glycosylation 
takes place co-translationally in the ER in which the precursor glycan is exposed to the 
active site of the oligosaccharyltransferase enzyme over a short period of time. This 
means lowering of the rate of polypeptide elongation would increase the exposure time 
(Butler, 2006). With respect to this, Shelikoff et al. (1994) showed that when the elongation 
rate of prolactin polypeptides was inhibited by cycloheximide, the site occupancy was 
increased, thereby enhancing the glycosylation of the translocated proteins. 
As expected for transfectants with relatively high Sp35:Fc DNA, UPR was 
constitutively activated during the cell cultivation in response to ER stress. In this scenario, 
the UPR has three primary functions: (i) to restore normal function of the cell by halting 
protein translation, (ii) to increase the synthesis of molecular chaperones involved in 
protein folding and secretion and (iii) to degrade excess unfolded proteins (and misfolded 
proteins) via ERAD mechanism thereby diminish the folding demand. In certain cases, 
however, the activation of the UPR may be insufficient to overcome ER stress and the 
prolonged accumulation of unfolded and misfolded proteins in the ER may have toxic 
effects, eventually leading to apoptosis (Chakrabarti et al., 2011). The comparisons of 
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UPR signalling branch activation reveal intrinsic features of UPR stress sensor induction in 
response to varying degree of ER stress. The complexity of cell cellular mechanisms, 
however, may necessitate empirical modelling approach to systematically elucidate 
differences in the cell functions under different conditions (Trusina et al., 2008). 
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This chapter presents a mathematical model for the synthesis and secretion processes of Sp35:Fc 
fusion protein in CHO cells. The aims are to systematically and quantitatively describe the 
cellular kinetics, and evaluate the impact of each cellular process to improve the production of 
this difficult-to-express protein. Overall, the in silico analysis reveals cell functions in 
maintaining cellular homeostasis, and importantly predicts the relative importance of different 
engineering targets. 
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Systems and synthetic biology have significantly improved our understanding of the 
recombinant protein synthetic process and how to improve/control it in both stable and 
transient gene expression systems (O'Callaghan and James, 2008). Whilst progression in 
molecular biology and analytical techniques have provided imperative information on 
intricate cellular systems, mathematical modelling has been recognised as a rational 
approach to systematise the empirical data with the objective of identifying the key 
bioreactions, reactants and process parameters (Naderi et al., 2011). Although the 
application of mathematical models are still by and large limited in the development and 
production of biologics (mainly due to the complexity and unpredictability of host cell 
systems; Ho et al., 2012), the advancement of computational research have successfully 
led to the identification of growth limiting factors (deZengotita et al., 2000) and optimisation 
of medium design and feeding strategies (Dhir et al., 2000; Xie and Wang, 1994). More 
recent works have also demonstrated that mathematical tools are highly valuable for rapid 
identification and/or testing of rational engineering targets (e.g. Ho et al., 2006; 
O'Callaghan et al., 2010; Pybus et al., 2014a). 
Mechanistic models can be built using a priori knowledge such as chemical, physical 
or biological laws and/or a posteriori knowledge based on experimental or empirical 
evidence. Such knowledge dictates the model structure that normally contains adjustable 
parameters which may or may not have physical meaning. Structured modelling for 
instance incorporates biological knowledge by dividing the cells into cellular processes and 
compartments that are physically or chemically distinct. Typically, one desires to include all 
explicit model components and precisely determine the parameter values as well as to 
validate the model statistically. Nevertheless, collecting the data that are needed to 
construct and validate a biological model, especially in the case of mammalian cell 
systems, are often resource intensive and time consuming (Franceschini and Macchietto, 
2008; Kontoravdi et al., 2007). It is therefore a challenge to have a "reduced" model while 
maintaining an accurate description of the components/reactions that is required to provide 
reliable results (e.g., an unfolded protein response (UPR) model; Trusina et al., 2008).  
In order to systematically understand the production mechanism of the Sp35:Fc 
fusion protein used in this study, we employ an empirical modelling approach to 
quantitatively describe the cellular constraints on recombinant Sp35:Fc synthesis and 
secretion. The main benefits of this mathematical approach lie in its ability to elucidate the 
behaviour of a multicomponent system and calculate the relative importance of specific 
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cellular reactions on overall flux (i.e. qP). This information can be subsequently utilised to 
identify/predict corresponding cellular processes for cell or process engineering. For 
instance, while the experimental data presented in Chapter 4 (Figures 4.4‒4.8) indicate a 
connection between cell growth, Sp35:Fc synthesis and secretion and UPR induction by 
elevated expression, we have no systematic information of their relative influence―it is 
reasonable to assume that UPR induction by DTE Sp35:Fc can occur via several routes, 
which may include combinations of Sp35:Fc folding/assembly kinetics, aggregate 
formations and transport/secretion rates. Consequently, it is difficult to identify specific 
cellular engineering targets that could result in significant improvement of DTE Sp35:Fc 
production. 
The structured model of Sp35:Fc secretory pathway presented in this study stems 
from the antibody synthetic model originally proposed by Bibila and Flickinger (1991, 
1992), which also formed the basis of previous MAb models built in this laboratory (Davies 
et al., 2011; McLeod et al., 2011; O'Callaghan et al., 2010; Pybus et al., 2014a). Based on 
the previous experimental observations in Chapter 4, a simplified cellular structure for 
homodimeric Fc-fusion protein production is introduced with respect to the process of 
synthesis, folding and secretion in order to develop a modelling framework that could be 
used in identifying major cellular rate limiting steps (Figure  5.1). However, we are reluctant 
in our approach to extending our model to include UPR-related proteins such as eIF2α and 
XBP1 and their effects (e.g. upregulation of ER chaperones; see below). 
 
 
Figure ‎5.1: Proposed Sp35:Fc fusion protein synthesis, folding and aggregation pathway 
in CHO cells that forms the structured model of Sp35:Fc production. The translation of 
Sp35:Fc mRNA in the cytoplasm would produce a nascent Sp35:Fc monomer polypeptide 
which is then transported to the endoplasmic reticulum. Two monomer polypeptides fold and 
assemble into a functional dimer before being transported to the Golgi complex followed by 
secretion into the extracellular medium. A dimer protein may also form a tetramer aggregate by 
cross-linking with another dimer, or a hexamer aggregate by linking to a tetramer. 
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Indeed, the UPR comprises a complex series of network that dynamically vary. For 
example, recent studies have identified a translation suppression network that is 
independent of the phosphorylated eIF2α signalling (Guan et al., 2014). Even though it is 
possible to introduce a reduced UPR system in our model (e.g., a minimal UPR regulatory 
loop to capture the link between recombinant polypeptide level, cell growth rate and ER 
folding capacity; Pybus et al., 2014a), such empirical model is also incapable of predicting 
the effects of engineering specific UPR components that can be particularly useful for DTE 
protein productions. The guiding principle in our model development is to minimise the 
number of parameters needed for estimation from the available empirical/experimental 
measurements (Jaqaman and Danuser, 2006). This reduces the need for model validation 
and removes excessive degrees of freedom in our mathematical description of the key 
intracellular processes of Sp35:Fc synthesis and regulation. Nevertheless, our model does 
capture the major UPR events observed, namely the reduction in cell growth and ERAD 
pathway (via protein ubiquitination). 
Figure  5.2 summarises the major steps of model development framework of this 
study. On the whole, the Sp35:Fc model developed consists of 24 differential and 
algebraic equations containing 26 parameters. The parameters were fitted to the empirical 
data obtained in Chapter 4 for five different CHO transfectants (containing different rDNA 
loads), followed by local sensitivity analysis to evaluate the impact of specific cellular 
mechanisms on Sp35:Fc productivity at different transgene copy numbers. This 
computational approach enables systematic understanding of cellular regulation in 
producing Sp35:Fc, and at the same time provides a rational and predictive cell 
engineering platform to increase Sp35:Fc protein productivity based on in silico 
engineering of discrete cellular functions. 
 
 
Figure ‎5.2: Model development framework for Sp35:Fc fusion protein production system. 
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A mathematical model consisting of a set of ordinary differential equations was developed 
based on a previously published model for MAb synthesis in this laboratory (McLeod et al., 
2011; O'Callaghan et al., 2010). In order to reflect the Sp35:Fc synthesis mechanism, 
several structural modifications were made on the previous MAb model by (i) removing the 
unrelated light-chain polypeptide equations and expressions, and (ii) adding protein 
aggregate formations and secretion pathways based on the experimental observations. 
The model topology is shown in Figure  5.3. We acknowledged that protein synthesis is a 
complex mechanism that could not be fully captured in our model. For example, to 
characterise the actual translational frequency in a cell, one also need to determine the 
protein turnover rate (half-life) in addition to the pure production and ubiquitination levels. 
Therefore, this simplified model was merely an estimation of the main cellular activities to 
allow systematic comparisons of the different transfectants. 
 
 
Figure ‎5.3: Schematic representation of the mathematical model of Sp35:Fc 
biosynthesis, aggregation, degradation and secretion pathway. Rectangles represent 
reactions (e.g. transcription) and grey circles represent species (e.g. mRNA). The numbers 
indicate the associated model's continuity equation described in the text. Dimer and aggregate 
formations were assumed to be irreversible events. 
Dilution by 
growth 
Tetramer aggregate 
formation 
  
  
1  2 
Translation 
mRNA  
mRNA 
degradation 
Dilution 
by growth 
Nascent 
monomer 
 
Dilution by 
growth 
 
Dimer 
formation 
3 
 
Dimer 
ER  
 
  
Hexamer 
aggregate 
formation 
4 
Hexamer
ER 
 
Dilution by 
growth Tetramer 
ER 
 
 
 
Dimer 
secretion 
5 
 
Hexamer 
secretion  
Tetramer 
secretion 
 
Dilution 
by growth 
 
 
Dilution by 
growth 
 
Dilution 
by growth 
Hexamer 
ER to Golgi 
transport 
Dimer ER to 
Golgi 
transport 
8 
9 
10 
Hexamer
Golgi 
Dimer 
Golgi 
Tetramer 
Golgi 
 
Dimer 
ubiquitination 
Monomer 
ubiquitination  
 
Tetramer 
ubiquitination 
 
Hexamer 
ubiquitination 
Dilution 
by growth 
Tetramer ER 
to Golgi 
transport 
Ubiquitinated 
monomer  
Ubiquitinated 
dimer  
6 7 
Transcription 
Chapter 5 
 
76 
The structured model of the complete Sp35:Fc protein synthesis and secretory 
pathway is presented below. It describes the process of recombinant protein synthesis and 
secretion in the nucleus, ER and the Golgi complex for a homodimeric Fc-fusion protein-
producing cell. The zero, first or second-order rate equation for a chemical reaction was 
applied in order to obtain the reaction (formation) rate based on the concentration of the 
reactants. For example, the formation rate of nascent Sp35:Fc monomer molecules was 
determined according to the formation kinetics, TP and the mRNA concentrations, [m]. A 
description of the mathematical notations can be found in the Nomenclature section.  
 
Firstly, the accumulation of Sp35:Fc mRNA molecules within a cell can be represented as 
follows: 
𝑑[𝑚]
𝑑𝑡
= 𝑁gene 𝑆𝑚 − 𝑘deg  𝑚 − µ 𝑚                                                                                 (1) 
where 
𝑘deg =
ln 2
𝑡1/2,𝑚
                                                                                                                          (1𝑎) 
The intracellular balance of Sp35:Fc monomer, dimer, tetramer and hexamer in the ER are 
represented by the following equations: 
𝑑 P 
𝑑𝑡
= 𝑇P 𝑚 − 2 𝑅P2 − 𝑘ubq ,P P − µ P                                                                      (2) 
𝑑[P2]ER
𝑑𝑡
= 𝑅P2 − 2 𝑅P4 − 𝑅P6 − 𝑘ER ,P2[P2]ER − 𝑘ubq ,P2[P2]ER − µ[P2]ER             (3) 
𝑑[P4]ER
𝑑𝑡
= 𝑅P4 − 𝑅P6 − 𝑘ER ,P4[P4]ER − 𝑘ubq ,P4[P4]ER − µ[P4]ER                             (4) 
𝑑[P6]ER
𝑑𝑡
= 𝑅P6 − 𝑘ER ,P6[P6]ER − 𝑘ubq ,P6[P6]ER − µ[P6]ER                                         (5) 
where R is the rates of consumption of protein polypeptides in the assembly or 
aggregation process determined using second-order kinetics; 
𝑅P2 = 𝑘fa  P  P                                                                                                                      (3𝑎) 
𝑅P4 = 𝑘agg ,P4 P2  P2                                                                                                            (4𝑎) 
𝑅P6 = 𝑘agg ,P6 P4  P2                                                                                                            (5𝑎)   
and 
𝑘ER ,P2 =
ln 2
𝑡1/2,[P2]ER
                                                                                                               (3𝑏) 
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𝑘ER ,P4 =
ln 2
𝑡1/2,[P4]ER
                                                                                                               (4𝑏) 
𝑘ER ,P6 =
ln 2
𝑡1/2,[P6]ER
                                                                                                               (5𝑏) 
The ubiquitinated Sp35:Fc monomer and dimer in the ER are described as follows: 
𝑑[P]ubq
𝑑𝑡
= 𝑘ubq ,P P − µ P ubq                                                                                           (6) 
𝑑[P2]ubq
𝑑𝑡
= 𝑘ubq ,P2[P2]ER − µ[P2]ubq                                                                                (7) 
where 
𝑘ubq ,P =
ln 2
𝑡1/2,[P]
                                                                                                                      (6𝑎) 
𝑘ubq ,P2 =
ln 2
𝑡1/2,[P2]
                                                                                                                  (7𝑏) 
The fully formed dimeric Sp35:Fc and tetramer and hexamer aggregates are then 
transported to the Golgi apparatus. 
𝑑[P2]G
𝑑𝑡
= 𝑘ER ,P2[P2]G − 𝑘G,P2[P2]G − µ[P2]G                                                                   (8) 
𝑑 P4 G
𝑑𝑡
= 𝑘ER ,P4 P4 G − 𝑘G,P4 P4 G − µ P4 G                                                                   (9) 
𝑑[P6]G
𝑑𝑡
= 𝑘ER ,P6 P6 G − 𝑘G,P6 P6 G − µ[P6]G                                                                   (10) 
where 
𝑘G,P2 =
ln 2
𝑡1/2,[P2]G
                                                                                                                   (8𝑎)   
𝑘G,P4 =
ln 2
𝑡1/2,[P4]G
                                                                                                                   (9𝑎) 
𝑘G,P6 =
ln 2
𝑡1/2,[P6]G
                                                                                                                   (10𝑎) 
Finally, biomass-specific secretion rates of Sp35:Fc native dimer and tetramer/hexamer 
aggregates are described by the following equations: 
𝑞Pdimer = λP2𝑘G,P2 P2 G                                                                                                      (8𝑏)                                                                                      
𝑞Ptetramer = 2 λP2𝑘G,P4 P4 G                                                                                              (9𝑏)                                                                                 
𝑞Phexamer = 3 λP2𝑘G,P6 P6 G                                                                                              (10𝑏)        
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The model was built and solved using Systems Biology Toolbox 2 (SBToolBox2; Schmidt 
and Jirstrand, 2006) for MATLAB software (MathWorks, Natick, MA). The full model syntax 
is presented in Appendix B. For each transfection condition the model of Sp35:Fc 
synthesis was solved using a steady-state assumption. All model parameters were fitted to 
the experimental data (Chapter 4) using a particle swarm optimisation method to yield the 
best-fit model parameters. The method utilises a stochastic pattern search algorithm to 
minimise the sum of squared errors between measurement (empirical data) and simulation 
outputs. A detailed description of the underlying algorithm is described in Vaz and Vicente 
(2007). A successful fit was defined to have a sum of squared errors <0.5.  
 
 
A local sensitivity analysis was performed on the fitted model to calculate sensitivity 
coefficients for each cellular reaction/process involved in Sp35:Fc production. For each 
parameter, pi, the response coefficient R
qP
 was numerically calculated using 1% 
perturbations as follows: 
𝑅𝑖
𝑞P
=
 𝑞P|1.01𝑝𝑖 − 𝑞P|0.99𝑝𝑖 
 𝑞P|1.01𝑝𝑖 + 𝑞P|0.99𝑝𝑖 0.01
                                                                                     (5.1)   
The response coefficient was calculated using a programme written within MATLAB 
software (Appendix C). 
 
 
 
To further investigate which trafficking step is the main rate-limiting in the model Sp35:Fc 
biosynthesis and secretion, we utilised an empirically-based mathematical modelling 
technique to systematically analyse the influence of specific cellular processes on qP. For 
each rDNA load transfection an empirically derived mathematical model of Sp35:Fc 
production was built using the model topology outlined above (Figure  5.3) based on the 
previous work in this laboratory for MAb synthesis (McLeod et al., 2011; O'Callaghan et al., 
2010). The parameters of each model were fitted to the empirical data using statistical 
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best-fit parameter sets determined using the particle swarm algorithm. A successful fit was 
defined to have a sum of squared residuals <0.5, where the residual is the absolute 
difference between the model calculated value in logarithmic space and the empirically 
derived level. This analysis produced a transfectant-specific set of estimated model 
parameter values representing the statistical best fit to the biological data. 
The mean value of the sum of squared residuals was 0.127 with a standard deviation 
of 7.8% of the mean, indicating that the model-calculated species (e.g. mRNA) levels are 
highly comparable to the empirically derived data points. The fitted parameter values are 
tabulated in Table  5.1. The following assumptions and/or qualifications regarding the 
model were made. Firstly, it was assumed that the tetramer aggregate was an irreversible 
product of two dimer molecules and the hexamer aggregate must necessarily pass through 
a tetramer state before merging with another dimer. Secondly, as ubiquitinated tetramer 
and hexamer aggregates were below minimum detection threshold, dimer ubiquitination 
rates were used as the minimal degradation rates. The rate constants for ubiquitinated 
protein tetramer and hexamer in this study could be set to their nominal values as the 
proteins present in minute amount and did not affect the qP. Lastly, as Endo H sensitive 
and resistant high molecular weight Sp35:Fc could not be resolved using non-reducing 
SDS-PAGE and had to be analysed in the reduced form, the proportions of Sp35:Fc dimer, 
tetramer and hexamer in the ER and Golgi were assumed to follow the overall percentage 
of fully disulphide bonded oligomers in the ER/Golgi shown in Figure  4.6B of Chapter 4. 
This set of model-derived parameter values (Table  5.1) is generally comparable to 
the previous reports from this laboratory using mathematical approaches to improve our 
understanding of the control of MAb production (Davies et al., 2011; McLeod et al., 2011; 
O'Callaghan et al., 2010; Pybus et al., 2014a) and does not deviate from the biologically 
plausible values. For instance, the transport rates (kER and kG) are close to the typical rates 
for ER-to-Golgi and Golgi-to-medium transports in constitutive secretory pathways which 
have been reported to be 0.2–1.4 h-1 and 2–25 h-1, respectively (Bibila and Flickinger, 
1992; Dahm et al., 2001). Nevertheless, model-derived parameters are influenced by a 
wide variety of factors including the recombinant protein product, host cell line and cell 
culture process which can be expected to generate considerable model variation. This 
means mathematical models often require recombinant protein product, cell line and cell 
culture process-specific empirical measurements to optimise their usefulness as a tool to 
inform cellular constraints on productivity and/or cell engineering strategies. 
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Table ‎5.1: Best-fit parameter values for transfectants with different Sp35:Fc DNA loads. The 
nomenclature used is described in the Nomenclature section. 
Parameter 
Sp35:Fc plasmid DNA per 4.5×10
6
 cells 
0.25 µg 0.5 µg 1 µg 2 µg 3 µg 
Cell growth  
   µ (h
-1
) 0.0282 0.0259 0.0232 0.0226 0.0226 
Transcription and translation  
   Sm ((mRNA copy) gene
-1
 h
-1
) 1.33×10
-3
 1.33×10
-3
 1.33×10
-3
 1.33×10
-3
 1.33×10
-3
 
   kdeg (h
-1
) 0.058 0.058 0.058 0.058 0.058 
   TP (molecule (mRNA copy)
-1
 h
-1
) 253.9 177.1 110.9 59.5 42.0 
Folding/assembly and aggregation  
   kfa (cell molecule
-1
 h
-1
) 1.07×10
-1
 1.79×10
-2
 4.87×10
-3
 9.32×10
-4
 4.06×10
-4
 
   kagg,P4 (cell molecule
-1
 h
-1
) 4.18×10
-8
 3.70×10
-8
 6.45×10
-8
 6.03×10
-8
 6.02×10
-8
 
   kagg,P6 (cell molecule
-1
 h
-1
) 4.04×10
-9
 1.04×10
-8
 7.80×10
-8
 8.03×10
-8
 8.04×10
-8
 
Degradation 
   kubq,P (h
-1
) – – 3.63×10-4 6.60×10-4 9.17×10-4 
   kubq,P2 (h
-1
) 2.33×10
-5
 2.07×10
-5
 2.53×10
-5
 4.78×10
-5
 7.92×10
-5
 
Transport and secretion  
   kER,P2 (h
-1
) 1.044 0.468 0.267 0.233 0.224 
   kER,P4 (h
-1
) 1.234 0.503 0.188 0.156 0.137 
   kER,P6 (h
-1
) 1.288 0.557 0.274 0.200 0.128 
   kG,P2 (h
-1
) 36.25 38.36 42.31 42.76 42.52 
   kG,P4 (h
-1
) 43.24 41.53 38.15 37.94 43.32 
   kG,P6 (h
-1
) 44.58 44.72 44.72 45.15 39.84 
 
 
Overall, the model-derived parameters exhibit clear trends across the transfection 
conditions (Table  5.1). Whilst the cells managed to maintain the Sp35:Fc mRNA 
transcription rate Sm at high rDNA loads thus resulting in a proportional increase in the 
mRNA content (Chapter 4, Figure  4.4C), they were unable to retain the rate of post-
transcriptional processes, specifically translation (TP), folding/assembly (kfa) and ER-to-
Golgi transport (kER). Conversely, the rate of aggregate formation (kagg) and protein 
degradation (kubq) were intensified at 1 µg rDNA load onwards. Therefore it was obvious 
that the cellular process rates were transfectant-specific depending on the recombinant 
gene copy abundance. Cells with 0.5 µg rDNA load characterise the most efficient cell 
factory via a fast/proper recombinant mRNA translation, folding and secretion in 
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conjunction with rapid cell proliferation rate, resulting in a relatively high product titre and 
low aggregate content. 
 
 
In order to understand how individual model parameters affect the qP (of native dimer), we 
performed metabolic control analysis (MCA) to obtain a quantitative description of 
substrate flux in response to changes in system parameters. MCA is a type of local 
sensitivity analysis that can be applied to protein synthesis and secretion pathways around 
a given steady state (Dimelow and Wilkinson, 2009; O'Callaghan et al., 2010). The 
empirical data obtained in Chapter 4 imply that the polypeptide synthesis processes (i.e. 
transcription/translation) would not have a significant effect at high rDNA loads, whereas 
post-translational activities would become limiting. We calculated response coefficients 
(RCs) for each cellular process involved in Sp35:Fc production which define the extent to 
which qP changes relative to a 1% perturbation of a discrete cellular process. This analysis 
is shown in Figure  5.4, where all parameters vary in a biologically meaningful manner. 
 
 
Figure ‎5.4: Parameter local sensitivity analysis demonstrating the qP response 
coefficient in each transfectant resulting from a 1% change in the rate constant of each 
synthetic process. Response coefficients were derived from a 1% increase in transcription 
rate (Sm), translation rate (TP), folding/assembly rate (kfa), ER-to-Golgi transport rate (kER) and 
Golgi-to-medium secretion rate (kG,P2) and from a 1% decrease in mRNA degradation rate (kdeg) 
and aggregation rate (kagg). 
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Overall, the intracellular transport rates of the Sp35:Fc molecule from the ER to the 
Golgi complex (kER) and subsequently to the extracellular medium (kG) have little impact on 
the qP as reflected by the low response coefficients. This is in contrast to the protein 
synthesis processes, namely transcription (Sm) and translation (TP). Indeed, transcription 
and translation parameters have been reported to display a universal, full control over 
recombinant protein production (e.g. Ho et al., 2006; O'Callaghan et al., 2010). Moreover, 
the mRNA degradation rate (kdeg), although not directly measured in this study, also 
showed significant influence on qP as reported by other studies (O'Callaghan et al., 2010). 
The difference in the response sensitivities may be explained by the fact that an increase 
in the rate of intracellular transport will lead to a depletion of the intracellular recombinant 
protein pool that is mainly regulated through the processes of transcription and translation, 
i.e. the increased transport rate cannot be sustained without a parallel increase in 
transcription and translation rates (Ho et al., 2006). Consequently, the effects of transport 
rates kER and kG on increasing Sp35:Fc productivity tend to be significantly lower than 
those of the transcription (Sm) and translation (TP) parameters. 
However, the sensitivity analysis reveals that the ER-to-Golgi secretory rate constant 
(kER) became more sensitive at higher rDNA loads which exhibits a specific limitation in 
this process (Figure  5.4). This is consistent with the finding that high gene expression 
resulted in the retention of intracellular Sp35:Fc in the ER which eventually led to limited 
secretion rate. The consequence is also evident as observed earlier where an increase in 
intracellular dimer did not result in a corresponding increase in dimer secretion rate 
(Chapter 4, Figure  4.6A and B). Additionally, the aggregation rate constant (kagg) also 
displayed sensitiveness, albeit at insignificant levels (RC ≤ 0.05), when the rate of 
aggregate formation competed with ER export machinery for the supply of newly folded, 
export ready Sp35:Fc in the ER lumen. In this case, the yield of native protein was 
determined by the rates of the competing first-order ER-Golgi secretion and second-order 
aggregation reactions. The formation of aggregates, however, did not make a considerable 
impact on the qP due to the fact that they made up only up to 5% w/w of the total secreted 
Sp35:Fc protein yield.  
Unexpected results were observed with the transcription (Sm) and translation (TP) 
processes where the high sensitivities were maintained at high rDNA loads (Figure  5.4). 
These results indicate, on the contrary to the empirical data (Chapter 4), that qP could be 
increased at high rDNA loads by these two processes. Equally, the response of the 
folding/assembly rate constant (kfa) unpredictably appeared to be of negligible importance 
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even though the rate became notably low at 3 µg rDNA transfection (Table 5.1)—implying 
that the assembly process was not a rate-limiting step as hypothesised. With regard to kfa, 
in silico retro-engineering test showed that the response coefficient became significant (RC 
> 0.1) only when the lowest reaction rate in Table 5.1 was further decreased from 10
-4
 to 
10
-7
 cell molecule
-1
 h
-1
. Such large reduction is biologically possible, where MAb heavy and 
light chain assembly rates are known to differ over six orders of magnitude (Bibila and 
Flickinger, 1992). This large variation is largely due to the nature of second-order 
assembly reaction compared to first-order reaction of transcription, translation, etc. 
Previous work in this laboratory (O'Callaghan et al., 2010) for instance had shown that GS-
CHO cell lines with varying qP had assembly rate constant of heavy chain dimer between 
10
-7
 and 10
-1
 cell molecule
-1
 h
-1
. To understand these unexpected results, we performed in 
silico retro-engineering on the cellular parameters (see below). 
 
 
In order to investigate as why the drop in dimer assembly rate kfa at high rDNA load was 
relatively insignificant even though there was an apparent saturation in assembled dimer 
(Chapter 4, Figure 4.6B), we analysed the cell translational rate (TP) across the 
transfectants (Table  5.1). The decrement in translational rate at higher rDNA loads 
suggests the effect of mRNA translational attenuation in the cells. Increased levels of 
unfolded and/or misfolded proteins in the ER of all eukaryotes are known to trigger the 
UPR which in turn activates global translational attenuation (Chakrabarti et al., 2011). 
Therefore, this translational attenuation enabled the unfolded nascent monomers (Chapter 
4, Figure  4.6B) to increase almost proportionally to the mRNA copy numbers (Chapter 4, 
Figure  4.4C) or else there would be a rapid accumulation of unfolded monomers due to the 
decrease in dimer assembly rate (note the slightly exponential curve of the monomer 
species in Figure  4.6B). In other words, the translational attenuation mechanism cushioned 
the impact of saturated assembled dimer in the ER—resulting in only a relatively small 
decrease in the assembly rate and at the same time keeping the unfolded monomer at an 
appropriate level in order to retain the cell's normal cellular function.  
If our hypothesis is correct, the mathematical model would predict that without the 
translational attenuation (i.e., invariable translational rate at different rDNA loads) the 
folding/assembly rate would decrease drastically as the saturation of intracellular dimer 
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would be solely due to the folding/assembly factor, and this in turn would result in an 
adverse accumulation of the unfolded monomer. To verify this, we performed in silico cell 
engineering on the empirical/experimental data (Figure  5.5A) by artificially keeping the 
translational rate TP at different rDNA transfections constant as illustrated in Figure  5.5B. 
The model was simulated to see the changes in the monomer amount and then re-fitted as 
described earlier to obtain a new folding/assembly rate kfa for each transfectant. 
 
 
Figure ‎5.5: In silico cell engineering reveals the intrinsic ability of cells to restore 
homeostasis between folding demand imposed on the ER and its folding capacity. (A) 
The empirical data showed that a translational attenuation (TA) mechanism, i.e. a decrease in 
translational rate (TP), enabled nascent monomers to increase linearly and resulted in an 
insignificant decrease in the folding/assembly rate (kfa) from 10
-1
 to 10
-3
. (B) By artificially 
keeping the translational rate TP at different rDNA loads constant to mimic the absence of 
translational attenuation, the accumulation of unfolded monomers increases exponentially. 
Without the translational attenuation mechanism to prevent the rapid accumulation of unfolded 
monomers, the folding/assembly rate decreases by nine orders of magnitude from 10
-1
 to 10
-10
. 
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In agreement to the hypothesis, the simulation outcome demonstrated that at a 
constant translational rate (TP) of 254 molecule mRNA
-1
 h
-1
, the folding/assembly rate (kfa) 
decreased dramatically from 10
-1
 to 10
-10
 cell molecule
-1
 h
-1
 as the amount of monomer 
increased rapidly (Figure  5.5B). The sensitivity analysis also revealed that the response 
coefficient of folding/assembly rate constant became notably significant (RC up to 0.72; 
Figure  5.6) indicating that in the absence of translational attenuation the folding/assembly 
process is now a rate-limiting step in the Sp35:Fc production mechanism. Conversely, the 
response coefficient of the transcription rate Sm and the translation rate TP became 
progressively lower, indicating that the parameters exerted less control at higher rDNA 
loads. To this end, the model predicts that engineering the folding/assembly could produce 
a greater return in terms of qP―much in agreement to our hypothesis. 
 
 
Figure ‎5.6: The response coefficient pattern changes when the translational attenuation 
mechanism of the cells is artificially removed via in silico engineering. Without cell's 
translational attenuation mechanism, the folding/assembly rate (kfa) becomes highly sensitive at 
high rDNA load. Conversely, the sensitivity of transcription rate (Sm) and translation rate (TP) is 
reduced implying that the parameters exercise less control at higher rDNA loads. 
 
Two imperative outcomes of the mathematical modelling and sensitivity analysis are (i) the 
identification of the major cellular production constraint at elevated expression and (ii) a 
systematic understanding of how cells cope with intracellular stress. With respect to the 
latter, it is important to note that cellular rates of mRNA translation and protein folding are 
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functionally linked by complex intracellular signalling pathways such as the UPR which is 
not readily perceived by empirical data alone. Mathematical modelling therefore allows the 
organisation of experimental information systematically and coherently, which in turn 
facilitate the analysis and identification of essential, qualitative features in complex 
biological systems. Our study highlights that UPR regulates the protein-folding capacity of 
the ER according to cellular demand. As such, it gives further insights toward 
understanding how ER stress sensors can confer different responses to achieve optimal 
cellular function and their impact on DTE protein production rate. 
A persistent UPR, however, would be highly undesirable in a stable production cell 
line as it would reduce protein synthesis and lead to ERAD and ultimately cell apoptosis. 
Previous studies in this laboratory comparing the proteomes of MAb-producing GS-NS0 
cell lines showed that cells with relatively high qP had a considerably higher abundance of 
ER functional proteins including the chaperones BiP, PDI and GRP94. Despite the 
variations in ER resident proteins, the levels of spliced XBP1 and cleaved ATF6 were 
similar in all cells lines studies, i.e. the UPR was not induced in cells with high qP, 
suggesting that stable cell lines utilise some cellular strategies to avoid or minimise UPR 
activation (Dinnis and James, 2005; Dinnis et al., 2006; Smales et al., 2004). Thus we 
predict that the generation of stably transfected cells with >1 µg Sp35:Fc DNA using the 
present system will mostly result in instability of Sp35:Fc production (loss of protein 
production, protein aggregation, cell death, etc), rendering the clone screening and 
selection processes difficult and with a low probability of success. 
Apart from systematic understanding, mathematical models can be utilised for the 
effective control and optimisation of bioprocess performance. Using our model, we 
propose that the rational design of cell engineering strategies to improve volumetric 
Sp35:Fc product yield for this system would be increases in (proper) folding/assembly rate, 
for example through metabolic and cell engineering approach. This is comparable to the 
previous study in this laboratory modelling transient difficult-to-express MAbs (Pybus et al., 
2014a), and in contrast to easy-to-express MAb production in stable cell lines which 
emphasised on transcription and translation processes (Davies et al., 2011; McLeod et al., 
2011; O'Callaghan et al., 2010) as rational targets to improve productivity. An increase in 
Sp35:Fc translation rate (and recombinant mRNA abundance) without improving the 
folding and assembly machinery would exacerbate the accumulation of nascent 
polypeptides in the ER and destroy cell's translational attenuation control capability, and is 
likely to shift the bottleneck further downstream in the Sp35:Fc secretion pathway.  
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Finally, while sensitivity analysis is a valuable tool to evaluate the control of 
recombinant protein synthesis exerted by specific cellular processes and aid rational 
engineering strategy, it does not represent the effect per se. The model can be further 
utilised/developed as a predictive tool for cell engineering and/or cell line selection. For 
example, using the observed range of parameter values across the transfectants (Table 
 5.1) as biologically possible cellular processing rates within this CHO host cell, we created 
a theoretical engineered cell line in silico using the optimal translation, folding/assembly 
and secretion rates. The modelled qP increased from 0.18 to 1.17 pg cell
-1
 day
-1
 for a 3 µg 
rDNA load transfectant, a substantial 6.5-fold increase. Certainly, for another Fc-fusion 
protein product or cell line different limitations on cellular productivity may pertain. We 
propose that this iterative cell factory reverse-engineering approach could be implemented 
as a generic framework for Fc-fusion proteins, with the objective of using it as an initial 
groundwork to better understand the factors underlying Fc-fusion protein synthesis and 
processing, and subsequently propose predictive, rational engineering strategies to 
overcome the limiting production factors in mammalian cultivation systems. 
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This chapter explores the hypothesis that it is feasible to exploit functional/genetic 
heterogeneity in the parental CHO cell population to select clonal variants with desirable 
characteristics. The aims are to identify functional variations that may contribute to enhanced 
production of difficult-to-express Sp35:Fc protein, and eventually generate new cell lines that 
are inherently more fit for this purpose. 
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Mammalian cell populations are highly and inherently heterogeneous. Discrepancies 
among clonal cells are present at both genetic (Derouazi et al., 2006; Oh et al., 2003) and 
phenotypic levels (Barnes et al., 2006; Pilbrough et al., 2009). Stockholm et al. (2007) 
have demonstrated, using both in silico and in vitro approaches, that the phenotypic 
heterogeneity in a clonal mammalian cell population can arise due to ―extrinsic‖ and 
―intrinsic‖ mechanisms of the cells. Even though the impacts can be unfavourable (e.g. 
loss of productivity; Lee et al., 1991) and difficult to be dealt with, it is also desirable to find 
out which components of the observed variation serve a biological function that may be 
harnessed for cell line development. In this context, genetic heterogeneity allows the 
selection of cell lines with advantageous phenotypes as a complement to or replacement 
for cell engineering method. 
The potential exists in many cases to select natural variants with a desired feature, 
either as candidate lines for production or to provide a platform for the analysis of factors 
contributing to improved characteristics. Whilst cell selections typically focus on 
productivity and cell growth/density (Pichler et al., 2011; Prentice et al., 2007), novel 
variant cell lines have also been selected with the ability to consume lactate (Browne and 
Al-Rubeai, 2011), the ability to grow in glutamine-free medium (Hernández Bort et al., 
2010), the ability to be transfected with adenovirus (Condon et al., 2003), resistance to 
oxidative stress (Keightley et al., 2004) and resistance to high medium osmolarity (Liu et 
al., 2010). Unlike cell engineering method, this approach does not require extensive 
knowledge of the genes and cellular mechanisms of the cells which can be a bottleneck in 
cell development process (Dietmair et al., 2011; Dinnis and James, 2005). However, to our 
knowledge, there are no reports describing how genetic/phenotypic heterogeneity can be 
purposely managed or controlled to produce improved mammalian cell hosts specifically 
for difficult-to-express (DTE) protein production. 
In this study, we evaluate the functional performance of clonally derived Chinese 
hamster ovary (CHO) cell populations to produce DTE Sp35:Fc in transient expression 
systems. This is theoretically possible as mammalian host cells have been shown to vary 
considerably in their intrinsic ability to manufacture a given recombinant protein 
independent of transgene copy numbers (Charaniya et al., 2009; Kennard et al., 2009). 
Nevertheless, previous studies analysing clonally-derived cell populations transiently or 
stably expressing MAb and/or green fluorescent protein (GFP) have also demonstrated 
that a functional trait is subject to stochastic cell-to-cell variation (Merritt and Palsson, 
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1993; Pilbrough et al., 2009) and not always heritable (Davies et al., 2013; Pichler et al., 
2011). With this in mind, we purposely utilise population-averaged measurements taken 
over many generations (i.e. extended serial subculture) to assess the heritability of key 
functional traits, in which temporary cell-to-cell phenotypic variability that may arise from 
micro-environmental differences (Snijder and Pelkmans, 2011) or stochastic gene 
expression (Raj and van Oudenaarden, 2008) is effectively irrelevant. Somewhat on the 
contrary, we also hypothesised that the routine cell culture procedures are a logical route 
to effectively increase genetic and functional variations within and between sub-
populations that in turn may increase the probability of selecting new cell lines with 
superior capabilities to produce DTE Sp35:Fc. Over many generations, the physically 
isolated cultures evolve randomly/independently and undergo genetic drift to yield their 
own heterogeneous parental CHO cell populations (Merlo et al., 2006)  
The CHO-S cell lineage used in this study had been previously bioreactor adapted as 
a pool by Biogen Idec and remained that way subsequently (i.e., not sub-cloned) with the 
idea of providing as much population heterogeneity as possible (Marty Sinacore, personal 
communication). Taking advantage of this high heterogeneity potential, we isolate 70 
clonal variants and subject a subset of 33 untransfected clonal populations to parallel 
prolonged culture (over 120 generations) to intensify the naturally occurring variations. We 
evaluate the variation/heritability of key phenotypic traits, namely specific proliferation rate 
(µ), peak viable cell density VCD, cell size and cell biomass content. By expressing 
Sp35:Fc and GFP in a sub-subset of 16 clones at 3 different generations, we critically 
assess the effect of routine cell culture procedures on the clones‘ functional performance 
in manufacturing the two distinct recombinant proteins. We effectively identify several 
CHO-S host cell variants that possess superior cellular machinery for transient Sp35:Fc 
production as well the general cell characteristics that could be beneficial in producing 
DTE proteins. 
 
 
 
Single cell clones were isolated by one round of limiting dilution cloning (LDC) of the 
parental CHO-S cell line (Biogen Idec, Cambridge, MA). Cells were plated out into Greiner 
CellStar® 96-well plates (Greiner Bio-One, Frickenhausen, Germany) at 0.125 cells per 
well in CD-CHO medium supplemented with 8 mM L-glutamine (Life Technologies, 
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Paisley, UK). The probability of clonality by LDC was calculated according to Clarke et al. 
(2002) using the following equation: 
𝑃 clonality =
𝑃  one colony per well 
𝑃  at least one colony per well 
=
𝑠𝑑 × 𝑒−𝑠𝑑
1 − 𝑒−𝑠𝑑
                                 (6.1) 
where sd is the seeding density. Individual wells were further subjected to image analysis 
(CloneSelect™ Imager, Genetix, Hampshire, UK) to ensure selection of clonal populations 
derived from a single cell. Plates were incubated in a humidified incubator at 37°C in 5% 
CO2 and culture medium was replenished on Day 9. On Day 13, static culture of 70 
colonies at 40–70% confluency were scaled up to 24-well plate at 5‒10% seeding 
confluency (3 days culture) followed by 6-well plate (3 days culture), and eventually to 125 
mL shake flasks (Corning Incorporated, Acton, MA) at which the generation number was 
reset to zero. Shake-flask cultures were maintained at 37°C in 5% CO2 under 140 rpm 
agitation. Cells were sub-cultured every 4 days by centrifuging at 200×g for 5 min to 
remove the spent medium and re-seeding into fresh medium at a concentration of 2×10
5
 
cells mL
-1
. Accumulated generation number was calculated using Equation 6.2;  
Generation number =
ln (𝑋2/𝑋1)
ln(2)
=
𝜇 (Δ𝑡)
ln(2)
                                                                  (6.2) 
where X are the viable cell density (VCD) at the first or second time point, µ is the cell 
proliferation (growth) rate and t is the time. Cryopreservation in liquid nitrogen was carried 
out on the clonally derived cell populations at 15, 45 and 105 generations as described in 
Section 3.1.2. 
 
 
Average cell diameter based on forward scatter was determined using a Vi-CELL™ Cell 
Viability Analyser (Beckman Coulter, Brea, CA). Diameter range was determined to be 
between 6 and 24 µm to exclude cell debris and aggregates (Seewöster and Lehmann 
1997). 5,000‒8,000 cells at mid-exponential phase were used for the analysis and 
duplicate readings were taken from two passages. The average cell diameter (D) was 
used to calculate the average cell volume (V) by assuming a spherical shape: 
𝑉 =
4
3
𝜋  
𝐷
2
 
3
                                                                                                                          (6.3) 
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Total cellular protein content was determined from whole cell lysates. Triplicate samples of 
1×10
6
 cells were washed twice in DPBS (Sigma-Aldrich, Poole, UK) then immediately 
stored at –20°C. Prior to extraction, samples were rapidly thawed on ice and then lysed in 
100 µL RIPA buffer (50 mM Tris–HCl, pH 8.0, with 150 mM sodium chloride, 1.0% Igepal 
CA-630 (NP-40), 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate (Sigma-
Aldrich)) supplemented with 1X Protease Inhibitor Cocktail Set III (Merck Chemicals, 
Nottingham, UK) at 4°C for 10 min. Samples were clarified by centrifugation at 8,000×g for 
10 min at 4°C. Soluble protein concentration was determined using Pierce™ BCA Protein 
Assay Kit (Thermo Scientific, Cramlington, UK) microplate procedure according to the 
manufacturer‘s instructions using BSA as a calibrant. Samples were diluted 1:8 in working 
reagent and concentrations determined using a PowerWave™ XSTM (Bio-Tek, Potton, 
UK) microplate reader at 570 nm. KC4 3.1 software (Bio-Tek) was used to generate the 
standard curve and interpolate the protein concentration in cell lysate (Figure  6.1). The 
average protein biomass content per cell was calculated from the total protein amount and 
the number of cells lysed. 
 
 
Figure ‎6.1: Example standard curve generated using BCA protein assay. The curve 
generated was used to determine the protein concentration in whole cell lysate. 
 
33 selected clones and the parental cell line were revived from the cell bank and seeded at 
3×10
5
 cells mL
-1
 in 125 mL Erlenmeyer shake flasks. Prior to transfection, clonally derived 
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cell populations were maintained for 4 passages (15 generations). All clones utilised CD-
CHO medium supplemented with 8 mM L-glutamine at 37°C in 5% CO2 and 140 rpm 
agitation. For a small-scale production, transient transfection was conducted at Day 2 of 
culture and each clone was transfected in triplicate using the Amaxa® Nucleofector® 96-
well Shuttle
TM
 protocol for CHO-S cells (Lonza, Basel, Switzerland). Briefly, 1.5×10
6
 cells 
per well were centrifuged at 90×g for 10 min. Cell pellet was resuspended in 20 µL 
Nucleofector solution SG and transferred onto the Nucleocuvette® plate with 0.33 µg of 
Sp35:Fc DNA. Following transfection, cells were diluted in 100 µL of culture medium and 
transferred into a 6-well plate at a seeding density of 1×10
5
 cell mL
-1
. Cells were cultured 
in CD-CHO supplemented with 8 mM L-glutamine at 3 mL/well working volume and 
incubated in a static incubator at 37°C, >85% humidity and 5% CO2 for 48 h prior to 
Sp35:Fc quantitation. For a larger scale suspension culture production, a subset of 16 
clones were co-transfected with 1 µg Sp35:Fc plasmid and 1 µg pmaxGFP® vector 
(Lonza) using the Amaxa Cell Line Nucleofector Kit V system (Lonza) and cultured in a 
TubeSpin for 96 h as described in Section 3.3.1.  
 
 
 
CHO-S clones were derived from the parental cell line in static microplate culture using a 
single LDC procedure at a probability of clonality of 0.939. The presence of a single cell-
derived colony was identified using automated image analysis of individual wells. After 19 
days of static microplate culture, 70 individual subpopulations were transferred to shake 
flask suspension culture with a strict 4-day sub-culturing regime in which clone-specific 
proliferation rate (µ) and accumulated generation number were routinely calculated. At 30 
generations of suspension culture, the clonal populations exhibited 1.5-fold variation in µ 
and 2.6-fold variation in peak VCD and there was a significant positive correlation between 
the two traits (Pearson‘s product moment correlation coefficient, PPMCC r = 0.849, P < 
0.0001; Figure  6.2). As we were parsimonious in our approach to study the 
heritability/evolution of clone functional phenotypes, a subset of 33 clones with varying µ 
and peak VCD were selected from this data and subjected to parallel prolonged culture 
(>120 generations, up to 100 days). 
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Figure ‎6.2: CHO-S clonal populations isolated by limiting dilution cloning exhibit large 
variations in phenotypic traits. At 30 generations of suspension culture, the specific 
proliferation rate, µ, varied by 1.5-fold while the peak viable cell density (VCD) varied by 2.6-
fold. The two traits are also positively correlated (PPMCC r = 0.849, P < 0.0001). The donor 
CHO-S parental cell population (white symbol) had an average µ and peak VCD of the clones. 
The clonally-derived cell populations varied markedly in µ throughout long-term 
suspension culture (Figure  6.3). This was most obvious at the first passage immediately 
following transfer from static into suspension (µ ranged from 0.398 to 0.914 day
-1
, or 2.3 to 
5.3 generations), although by the third passage, clone-to-clone variation in µ had narrowed 
to 0.655–1.037 day-1 (3.8‒6.0 generations). Additionally, the majority of clones displayed 
larger fluctuation in µ early in suspension culture and gradually became stable. Despite the 
general increase and stabilisation in µ during the long-term culture, the isolated clonal 
variants did not necessarily achieve the same growth fitness under the governing selective 
pressure (i.e., reach the maximum proliferation rate achievable by other variants). At 120 
generations, the µ still varied between 0.951 and 1.176 day
-1
 (up to 24% difference). 
In order to systematically quantify and compare the rate at which clone specific µ 
converged during the long-term suspension culture, the calculated values of µ for each 
clone during serial sub-culture were fitted to either a linear, second-order polynomial or  
logarithmic regression model depending upon the line that best fitted each data (mean R
2
 
= 0.605). For each clone, we then determined the average specific rate of increase in µ (% 
per generation) between 5 and 120 generations in suspension culture using values for μ 
derived from the line of best fit and Equation 6.4. 
Δ𝜇 =   
𝜇120
𝜇5
 
(1/(120−5))
 − 1                                                                                    (6.4) 
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Figure ‎6.3: CHO-S clones exhibit great variation in specific proliferation rate and peak 
viable cell density during long-term shake flask culture. (A) Specific proliferation rate (µ) of 
33 individual CHO-S clones and the parental cell line during shake flask culture for >120 
generations. The clones display a general increase in µ over time. (B) For each clonal isolate in 
A, calculated values for µ during serial sub-culture were fitted to the best fit model in each case. 
Plot shows that the clone-specific rate of change of µ (Δµ) is inversely proportional to initial µ 
(fitted µ at 5 generations). (C) Fast-growing clones tend to have higher peak viable cell density 
(VCD), and as the clones increase their µ between 30 and 120 generations, their peak VCD 
also increases. 
where µ5 is fitted µ at 5 generations in shake flask culture and µ120 is fitted µ at 120 
generations in suspension culture. Figure  6.3B shows that the clone-specific rate of 
change in µ varies greatly between 0.048 and 0.494% per generation (median Δµ = 
0.118% per generation), and that there was a strong negative correlation between initial µ 
(fitted at 5 generations) and the subsequent average rate of increase in µ (PPMCC r = 
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‒0.821; P < 0.0001). Together, the data in Figure 6.3A and B corroborate a recent study in 
this laboratory using CHOK1SV cells (Davies et al., 2013) that whilst clones further from 
the maximal observed µ at the beginning of serial-sub culture tend to increase their µ more 
rapidly than those with an intrinsically higher initial µ, clonal variation in growth 
characteristic persisted throughout prolonged culture. 
Interestingly, 12 clones and the parental cell line demonstrated significant increases 
in peak VCD (P < 0.001; mean increase 4.25×10
6
 cells mL
-1
) as they acquired their optimal 
µ after 120 generation, while 10 clones displayed slight improvements in peak VCD (P < 
0.05; mean increase 1.69×10
6
 cells mL
-1
). The rest of the clones (12 clones) did not show 
significant changes (P > 0.05). This data is illustrated in Figure  6.3C which shows a 
general shift in µ and peak VCD from 30 generations to 120 generations. We note that at 
both points of culture there was a positive correlation between µ and peak VCD (overall 
PPMCC r = 0.805, P < 0.0001). As the population-averaged cell culture processes and 
measurements are devoid of population and temporal noises (Brock et al., 2009), we 
deduce that the majority of clonally derived populations gradually underwent genetic drift 
where fast proliferating clonal variants were in sufficient abundance to permit their 
selection during serial sub-culture procedures and eventually became predominant. 
 
 
To study if the observed variations in clone-specific proliferation rate were correlated to 
differences in cell biomass and volume control, both parameters were examined using the 
33 clonal populations and the parental population that had undergone 60 generations. We 
reasoned that at this generation number, the cell populations were relatively stable (i.e., 
less susceptible to stochastic temporary variations in µ) and had minimal phenotypic 
diversity within a population. Clones were revived from the cell bank at 45 generations, 
cultured for 4 passages (approximately 15 generations) then sampled simultaneously at 
mid-exponential phase (Day 4). Average cell spherical volume was determined by image 
analysis (measured as mean diameter in µm of 5,000‒8,000 cells per sample) and total 
extracted cellular protein was determined by biochemical assay as an estimate of mean 
cell biomass content. These data are shown in Figure  6.4.  
Data from the biochemical assay revealed the variation in cell protein content (1.42-
fold) was positively correlated to cell volume (PPMCC r = 0.718; P < 0.0001, Figure  6.4A)  
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Figure ‎6.4: Relationship between the specific proliferation rate, protein biomass content, 
size and density at 60 generations. Clones were sampled simultaneously 96 h post-
inoculation. (A) Mean cell protein biomass of the clones positively correlates with mean cell size 
(volume) determined by automated image analysis, and (B) negatively correlates to clone-
specific proliferation rate, µ. (C) µ is also influenced by cell size, but (D) not by cell density. 
and was negatively correlated to µ (PPMCC r = –0.774; P < 0.0001; Figure 6.4B). 
Additionally, we note a negative correlation between µ and cell volume (PPMCC r =           
–0.745; P < 0.0001; Figure  6.4C). In other words, those clones that had large mean 
biomass and volume essentially required longer time to accumulate their biomass (lower µ) 
whereas clones with small mean cell biomass and volume required shorter time (higher µ). 
These data imply, in contrast to Davies et al. (2013), that the biomass accumulation rate of 
the clones are a largely similar of around 92‒115 pg cell-1 day-1 (1.25-fold variation). 
Accordingly, the variation in cell density (1.27-fold) was less clear than that of size (1.41-
fold) and there was no relationship between the former and µ (PPMCC r = –0.112; P > 
0.05; Figure  6.4D). Nevertheless, at the extremes of the observed diversity, the clonal 
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phenotypes could also be either "biomass efficient" (high cell protein content and high µ) or 
"biomass inefficient" (low cell protein content and low µ) that could potentially impact 
biomanufacturing processes. Significant clone-to-clone heterogeneity in size/biomass 
control was therefore evident. 
 
 
To narrow down the number of clones to be tested for Sp35:Fc expression capabilities, 
preliminary small-scale transient transfections were performed using plate-based 
Nucleofection system on the subset of 33 clones and the parental population (all at 30 
generations). Cell line specific recombinant protein production has been demonstrated to 
be significantly less variable using this transfection method (i.e. Nucleofection) than for 
lipoplexes (Davies et al., 2013) and polyplexes (Thompson et al., 2012) mediated 
transfections, as well as other electroporation methods (Zeitelhofer et al., 2007). After 48 h 
of static culture, the supernatant from each transfectant pool was analysed using ELISA. 
This analysis shows that the Sp35:Fc production capability of the clones vary by up to 2-
fold (P < 0.0001; Figure  6.5).  
 
 
Figure ‎6.5: CHO-S clones exhibit variation in transient difficult-to-express Sp35:Fc 
protein production. 33 clones and the parental population at 30 generations were each 
transfected in triplicate using plate-based Nucleofection system. The extracellular Sp35:Fc titre 
was measured by ELISA after 48 h of static culture. Clone-specific Sp35:Fc production is 
shown relative to that of parental CHO-S cell line used to normalise assays. Error bars 
represent the standard deviation of three technical replicates. 
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Based on the data in Figures 6.3A and 6.5, a sub-subset of 16 clones with varying 
proliferation rates and volumetric titres were selected. This is akin to the traditional 
screening of the highest stable producers in static culture following cloning before analyses 
in suspension culture. We acknowledge that there are differences in static and suspension 
cultures (e.g. oxygen transfer rate, cell confluency/density) that could affect cells behaviour 
and recombinant protein production. Therefore, cells with low productivities/titres in static 
culture might actually exhibit high production in suspension mode, or vice versa. Despite 
the differences, studies have shown that there are still good confidence intervals―for 
example, if one were to obtain the highest producer in suspension culture, the selection of 
the top 30% of the highest producers in static culture would give a 1% probability of 
incorrect rejection (Brand et al., 1994). As we were to select 50% of the clones, this small-
scale production data gave a higher chance in selecting high, mid and low producers than 
relying on the cell proliferation data alone. 
For each clone (from the sub-subset) as well as the parental population, transient 
transfections were performed at 30, 60 and 120 generations and cultured in suspension. At 
the latter generation number, the clonal populations were the most "evolved" with regard to 
µ and peak VCD. Thus, we hypothesised they exhibited the greatest genetic and functional 
diversities deriving from genetic drift and population dynamics both between and within 
physically isolated clonal populations. Additionally, to test the hypothesis that it was 
possible to obtain clonally-derived cell lines with intrinsic cellular capability to produce 
specific (DTE) recombinant proteins, the clones were tested for their ability to 
simultaneously express the difficult-to-express Sp35:Fc and an easy-to-express GFP. Both 
recombinant genes utilised CMV promoter encoded on different plasmid expression 
vectors, and transfected at the same DNA load. We reasoned that co-expression of two 
recombinant proteins with inherently distinct cellular requirements and using the same type 
of promoter would permit direct evaluation of both generic (e.g., cell transfectability) and 
protein specific (e.g., intracellular or extracellular secretion, cytosolic or ER 
folding/assembly) functional capabilities with minimal promoter interference (Huliak et al., 
2012). 
Transfections were performed using cuvette-based Nucleofection and cultured in 
suspension for a restricted 96 h period to minimise loss of recombinant plasmids (i.e., the 
effect of plasmid dilution on protein expression; Codamo et al., 2011). Cell viability of the 
clones measured 2 h post-transfection was 75.3‒85.6% (median 82.9%). The transfection 
efficiencies determined by measurement of intracellular GFP fluorescence by flow 
cytometry (example plot shown in Figure  6.6) at 48 h post-transfection revealed that 
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transfection efficiency of the clones were highly comparable, i.e. between 96.5% and 
99.6% (median 98.4%), with relatively homogenous transfected population compared to 
the parental cell line (Chapter 4, Figure 4.3). However, we observed that the mean and 
median fluorescence between clones varied by up to 5-fold (Figure  6.6B). Similar results 
were observed at 96 h post-transfection but with slightly lower clone-specific mean/median 
fluorescence intensity (data not shown) that can be ascribed to the effect of recombinant 
plasmid dilution/loss at high cell generation number post-transfection. 
 
 
Figure ‎6.6: Example flow cytometry plots of GFP content of different clones. Cells were 
co-transfected with an equal amount of Sp35:Fc and pmaxGFP plasmids. GFP fluorescence 
was quantified 48 h post-transfection against negative control cells that were mock-transfected. 
Transfection efficiency obtained was 96.5–99.6% and mean/median fluorescence varied by up 
to 5-fold. (A) Cell population gated for granularity and size. (B) Example histogram of two clonal 
populations with low fluorescence (black) and high fluorescence (grey).  
Figure  6.7 shows the transient Sp35:Fc production and IVCD for 16 selected clones 
and the parental population at 30, 60 and 120 generations. With respect to the IVCD, the 
majority of clones acquired significant increases in µ (effectively the "efficiency" of biomass 
synthesis) between 30 and 120 generations which was consistent with the long-term 
culture data (Figure  6.3A), indicating that it was possible to maintain the clones growth 
characteristic during cryopreservation procedure. Furthermore, it is interesting to highlight 
that all of maximally "evolved" clones (i.e., cells at 120 generations) except clone 8 
exhibited an IVCD below that of the donor CHO-S parental population (Figure  6.7). This 
could be explained by the population dynamics within the highly heterogeneous donor 
population, in which fast proliferating clonal variants progressively became predominant 
resulting in a relatively high population-averaged µ (Davies et al., 2013).  
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Figure ‎6.7: "Evolution" of CHO-S clones impact their transient recombinant Sp35:Fc 
protein production capability. Each clone at 30 generations (A), 60 generations (B) and 120 
generations (C) was transfected in duplicate and maintained in suspension culture for 96 h. 
Integral of viable cell density (IVCD) was calculated from the daily viable cell density, while 
secreted Sp35:Fc was measured 96 h post-transfection. Clones are ranked in order of 
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ascending titre at 30 generations. Clone-specific IVCD, Sp35:Fc titre and qP are shown relative 
to that of parental cells at 30 generations used to normalise assays. Error bars represent the 
standard deviation of two biological and two technical replicates. 
Unlike the generally acquired increment in clone µ during the long-term culture, 
divergence in the clone-specific ability to manufacture recombinant Sp35:Fc was bi-
directional (Figure  6.7). In this case, difference in qP changed on a clone-by-clone basis 
and therefore there was not a similar conserved trend in the change in clone Sp35:Fc 
process titre. On the extremes, C24, which was the lowest producer at 30 generations, 
evolved to become the highest producer after 120 generations, whereas C46 and C56 
which were among the early promising candidates (at 30 and 60 generations) lost the 
production capability during long-term culture. Several high-producing clones exhibited 
heritably improved transient Sp35:Fc production, and this could be achieved via an 
increase in either IVCD (C13) or qP (C20 and C69). 
We observed in Figure 6.7 that there was an inverse relationship across the clones 
where fast proliferating clones had relatively low Sp35:Fc qP (e.g. C8, C39) compared to 
slower growing cells (e.g. C26). Additionally, despite the 25% average increase in IVCD 
from 30 to 120 generations, the clones‘ average qP decreased by 9% and only one clone 
(C24) showed significant improvement. Analysis of these data show that there was a 
significant negative correlation between the qP and IVCD (PPMCC r = –0.784, P < 0.0001; 
Figure  6.8A). This inverse relationship was not (solely) due to the faster dilution of Sp35:Fc 
plasmid DNA in fast-proliferating cells as no correlation was observed with median (or 
mean) GFP fluorescence on any day of culture (best PPMCC r = 0.126, P > 0.05; Figure 
 6.8B). Indeed, our early transfection optimisation work using GFP on the parental cell line, 
as well as other work in this laboratory using different cell lines, demonstrated that GFP 
fluorescence intensity was always in proportion to the transgene copy numbers (data not 
shown). Therefore, we hypothesise that the negative correlation between µ and Sp35:Fc 
qP was rather derived from increased host cell competition for energy and synthetic 
resources for the production of either cell own protein biomass or the DTE protein. 
We further analysed the relationship between the specific productivity and the protein 
biomass of each clone (untransfected clonal populations) at their respective generations. 
This analysis revealed that qP was directly correlated to the cell size/biomass content 
(PPMCC r = 0.759, P < 0.0001; Figure  6.8C) but this was not the case with GFP where 
there was no correlation between cell biomass and median (or mean) fluorescence (best 
PPMCC r = 0.060, P > 0.05; Figure  6.8D). Together, these data show that cell lines with the  
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Figure ‎6.8: Difficult-to-express Sp35:Fc production rate correlates to cell-specific 
proliferation rate and biomass content but no relationship is observed in the case of 
GFP. (A) Fast-growing cells tend to have low Sp35:Fc specific productivity (qP), (B) whilst no 
such correlation is observed with GFP. (C) Cells that are good in manufacturing cell protein 
biomass (and thus have large size) are good in manufacturing Sp35:Fc, (D) but not necessarily 
GFP. (E) No apparent relationship is observed between GFP content and Sp35:Fc productivity, 
(F) although a weak correlation is observed with the volumetric titre. Data shown are for 96 h 
culture. 
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capability to accumulate high biomass while maintaining relatively high proliferation rate 
compared to the parental cell line were very likely to be high producers for DTE Sp35:Fc 
protein. In contrast, cells that were good in producing GFP were not necessarily good 
Sp35:Fc producers (Figure ‎6.8E), even though we did observe a weak correlation between 
median GFP fluorescence and Sp35:Fc volumetric titre (PPMCC r = 0.352, P < 0.05; 
Figure ‎6.8F). However, we acknowledge that the lack of correlation, although unlikely, 
could also be due to different ratio of GFP plasmid to Sp35:Fc plasmid uptake. We deduce 
that it is feasible to isolate variant parental clones that exhibit enhanced, heritable trait(s) to 
produce a particular DTE protein such as Sp35:Fc, or to harness the heterogeneity within 
the cell populations for this purpose. 
 
 
Non-reducing SDS-PAGE and immunoblotting for Sp35:Fc showed the presence of high 
molecular weight complexes (i.e., 400 kDa tetramer and 600 kDa hexamer aggregates) in 
all clonal cell lines (at different generations) tested as shown in Figure  6.9A. Under 
reducing condition, these high molecular weight complexes were reduced to 100 kDa 
monomer (data not shown) as previously observed with the parental cell line (Chapter 4, 
Figure  4.5), which indicated that the aggregates were disulphide bonded.  
Despite the significant clone-to-clone variations in qP (Figure  6.7), the quantitative 
analysis showed that all clones at different generations produced comparable amount of 
aggregates (Figure  6.9B). Only two clones, C26 and C69, demonstrated appreciably (and 
consistently) lower aggregate levels compared to the CHO-S parental cell line at 30 
generations (P < 0.1). Even though we were still able to establish a negative correlation 
between qP and aggregate amount (PPMCC r = -0.571, P < 0.0001; Figure  6.10), the 
large measurement noise/error produced from the immunoblotting technique might 
diminish the statistical confidence. An orthogonal method for aggregate quantification, 
preferably a more robust and sensitive one such as analytical ultracentrifugation or 
dynamic light scattering (Arakawa et al., 2007), is required to cross-check the Western blot 
data. However, it is worth noting that the two clones with noticeably lower aggregates (C26 
and C69) had relatively high qP compared to other clones and the parental cell line (Figure 
 6.7). We contemplate that these two clonal cell lines had better ER processing facilities for 
the production of DTE proteins. 
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Figure ‎6.9: CHO-S clones and the parental cell line at different generations did not differ 
significantly in the amount of Sp35:Fc aggregates produced. Cell culture supernatants 
from the parental cell line and 16 clones at 30, 60 and 120 generations were harvested 96 h 
post-transfection and subjected to quantitative Western blotting. (A) Representative Western 
blot image showing Sp35:Fc native dimer (200 kDa) and aggregates (400 and 600 kDa) 
produced by the parental cell line and clones at 60 generations. Under reducing condition, all 
bands were reduced to 100 kDa (data now shown). (B) Relative quantification reveals that most 
clones produce comparable amount of aggregates relative to the parental cell line. C26 and 
C69 demonstrated appreciably and consistently lower aggregate levels compared to the 
parental cell line at 30 generations (P < 0.1). Error bars represent the standard deviation of two 
biological and two technical replicates. 
 
This work demonstrates that it is practically possible to harness the intrinsic variability of 
CHO cells in heterogeneous parental populations to acquire clonal derivatives that exhibit 
heritable variations in key functional attributes (e.g. µ, biomass accumulation) that favour 
DTE protein productions. The most basic observations were related to the adaptation 
response of clonally-derived host cell populations in their µ during routine sub-culture. 
Importantly, rapidly proliferating CHO-S clones with enhanced Sp35:Fc production rate 
compared to the donor parental cell line could also be obtained. The clones steadily 
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Figure ‎6.10: Clones that have a high capacity to manufacture difficult-to-express Sp35:Fc 
may produce less aggregates. There is a weak but highly significant negative correlation 
between clone specific Sp35:Fc productivity and the amount of aggregates produced across the 
clones at different generations. 
increased their capability to efficiently acquire cell biomass (i.e., increase µ) towards their 
clone specific maximum as well as to achieve high peak cell density, although this was not 
the case for all clonally derived populations. We also observed a number of clones that did 
not respond to the imposed selective pressure, exhibiting a relatively constant, sub-
maximal µ and peak VCD throughout the study (e.g., C26 and C51), and two clones 
displayed a similar maximal µ and peak VCD throughout the long-term culture, constantly 
in excess of the CHO-S parental average. Underpinning this averaged evolution 
progression were diverse clone-specific adaptive phenotypes derived from genome 
mutation and genetic drift (Davies et al., 2013).  
The exact origins and molecular mechanisms underpinning genetic mutation or 
instability in mammalian cell lines are not yet fully understood. The most relevant and 
convincing evidence arises from the genetic instability models of cancer cell progression 
(O'Callaghan and James, 2008). Genetic instability is a characteristic of most cancers in 
which cancer cells display highly rearranged karyotypes characterised by translocations, 
deletions, inversions, abnormally banding chromosome regions, and extrachromosomal 
double minutes (Ma et al., 1993; Ruiz and Wahl, 1990). These, in turn, give rise to new 
(mutated) cells that tolerate some degree of malfunction in mitotic homeostasis and have 
survival advantages over their normal progenitors (Boland et al., 2009). Epigenetic 
changes may also be relevant in which they can collaborate with genetic changes to 
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perturb multiple key pathways in ways that promote carcinogenesis (Jones and Baylin, 
2007). For example, DNA hypomethylation has been associated with chromosomal 
instability (Wilson et al., 2007) whereas methylation of CpG island promoters is known to 
cause silencing of key regulatory genes, which leads to an increased frequency of 
mutations (Jones and Baylin, 2007). 
In the CHO-S donor parental cell population used in this study, such altered 
genotypes/phenotypes were apparently present at a frequency high enough to yield, after 
sorting 70 individual cells, at least 3 different stably improved subclones (C13, C20 and 
C69) with regard to µ and qP. Using these new clones, 1.4‒1.6-fold increases in volumetric 
titre were achievable, whilst further increase (up to 1.8-fold) could be obtained using the 
"highly evolved" C24 clone at 120 generations. Even though we were unable to identify 
host cell lines with significantly lower Sp35:Fc aggregates, this was not unexpected 
considering the fact that biopharmaceutical companies normally screen several hundred to 
several thousand clones to obtain a desirable production cell line. The fact that some of 
our top producers at 30 generations (e.g. C46 and C56) had a temporarily stable 
production characteristic was also not surprising—we had observed this in other 
experiments in this laboratory which dealt with phenotypic/functional properties that vary 
over long term culture (Davies et al., 2013; Fernandez-Martell et al., unpublished data). 
However, our long-term culture data suggest that the rate of acquirement of 
genetic/functional diversity in some clonal populations was sufficient to respond to the 
imposed selective pressure to yield high Sp35:Fc producers. In view of this, we 
hypothesise that subsequent cloning of Clone 24 at 120 generations, which displayed the 
substantial improvement in both growth rate and productivity, will yield sub-clonal 
populations with significantly improved transient Sp35:Fc production. 
It was observed that the CHO-S sub-populations exhibited substantial clone-specific 
difference in size and cell protein biomass that is directly correlated to µ. This data is in 
agreement with a mathematical analysis showing that mammalian cells exhibit variable 
control in mitotic timing mechanisms where cell proliferation rate is size-dependent 
throughout the cell cycle (Tzur et al., 2009). Additionally, difference in biomass 
accumulation rate obviously impacts mammalian cell-based manufacturing processes that 
utilise cellular protein biomass to create recombinant proteins. Recent studies have shown 
that biomass accumulation rate impacts the ability of clonal variants to perform specific N-
glycan reactions (Davies et al., 2013), whilst deliberate engineering of cell biomass 
synthesis, either via engineering amino acid transport (Tabuchi et al., 2010) or cell 
signalling systems (Dreesen and Fussenegger, 2011), has been positively associated with 
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increased productivity. In the case of DTE Sp35:Fc, we found that it was possible to 
directly compare the host cell‘s own commitment to biomass synthesis to that of the 
product, i.e. clones with high unit biomass per cell and large size had more efficient 
regulation of Sp35:Fc production (and potentially with minimal aggregates). Although it 
may be argued that the variation in clone-specific proliferation rate may influence the 
Sp35:Fc productivity (due to variation in plasmid dilution rate in the cell), another study in 
this laboratory by Syddall et al. (unpublished data) also demonstrated that large/high 
biomass CHOK1SV cells were better producers compared to their smaller CHOK1V 
counterpart that had similar µ. 
We speculate that the large CHO-S clones with high biomass have superior protein 
folding capacities in the ER, which in turn can be associated with large ER size and high 
mitochondrial mass (Bi et al., 2004). This leads to better processing and secretion of 
recombinant proteins that are relatively difficult to fold, resulting in higher productivity and 
better cell survival. Hu et al. (2013) showed that CHOK1 cells, which had relatively large 
ER size and mitochondrial mass, enabled stable cell line development for MAbs that are 
difficult to express in DUXB11-derived cells. Indeed, protein folding process consumes 
considerable energy (Dobson, 2003) which is supplied by the mitochondria, and therefore 
high mitochondrial mass may be advantageous for the production of DTE proteins (Bravo 
et al., 2011; Simmen et al., 2010). On the other hand, the significance of ER size can be 
recognised from the unfolded protein response (UPR), which drives expansion of the ER to 
boost its protein folding capacity and induce ER-associated degradation (ERAD) to 
degrade misfolded proteins (Bommiasamy et al., 2009; Sriburi et al., 2007). 
Overexpression of the active form of X-box binding protein 1 (XBP1s) in CHOK1 cell lines 
has been shown to expand the ER and the Golgi that lead to an increase in overall 
production capacity (Tigges and Fussenegger, 2006). 
In cell line development, GFP fluorescence represents a useful surrogate correlated 
to levels of the protein of interest. Often, there is a high correlation between clone 
production of GFP and (easy-to-express) protein of interest including MAb (Davies et al., 
2013; Kim et al., 2012) and growth factors (Freimark et al., 2010; Meng et al., 2000), thus 
enabling easy, rapid identifications of high producers. Yet, this could not be applied in the 
case of Sp35:Fc and possibly other difficult-to-express proteins. We hypothesise that this 
is due to the activation of the UPR during DTE protein expression that altered the cellular 
processes. Instead, we found that higher probability of success could be achieved by 
screening fast-growing cells (high µ) with large size or high biomass content. This data 
provides an important understanding for CHO host cell choice to express difficult to 
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produce recombinant proteins, even though advanced studies at cellular levels 
(transcriptomics, proteomics, etc; Charaniya et al., 2009; Dinnis et al., 2006) are required 
to reveal the underpinning factors. Increasingly complex recombinant protein products 
necessitate host cells with dedicated cell factories to achieve both high IVCD and qP. We 
anticipate that such cell lines would require an extensive "directed evolution" approach 
(Hernández Bort et al., 2010; Prentice et al., 2007) rather than mere exploitation of natural 
variation/mutation within the host cell populations. 
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This chapter describes a novel vector engineering approach specifically beneficial for difficult-
to-express (DTE) protein production. The objective is to construct an expression vector that can 
circumvent the impact of overexpression of DTE protein on cell growth whilst achieving high 
productivity. By incorporating ER stress elements into a vector and manipulating endogenous 
and/or exogenous UPR transactivors, we show that it is feasible to create a synthetic amplifier 
circuit that could lead to improved DTE protein production. 
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The CMV-ATF6c vector (Appendix A) was constructed by Dr Stefan Schlatter. The ERSE-
SV40 vectors driving Sp35:Fc, SEAP or ATF6c, as well as SV40 vectors driving Sp35:Fc 
or ATF6c (Appendix A) were constructed by Dr Nathan West. Recombinant SEAP assay 
for this chapter was performed by Dr Nathan West. 
 
 
Viable cell density (VCD) and cell specific productivity (qP) are two key factors in a 
biomanufacturing process using mammalian cells. As a molecular basis to the latter, 
efficient promoter/enhancer systems are a prerequisite for achieving high recombinant 
protein expression levels, especially for characteristically ―easy-to-express‖ (ETE) proteins 
where transcriptional rates have been quantitatively shown to exert high levels of control 
over production (Ho et al., 2006; McLeod et al., 2011; O'Callaghan et al., 2010). 
Accordingly, expression is generally directed by strong constitutive promoter/enhancer 
combinations to maximise recombinant gene transcription levels.  
Today, the human cytomegalovirus (CMV) promoter is utilised to drive expression of 
many biopharmaceutical products (Xia et al., 2006). It is a complex genetic element 
evolved by the virus to allow it to infect many different mammalian host cells including 
Chinese hamster ovary (CHO) cells (Stinski and Isomura, 2008). Yet, given its use for 
more than 25 years, the search for new expression promoting elements has become of 
major importance (Makrides, 1999). For example, powerful expression systems have been 
constructed from the promoter region of the Chinese hamster elongation factor-1α (EF-1α) 
gene and its 5' and 3'flanking sequences (Running Deer and Allison, 2004). Novel, strong 
promoters have also been synthetically derived (Brown et al., 2014; Schlabach et al., 
2010) in which they offer a potentially attractive advantage of removing repeat elements 
from the vectors that could contribute to long-term expression instability via promoter 
methylation and gene deletion events (Kim et al., 2011a). 
 Apart from the strength of a promoter, the design of a vector also plays an important 
role to yield high expression levels. For instance, a bi-directional promoter system 
(Chatellard et al., 2007) has been reported to achieve similar expression levels for multi-
chain proteins (antibodies, heterodimeric peptide hormones, etc) compared to 
conventional promoters without the use of gene amplification steps. Additionally, a single 
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open reading frame (ORF) expression vector driving both MAb heavy chain and light chain 
expressions can yield higher expression compared to dual ORF vector (Jostock et al., 
2010), even though contrary reports (Davies et al., 2011) have also been published. On 
the other hand, for difficult-to-express (DTE) proteins that have mis-matched kinetics of 
transcription, translation and folding reactions, maximising transcription alone is unlikely to 
be beneficial. Therefore, efficient expression systems also require optimised vector 
designs for specific proteins and/or mammalian cell hosts.  
Recent work in this laboratory by West (2014) has demonstrated that the 
transcriptional activity of the simian virus 40 (SV40) promoter can be increased when an 
ER stress response element (ERSE) is incorporated into the promoter's upstream region 
and is activated (Appendix D). ERSE, possessing a consensus sequence of CCAAT-N9-
CCACG, is present in the proximal promoter regions of many ER stress-responsive genes. 
This sequence is necessary and adequate for the induction of a number of ER chaperones 
including BiP, GRP94, and calreticulin during the unfolded protein response (UPR; 
Yoshida et al., 1998). Under normal conditions, only the general transcription factor NF-Y 
binds to the CCAAT motif of the ERSE. Under ER stress conditions, the cleaved ATF6 
(ATF6c) and spliced XBP1 (XBP1s) bind to the CCACG motif of the ERSE, resulting in the 
transcriptional activation of the ER chaperones and foldases (Yamamoto et al., 2004; 
Yoshida et al., 2000). Even though the enhancement effect of ERSE on SV40 promoter 
was not observed when the ESRE was fused to a human CMV promoter (West, 2014), the 
relatively weak ERSE-SV40 promoters could be utilised to provide optimised protein-
specific transcription activity kinetically coordinated with polypeptide-specific translation or 
folding rates. 
Clearly, some aspects of an endogenous UPR (e.g. translation attenuation, ERAD 
and apoptosis) and its sustained activation are incompatible with high expression of DTE 
recombinant proteins. Stable transfectants capable of DTE protein production effectively 
avoid UPR induction via minimisation of ER load through reducing the rate by which 
recombinant polypeptides enter the ER including reduced rDNA transcription and/or mRNA 
translation (Davies et al., 2011; Mason et al., 2012). On the other hand, for any given 
transient expression of DTE protein, a balance of recombinant polypeptide synthesis 
activity (i.e., mRNA transcription and translation rates) and host cell UPR activation act in 
concert to define the sub-optimal productivity. Consequently, cell engineering solutions to 
improve DTE protein production typically act to minimise UPR induction (Pybus et al., 
2014a), whereas conventional gene expression control via gene copy number or promoter 
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strength (Brown et al., 2014) does not allow discrete control/change over expression 
during the culture process.  
We hypothesised that it was possible to control recombinant protein expression by 
incorporating ERSE into an expression vector and manipulating endogenous/exogenous 
UPR transactivation. To achieve this, we constructed several vectors containing the ER-
stress responsive promoter (ERSE-SV40) driving Sp35:Fc, SEAP (as a model ETE 
protein) or the active form of the UPR transactivator ATF6. We then expressed these in 
CHO cells in various combinations using short-term transient platforms as well as in a fed-
batch mode. We tested the general hypothesis that we can create a small synthetic 
"amplifier/dual activator" circuit specifically beneficial for DTE proteins, where expressed 
ATF6c both amplifies its own expression via transactivation of ERSE-SV40, and activates 
Sp35:Fc expression via the same mechanism, whilst generally transactivating cellular ER 
capacity via endogenous ERSEs (Figure  7.1). 
 
 
 
 
 
 
Figure ‎7.1: Schematic diagram of the synthetic "amplifier" circuit designed for a dynamic 
rDNA expression. Expression of difficult-to-express Sp35:Fc activates the UPR and cellular 
ER capacity via endogenous ERSEs. Expressed ATF6c both amplifies its own expression and 
Sp35:Fc expression via transactivation of ERSE-SV40 whilst the endogenous UPR proteins 
further amplify the recombinant gene expressions. 
 
 
pSEAP2-Control plasmid (Clontech, Mountain View, CA) was used as the SV40 vector 
backbone for all ERSE-SV40 vectors as well as the SV40-Sp35:Fc and SV40-ATF6c 
vectors. The ERSE vectors were created by inserting oligonucleotides containing the 
ERSE sequence upstream of the SV40 promoters using a method described by Jobbagy 
et al. (2002) for the unidirectional (same orientation) insertion of repeated DNA sequences. 
ATF6c Sp35:Fc 
ATF6c UPR Sp35:Fc 
Vector 
Protein 
ERSE-SV40 ERSE-SV40 
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The CMV-ATF6c vector was created by inserting the ATF6c gene, which is based on the 
mouse (Mus musculas) coding DNA sequences, into the pcDNA™3.1(+) vector backbone 
(Life Technologies, Paisley, UK). GeneArt® pMA DNA vector (Life Technologies) 
containing Sp35:Fc gene but no promoter was used to equalise DNA load where 
necessary. 
 
 
Transient transfection was conducted using Lipofectamine® LTX with PLUS™ reagent 
(Life Technologies) as described in Chapter 3, Section 3.3.2. The cell cultures were 
agitated at 140 rpm and incubated at 37°C under 5% CO2. Nutrient supplementation 
started 6 h post-transfection using 10% v/v CHO CD EfficientFeed™ B (Life 
Technologies), followed by 10% v/v EfficientFeed B each on Days 2, 4, 6 and 8, giving a 
total of 50% v/v EfficientFeed B throughout culture. 
 
 
 
A total of nine different expression vectors were constructed, harbouring either the CMV 
promoter, SV40 promoter or an ER-stress responsive promoter that drives either SEAP, 
Sp35:Fc or the active form of the UPR transactivator ATF6 (Figure  7.2). The ER-stress 
responsive promoter consisted of nine copies of ERSE units for optimal response, where 
these ERSEs were fused with an SV40 promoter in the vector construct, giving rise to the 
ERSE-SV40 promoter (henceforth called 'ERSE promoter'). Additionally, UPR 
transactivator ATF6c was utilised as it had been shown to give higher induction effect on 
ERSE than XBP1s (West, 2014; Appendix D). Both SEAP and Sp35:Fc were used to show 
whether the addition of ERSE had any significant impact on DTE protein expression. CHO-
S cells were transfected with the same recombinant plasmid copy number (48,000 copies 
per cell) using the transient Nucleofection platform in various combinations as shown in 
Figure  7.3. Cloning plasmids containing no promoter were used to maintain the same total 
DNA load in all transfection experiments.  
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Figure ‎7.2: Schematic representation of nine different vectors containing CMV promoter, 
SV40 promoter or an ER-stress responsive promoter (ERSE-SV40) driving either 
Sp35:Fc, secreted alkaline phosphatase (SEAP) or the active form of the UPR 
transactivator ATF6 (ATF6c). The ERSE-SV40 promoter was constructed by fusing nine 
copies of ERSEs with an SV40 promoter. 
Figure  7.3A shows the transient expression experiments of the ETE SEAP, 
normalised to the CMV control culture. On their own, the SV40 and ERSE promoters 
possess less than one-third the activity of a control construct harbouring the CMV 
promoter, in agreement with previously published literature that the CMV promoter is 
stronger than the SV40 promoter in many cell lines especially CHO (Foecking and 
Hofstetter, 1986; Liu et al., 1997; Qin et al., 2010; Zarrin et al., 1999). Comparison of the 
control for both SV40-SEAP and ERSE-SEAP showed that their levels of expression were 
identical, showing that the incorporation of ERSE alone has no effect on recombinant 
promoter expression from a vector using the SV40 promoter. Co-expression CMV-SEAP 
vector with CMV-ATF6c vector resulted in 1.8-fold increase in qP compared to the CMV 
control culture. When the CMV-ATF6c vector was replaced with an equal amount of 
ERSE-ATF6c vector, an increase of 1.4-fold was observed. Even though the effect was 
halved, this is evidence that recombinant ATF6c is capable of transactivating a vector 
containing ERSE upstream of a SV40 promoter (considering the fact that SV40 promoter 
has only one-third activity of that of the CMV). Increasing the ERSE-ATF6c copy number 
ratio would also further increase the qP. In all cases, the cell growth was hardly affected, 
leading to net 1.3‒1.5-fold increases in volumetric titre. 
When comparing the SEAP protein expression between the SV40 vector transfection 
(alone) and the ERSE-SEAP and CMV-ATF6c vectors co-transfection, there was a 3.1-fold 
difference in qP (Figure  7.3A). This highly significant boost in SEAP expression is a good 
reflection on the positive effect of the inclusion of ERSE sequences upstream of the SV40 
promoter and the response to the ATF6c transactivator. However, the strength of SV40-
ATF6c and ERSE-ATF6c vectors were too weak to produce noteworthy effects on ERSE-  
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Figure ‎7.3: Effects of CMV, SV40 and ERSE-SV40 (ERSE) promoters on transient SEAP 
and Sp35:Fc productions, with and without ATF6c co-expression. The transfections were 
performed with an equal amount of 48,000 SEAP or Sp35:Fc DNA copies with a cloning vector 
used to equalise the total DNA load of 3.6 μg per 4.5×106 cells. Cell culture supernatant was 
harvested 96 h post-transfection and analysed by ELISA. (A) Transfections were carried out in 
various formats to systematically understand the effect of the ERSE system on easy-to-express 
SEAP expression. Each co-transfection was carried out at a specific SEAP to ATF6c rDNA 
copy number ratio as indicated under each transfection format. (B) Similar transfection formats 
were performed for difficult-to-express Sp35:Fc. All data are expressed as a relative (fold 
change) of the production exhibited by their respective CMV control promoter without any 
ATF6c co-expression. Error bars represent standard deviation of two biological and two 
technical replicates. 
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SEAP, even when the ERSE-ATF6c were doubled to 1:1 ratio. Indicatively, when a mixture 
of CMV-SEAP and ERSE-SEAP (1:1 ratio) was used, the SEAP expression was at about 
75% of the CMV control culture which was roughly the average of individual CMV promoter 
and ERSE promoter expression levels. 
Figure  7.3B shows the results for the DTE Sp35:Fc protein, in which very different µ 
(reflected in the IVCD) and qP profiles were observed. Firstly, even though the SV40 
promoter maintained its relative activity (qP) compared to the CMV control, the low-level 
expression of DTE protein also reduced the metabolic burden and minimised the impact of 
the UPR on the cells, hence enabling the cells to grow better. However, the presence of 
low-level endogenous UPR transactivators could still be observed where expression using 
the ERSE-Sp35:Fc vector alone was able to increase the recombinant protein expression 
compared to using SV40 vector, although this was offset by a reduction in cell growth. 
Unlike SEAP, the effects of ATF6c co-expression were less profound on CMV-Sp35:Fc 
productivity, with improvements of only around 1.3‒1.5-fold. We infer that this is related to 
the pre-existence of endogenous UPR transactivators in the cells that diminished the 
apparent effect of recombinant ATF6c. Moreover, the cell growth was significantly 
depressed, resulting in no benefits in terms of volumetric titre. Similarly, the ERSE-
Sp35:Fc vectors were generally less responsive to CMV-ATF6c co-expression.  
Interestingly, co-expression of either SV40-ATF6c or particularly ERSE-ATF6c with 
ERSE-Sp35:Fc resulted in relatively high activity of Sp35:Fc productivity (Figure  7.3B), 
especially when compared to SEAP production using the same strategies (Figure  7.3A). 
This suggests that a positive feedback loop existed between the ATF6c/endogenous UPR 
transactivators and ERSE-SV40 promoter activation, and that the system is particularly 
beneficial for DTE protein production. Furthermore, the mixture of CMV-Sp35:Fc and 
ERSE-Sp35:Fc (1:1 ratio) was able, to some extent, to induce the ERSE-Sp35:Fc vector 
that resulted in higher expression activity compared to SEAP. This again demonstrates 
that a vector containing ERSE upstream of an SV40 promoter is capable of responding to 
endogenous UPR transactivators. In the hindsight, as Sp35:Fc production was generally 
less responsive to ATF6c and/or resulted in considerable growth depression, no significant 
improvements in volumetric titre was observed in all cases. On the other hand, as we did 
not measure the levels of ATF6c, further work is required to validate that the lack of 
responses to ATF6c were not due to the inability of the cells to overexpress the UPR 
transactivator. Similarly, additional work is required to validate the synthetic circuit by 
measuring the levels of recombinant mRNA and UPR induction in each case. 
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In order to further understand the relationship between the ERSE system and endogenous 
UPR induction during DTE protein overexpression, we transfected the cells with 50% 
higher Sp35:Fc DNA copy number (72,000 copies per cell) to induce a higher UPR 
response as previously shown in Chapter 4 (Figure  4.7; equivalent to an increase from 2 to 
3 µg of Sp35:Fc DNA). We anticipated that the ERSE promoters would become more 
active at very high Sp35:Fc overexpression that in turn could lead to an increase in 
volumetric product titre. These results are shown in Figure  7.4. 
 
 
Figure ‎7.4: Cells were transfected with higher rDNA load (72,000 DNA copies per cell) to 
invoke more UPR response. A cloning vector used to equalise the total DNA load of 4.5 μg 
per 4.5×10
6
 cells. Cell culture supernatant was harvested 96 h post-transfection and analysed 
by ELISA. Data are expressed as a relative (fold change) of the production exhibited by CMV 
control promoter without any ATF6c overexpression. Error bars represent standard deviation of 
two biological and two technical replicates. 
At this high Sp35:Fc DNA copy number (72,000 copies per cell; Figure  7.4), the 
relative activity (qP) of SV40 promoter was approximately half of the CMV control culture, 
which is higher than the one-third activity achieved when 48,000 copies were used (Figure 
 7.3B). Together, these data reflect the saturation phenomenon of DTE protein expression 
using CMV as observed in Chapter 4 (Figure  4.4A). Significant activity of the ERSE 
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promoter can also be observed when the ERSE-Sp35:Fc vector was used on its own―a 
positive consequence of the high endogenous UPR transactivator activity (Figure  7.4). 
Expectedly, the qP of the ATF6c-overexpressing cells was considerably higher (1.5‒1.9-
fold increase compared to the CMV control culture; Figure  7.4) as opposed to the 1.3‒1.6-
fold increases obtained with 48,000 copies shown earlier (Figure  7.3B). Additionally, the 
ERSE-ATF6c promoter became slightly more active than the CMV-ATF6c (Figure  7.4), 
hence granting more benefit compared to cells with lower DNA copy number (Figure  7.3B). 
Importantly, we observed that the co-expression of ERSE-SP35:Fc with CMV-ATF6c or 
ERSE-ATF6c resulted in significant enhancement in the ERSE promoter activities and qP 
levels (Figure  7.4) compared to when 48,000 Sp35:Fc copies were used (Figure  7.3B). 
The combination of CMV-Sp35:Fc and ERSE-Sp35:Fc (1:1 ratio) also appeared to yield 
similar results to the CMV control. Yet again, in all cases, cell growth was substantially 
oppressed at high Sp35:Fc expression, and this negative relationship resulted in little or no 
improvement in product volumetric titre compared to the normal CMV culture control. We 
deduced that the full potential of the synthetic amplifier circuit could only be realised during 
fed-batch culture. 
 
 
We hypothesised that transition of CHO cells through an extended Sp35:Fc production 
process, with the associated dynamic variation in cell physiology and function (e.g., growth 
rate, UPR induction) may further amplify the relative proportion of hetero/endogenous 
factors affecting ERSE promoter activity. However, an initial experiment using 
Nucleofection system showed complete loss of productivity after 7‒8 days post-
transfection, and therefore transient transfection was performed using lipoplex-mediated 
transfection where cell culture and productivity could be maintained for about 8‒9 days in 
fed-batch mode. The lipid-based method was preferred over polymer-based (e.g. 
polyethylenimine) to ensure production variability was directly linked to differences in 
promoter activity rather than mediator-specific artefacts, where lipoplex-delivered plasmids 
have been shown to be more efficiently expressed than polyplex-delivered plasmids on the 
basis of protein expression per plasmid number in the nucleus (Cohen et al., 2009). 
Transfection efficiency was determined by measurement of intracellular GFP by flow 
cytometry which showed that transfection efficiency using this method was >96% at 96 h 
post-transfection (Figure  7.5). 
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Figure ‎7.5: Example flow cytometry plots of intracellular GFP content of different clones. 
25×10
6
 cells were co-transfected with 16.67 µg pmaxGFP plasmid and GFP fluorescence was 
quantified 96 h post-transfection against negative control cells that were mock-transfected with 
empty vector. (A) Cell population gated for granularity and size. (B) Example histogram of cells 
with fluorescent label with transfection efficiency >96%. 
In order to comprehend the dynamic ERSE promoter activity during fed-batch culture, 
we studied the co-expression of different Sp35:Fc and ATF6c vectors at a 1:0.5 ratio, 
namely the combinations of (i) CMV-Sp35:Fc promoter and CMV-ATF6c promoter 
(CMV/CMV), (ii) CMV-Sp35:Fc promoter and ERSE-ATF6c promoter (CMV/ERSE), and 
(iii) ERSE-Sp35:Fc promoter and ERSE-ATF6c promoter (ERSE/ERSE). The transfected 
cells were cultured alongside a CMV control culture with no ATF6c co-expression (CMV/‒). 
We observed that the differences in promoter activity observed in the 4 days culture 
(Figure  7.4) were further amplified in the fed-batch transient system.  
Figure  7.6A shows the VCD profile of the different vector engineering strategies. 
Most notably, the CMV/CMV and CMV/ERSE strategies had lower cell densities in the first 
4‒5 days due to the effect of Sp35:Fc and ATF6c overexpressions on cell growth. 
Additionally, the latter strategy appeared to further reduce the cell growth on Day 4 post-
transfection, as well as resulted in the lowest peak VCD. We infer this was the effect of the 
dynamic loop where expressed ATF6c amplifies its own expression over time via 
transinduction of ERSE-SV40. Despite the negative effect on cell growth, the CMV/ERSE 
strategy yielded the highest Sp35:Fc volumetric titre, which was 53% higher than that was 
obtained by the CMV control culture. This was followed by the ERSE/ERSE strategy (38% 
increase), and the lowest titre (23% increase) was obtained with the conventional 
CMV/CMV promoters. It is also interesting to point out that the ERSE/ERSE strategy had a 
relatively low titre level at the beginning of the culture, which was consistent with the 4 
days culture data (Figures 7.3B and 7.4), but eventually surpassed the control and 
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Figure ‎7.6: ERSE-SV40 (ERSE) promoters exhibit dynamic profile in Sp35:Fc fed-batch 
transient production process. CHO-S cells were co-transfected with different Sp35:Fc and 
ATF6c vector combinations (1:0.5 ratio), namely CMV-Sp35:Fc and CMV-ATF6c promoters 
(CMV/CMV,   ); CMV-Sp35:Fc and ERSE-ATF6c promoters (CMV/ERSE,   ); and ERSE-
Sp35:Fc and ERSE-ATF6c promoters (ERSE/ERSE,    ), and cultured alongside a CMV control 
culture with no ATF6c co-expression (CMV/‒,    ). The total DNA load was equalised using a 
cloning plasmid with no promoter. (A) Viable cell density (VCD) profile post-transfection. (B) 
Sp35:Fc titre profile measured by ELISA method. (C) Daily cell specific productivity (qP) profile 
based on the VCD and Sp35:Fc titre. The data represent two biological replicates. 
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CMV/CMV levels. This again demonstrated the dynamic, beneficial feature of ERSE 
promoters for DTE protein production over long-term culture. 
To understand the variations in the different CMV and ERSE promoter combinations, 
we further analysed the Sp35:Fc expressions in term of daily qP (Figure  7.6C). The 
CMV/CMV strategy showed a continuous decline in qP over time post-transfection that can 
be attributed to the dilution of plasmid DNA into daughter cells after successive rounds of 
cell division (Codamo et al., 2011). This normal cell engineering strategy, lacking the 
dynamic feature of ERSE promoter and combined with slow initial growth rate, resulted in 
only a 23% increase in volumetric product titre (Figure  7.6B) despite the very high initial 
qP. The most optimal strategy appeared to be the CMV/ERSE combination as 
demonstrated by the consistently high qP, yielding the highest improvement in volumetric 
product titre. Interestingly, the combination of ERSE/ERSE exhibited the most dynamic qP 
profile over the fed-batch culture, in which the qP level increased by about 1.5-fold from 
Day 1 to Day 7. Even though the peak qP achieved with this strategy was still considerably 
lower than the peak qP of CMV/CMV and CMV/ERSE strategies, a moderate increase 
(37%) in volumetric titre was still attainable. It is also worth mentioning, even though the 
data is not included here, that the combination of ERSE-Sp35:Fc with CMV-ATF6c 
(ERSE/CMV) in fed-batch culture was not particularly beneficial. The relatively weak 
ERSE-driven Sp35:Fc expression, combined with the progressive loss of CMV-driven 
ATF6c expression over time, resulted in an insignificant 11% increase (P > 0.05) 
compared to the CMV control culture (data not shown). 
 
 
Tunable promoters for controlled protein expression is not a new concept in synthetic and 
systems biology. Regulated transcription/translation can be achieved through the redesign 
of endogenous promoters (Alper et al., 2005; Tornøe et al., 2002), the creation of fully 
synthetic promoters (Brown et al., 2014; Yim et al., 2013) and the insertion of regulatory 
sequences (Bulter et al., 2004; Stapleton et al., 2012). To date, discrete control of protein 
expression in eukaryotic systems has been achieved in the form of promoter activation and 
repression for programmable expression (Blount et al., 2012; Farzadfard et al., 2013; 
Hurley et al., 2012) as well as an oscillating gene expression system for periodic induction 
of specific target genes (Tigges et al., 2009). With the further progression of biological 
research and development, including in the biopharmaceutical industry, the need for 
controlled expression of recombinant proteins is ever increasing. 
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This study describes a novel tunable vector system that utilises a UPR transcription 
factor and its DNA binding element. UPR, activated in the event of ER stress, regulates 
expression of genes encoding the resident ER molecular chaperones and folding enzymes 
(Chakrabarti et al., 2011). In view of that, UPR activating elements ATF6 and XBP1 
transcription factors have been extensively used in cell engineering to increase the 
expression of therapeutic recombinant proteins in mammalian cells, albeit with varying 
degrees of success (e.g., Campos-da-Paz et al., 2008; Ku et al., 2008; Pybus et al., 
2014a; Tigges and Fussenegger, 2006). Recently, their DNA binding elements, ERSE and 
UPRE, have also been introduced into DNA vectors as a non-invasive system for the 
detection and quantification of endogenous and induced UPR factors in CHO cells (Du et 
al., 2013). However, these two UPR components (i.e., the transcription factors and their 
binding elements) have not been utilised together as part of a cell/synthetic biology 
engineering strategy. We therefore, for the first time, simultaneously used the transcription 
factor ATF6c and ERSE incorporated SV40 promoter, and tested the synergistic effect of 
various co-expression formats on easy-to-express (SEAP) and difficult-to-express 
(Sp35:Fc) protein productions. 
For the ETE recombinant protein, we observed that the qP and volumetric titre could 
be increased by co-expressing UPR transactivator ATF6c, and the use of weak SV40 and 
ERSE-SV40 promoters were not desirable compared to CMV. Under these circumstances 
ERSE-SV40 promoter offers fewer advantages for ETE proteins as the expression of these 
proteins is limited primarily by transcription/translation (Chapter 4, Figure  4.4) and its 
overexpression does not easily invoke a UPR (Chapter 4, Figure  4.7). In contrast, for DTE 
production, the (originally) weak ERSE-SV40 promoter effectively reduces UPR induction 
via minimisation of ER ―input rates‖, which in turn grants the much needed rapid cell 
growth at the beginning of culture. Additionally, the relatively high level of endogenous 
UPR transactivators associated with DTE production forms an active, continuous loop with 
ERSE-SV40 promoter and amplifies its activity―yielding a dynamic (increasing) 
recombinant gene expression over time. From a mechanistic perspective we conclude that 
the ERSE-SV40 promoter enables a shift from fast-growing cells to high-producing cells 
during the transient production of DTE recombinant proteins using extended culture. 
Further work will validate this mechanism by measuring the levels of recombinant mRNA 
and UPR induction at different time points of culture. 
The dilution of recombinant plasmid DNA after repeated rounds of cell division post-
transfection is a major factor limiting yields with transient systems, where the expression 
level of the transgene per cell inevitably decreases with every generation. Even though it is 
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possible to (slightly) extend the transgene expression by using non-physical transfection 
methods such as lipofection and polyfection, this is likely due the different kinetics of gene 
delivery into host cells (Mehier-Humbert and Guy, 2005), as previous studies showed that 
the internalisation of cationic lipid/polymer–DNA complexes into cell nucleus is relatively 
slow (Carpentier et al., 2007; Zabner et al., 1995). To circumvent this issue, a range of 
episomal expression vectors has been developed that enable plasmid DNA amplification 
and/or maintenance extrachromosomally using viral genetic elements such as the Epstein-
Barr virus nuclear antigen-1 (EBNA-1; Kunaparaju et al., 2005). Even so, the qP in many 
cell lines employing these systems appears to peak between 1 and 3 days post-
transfection (Carpentier et al., 2007; Wulhfard et al., 2012) thus still leaving some room for 
improvement. Our data show that whilst the CMV promoter suffered from progressive loss 
of productivity, the ERSE-SV40 promoter maintained or even increased the qP during the 
exponential and stationary phases. Therefore we propose the ERSE-SV40 vector as an 
alternative or complement to episomal-based expression systems. 
One obvious drawback of the ERSE system is that it requires high expression level of 
DTE protein (to induce endogenous UPR) or co-transfection/expression of UPR 
transactivators, where the former can be difficult to achieve with the relatively weak ERSE-
SV40 promoter while the latter is not always desirable (e.g., limiting rDNA load of protein of 
interest, increased transfection toxicity). Additionally, the current system might not be 
compatible with stable expression systems where studies have shown that stable cell lines 
effectively avoid UPR as there were no indication of UPR-transactivator upregulations 
even in high producing cells (Dinnis et al., 2006; Smales et al., 2004), whilst the generation 
of stable UPR-transactivator expressing cell lines can be very difficult (Becker et al., 2008). 
Nevertheless, where co-expression of UPR transactivator is undesirable or intractable, it is 
possible to attain an adequate expression of a given DTE protein by combining the strong 
CMV promoter and the dynamic ERSE promoter at specific ratios. Our data on Sp35:Fc 
demonstrated that the CMV-driven Sp35:Fc expression was sufficient to transactivate the 
ERSE promoter to achieve at least the same qP to the CMV only control during short-term 
culture. Moreover, for ETE proteins or stable cell lines with low/no endogenous UPR, we 
surmise that the system limitation can be possibly overcome by invoking the UPR using 
chemicals such as dithiothreitol (DTT) and tunicamycin, where they can be easily titrated 
and added into culture medium at the desired time point for optimal results.  
We anticipate that the combination of ERSE-Sp35:Fc and ERSE-ATF6c vectors in 
this study would yield lower, or at least similar, amount of Sp35:Fc aggregates due the 
relatively low ER stress imposed (i.e., low qP) on the host cells throughout fed-batch 
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culture (Figure  7.6C). Accordingly, even though the combination of CMV-Sp35:Fc and 
ERSE-ATF6c resulted in the highest improvement in volumetric titre (Figure  7.6B), the 
repercussion of improved qP on aggregate formation needs to be determined as the 
system might not resolve the cellular bottlenecks associated with Sp35:Fc production 
(Chapters 4 and 5). Further study would address the impacts of the dynamic nature of 
ERSE systems on product qualities such as protein aggregates and glycosylation profile. 
Additionally, it would be interesting to know if XBP1s may yield better results when used 
on the systems (as a replacement or complement to ATF6c) where this UPR transactivator 
has been widely demonstrated to improve the secretory capacity of CHO cells (Codamo et 
al., 2011; Ku et al., 2008; Tigges and Fussenegger, 2006). 
The data presented in this study is only the first steps towards developing a 
mammalian controlled/dynamic expression system for difficult-to-express recombinant 
proteins and there are various potential applications including controlling the expression of 
multiple genes for heterologeous proteins as well as increasing ETE protein productions 
via artificial UPR induction. For example, for DTE monoclonal antibodies (MAbs) where the 
productivity is affected by the proportion of light to heavy chain polypeptides (Pybus et al., 
2014a), the optimal production condition may be self-regulated using an ERSE-SV40 
promoter transcribing the light chain polypeptide―under ER stress, the UPR will induce 
the light chain synthesis to improve the MAb assembly rate, and as ER homeostasis is 
restored the light chain synthesis is reduced to the preceding level. For other DTE 
recombinant proteins, the optimal engineering strategy is likely to be unique. Further 
refinement and expansion of this system will make it a very valuable tool not only for the 
production of recombinant proteins but many areas of biotechnology. 
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This chapter investigates the effects of cell and process engineering approaches on difficult-to-
express protein production. The aims are to find out which mitigation strategies can be utilised 
to alleviate the Sp35:Fc protein production bottlenecks, as well as the combined effects of 
specific strategies. We show that the integrated cell and process engineering strategies were 
able to improve the Sp35:Fc production by several fold due to restoration of normal cellular 
function. 
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Plasmid vectors encoding an activated form of UPR transactivator (cleaved ATF6 or 
spliced XBP1) were constructed by Dr Stefan Schlatter (Appendix A). 
 
 
Mammalian cells, including Chinese hamster ovary (CHO) cell lines, can be poorly efficient 
for high production levels of biologics due to limiting translational and/or post-translational 
mechanisms. The bottlenecks are exacerbated in the case of difficult-to-express (DTE) 
recombinant protein production using transient gene expression (TGE) systems as the 
host cells are easily overloaded with transgenes and nascent recombinant polypeptides. 
Consequently, for many recombinant products, productivity is unpredictably low; even 
monoclonal antibody (MAb) protein products in the same isotype/sub-class can display 
variable expression levels due to different translational and post-translational process rates 
(Pybus et al., 2014a). This can also be expected from artificial fusion proteins where they 
have not coevolved in which the two (or more) combined components are thought to have 
different folding and/or secretion requirements (Lee et al., 2007).  
Stable transfectants capable of efficient DTE recombinant protein expression avoid 
unfolded protein response (UPR) induction through reducing the rate of recombinant gene 
transcription and/or mRNA translation resulting in low stable expression (Mason et al., 
2012). Therefore, engineering strategies for improved TGE processes are desirable not 
only to increase the rapid preclinical supply of DTE recombinant proteins but also can 
provide strong preliminary data on stable ―manufacturability‖. Very low transient production 
titres indicate that considerably more cell development and/or process development may 
be needed to generate a stable production cell line with desirable attributes. Whilst the 
bioengineering of host cells may reduce the effort required to select clonal lines with high 
productivities (Cain et al., 2013), the transient production data itself can be used to inform 
on how to engineer the host cell line or process platform for enhanced stable performance 
(Nishimiya et al., 2013).  
Various studies have shown that endoplasmic reticulum (ER) chaperones, UPR 
components, and stress-mediated apoptosis pathway components could be co-expressed 
to improve the cell survival or to solve bottlenecks and cellular limitations caused by 
recombinant protein overflow (Dietmair et al., 2011; Schröder, 2008). With respect to the 
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latter, co-expression of functional proteins involved in protein secretion including binding 
immunoglobulin protein (BiP), protein disulphide isomerase (PDI) and signal recognition 
particle 14 (SRP14) had successfully improved the expression of DTE MAbs (Le Fourn et 
al., 2014; Pybus et al., 2014a). Other attempts included the ectopic expression of the 
activating transcription factor 6 (ATF6) and X-box binding protein 1 (XBP1), two 
transcription factors that regulates ER maintenance and expansion, to decrease ER stress 
and increase protein processing and secretion in CHO cells (Pybus et al., 2014a; Tigges 
and Fussenegger, 2006).  
Furthermore, treatment of mammalian cell cultures with the so-called chemical 
chaperones to increase expression/secretion of recombinant proteins is a method with a 
long-standing history. Sodium butyrate, a histone deacetylation (HDAC) inhibitor and 
arguably the most frequently used chemical chaperone, is known to increase gene 
transcription by enhancing gene accessibility to transcription factors (Jiang and Sharfstein, 
2008). This leads to the upregulation of many genes involved in protein processing, 
secretion and redox activity (Yee et al., 2008). Interestingly, different chemicals appear to 
act via distinct mechanisms and therefore can confer different/multiple benefits. There are 
various reports on the applications of chemical chaperones in reducing protein aggregation 
and suppressing ER stress (Chapter 2, Table  2.1) that can be particularly beneficial for 
DTE proteins. With regard to the former, chemical chaperones have the ability to help the 
correct folding of aggregation-prone proteins by promoting the expression of molecular 
chaperones, or to maintain their native state by interacting directly with them (Papp and 
Csermely, 2006; Vagenende et al., 2009).  
Despite the extensive reports on cell engineering and chemical chaperone strategies 
in mammalian cell-based production process, the combinatorial effects of different 
chemical and/or molecular chaperones have not been adequately explored. This is 
particularly relevant in mammalian cells which have very complex cellular regulations and 
may suffer from multiple production bottlenecks. Recombinant protein overexpression has 
been reported to induce a UPR that can affect global mRNA translation rates that lead to 
reduced cell growth and biomass content (Pybus et al., 2014a). On the other hand, the 
beneficial effects of many chemical chaperones on recombinant protein production are 
often compromised by their cytotoxic effect on cell growth via the activation of cellular 
apoptosis (Rodriguez et al., 2005). Therefore it is necessary to identify the most effective 
external manipulations that can overcome/minimise deleterious cellular regulation in 
optimising both the integral of viable cell density (IVCD) and cell specific production rate 
(qP) to achieve maximum volumetric product titre. 
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We have previously shown in Chapter 4 that the Sp35:Fc expression system became 
saturated above a specific threshold level as cells were not capable of processing more 
than a certain amount of nascent polypeptides. The overexpression, in turn, resulted in 
considerable protein aggregation and triggered the UPR to restore cellular homeostasis. 
Therefore, to overcome the cellular bottlenecks we compare the benefits of (i) co-
expressing a variety of molecular chaperones, foldases and UPR transactivators, and (ii) 
using chemical chaperones/inhibitor and mild hypothermic condition, to improve either the 
rate/capacity of folding reactions or cell growth as well as to suppress aggregate formation. 
Various combinations of the engineering strategies were also tested, while the design of 
experiment (DOE) methodology was employed to study and optimise the interactions 
between different effectors. We further show that the combined cell and process 
engineering strategies were able to improve the TGE system by several fold due to 
restoration of normal cellular function and was particularly beneficial for DTE recombinant 
protein production. 
 
 
 
Molecular chaperone and foldase genes, specifically human BiP, human PDI, human 
ERO1Lβ and human Cyclophilin B (CypB), were driven by CMV promoters encoded on 
plasmids from OriGene (Rockville, MD). UPR transactivators (active forms of ATF6 and 
XBP1) inserted into a pcDNA™3.1(+) (Life Technologies) vector backbone were driven by 
CMV promoters. Chemical chaperones sodium 4-phenylbutyrate (PBA), betaine, dimethyl 
sulfoxide (DMSO), glycerol and trimethylamine N-oxide (TMAO) were purchased from 
Sigma-Aldrich (Poole, UK) with deionised Milli-Q water used as a solvent and diluent. 
PERK inhibitor was purchased from Merck Chemicals (Nottingham, UK) with DMSO used 
as a solvent and diluent. Chemicals were added and cells were shifted to 32°C at 3 h post-
transfection. 
 
 
Transient transfection was conducted using Lipofectamine® LTX with PLUS™ reagent 
(Life Technologies) as described in Section 3.3.2. The cell cultures were agitated at 140 
rpm and incubated at 37°C under 5% CO2. Nutrient supplementation started 6 h post-
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transfection using CHO EfficientFeed™ Kit (Life Technologies) with a total of up to 60% v/v 
CHO CD EfficientFeed™ A and B throughout culture as follows; 10% v/v each on Days 0, 
3, 5, 7, 9 and if necessary, on Day 11. 
 
 
DOE software Design-Expert® 8.0 (Stat-Ease Inc, Minneapolis, MN) was used for the 
analysis of responses to chemical/molecular chaperones. The programme provided a 
mixture matrix, a fitted linear or quadratic mixture model, and a contour plot of the 
predicted elongation values of the three responses, namely recombinant product titre, 
IVCD and qP. The design analysis was performed using analysis of variance (ANOVA) 
where it provided the weights of the experimental factors for all of the responses. Each 
response was described by either a first-order linear model (Equation 8.1) or a second-
order polynomial model (Equation 8.2). 
𝑦 = 𝑏0 +  𝑏𝑖𝑥𝑖 +
𝑖
 𝑏𝑖𝑗 𝑥𝑖𝑥𝑗 + ℰ
𝑖𝑗
                                                                                  (8.1) 
𝑦 = 𝑏0 +  𝑏𝑖𝑥𝑖 +  𝑏𝑖𝑗 𝑥𝑖𝑥𝑗
𝑖𝑗
+  𝑏𝑖𝑖𝑥𝑖
2 + ℰ
𝑖𝑖
                                                            (8.2) 
where y is the response, b is the model coefficients that are estimated using a least square 
fit of the model to the experimental results, x is the input factor, i and j are the design 
variables and ε is the error. 
 
 
 
As Sp35:Fc folding and assembly reactions were limiting, we attempted to address the 
hypothesis that co-expression of specific functional proteins could improve ER capacity for 
Sp35:Fc folding and assembly reactions, increase secretion rate and/or relieve host cells 
from ER stress, where the major consequence of UPR activation is a decrease in cell 
growth. Specifically, we engineered the CHO cell protein factory by overexpressing the 
ER-resident proteins known to be involved in chaperone machineries (BiP, PDI, ERO1Lβ, 
CypB) and activated forms of UPR transactivators (the cleaved 50 kDa form of ATF6 and 
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spliced 54 kDa XBP1) known to generically upregulate the expression of ER 
chaperones/foldases, as well as by inhibiting PERK, which is involved in translation 
attenuation and cell cycle arrest mechanism (Pybus et al., 2014a; Schröder, 2008). 
ERO1Lβ was chosen (over ERO1Lα) as this isoform is induced during the UPR to alleviate 
ER stress (Pagani et al., 2000) and has been reported to enhance antibody production in 
transient systems rather than stable (Chapter 2, Table 2.2). All functional genes were 
human cDNAs driven by the human CMV promoter, while PERK inhibition was achieved 
by using an inhibitor (IC50 = 0.4 nM) added 3 h post-transfection at 0.04% v/v of total 
culture volume. For each transfection, Sp35:Fc gene load was kept constant and empty 
vector was utilised to equalise total DNA load where necessary. The ERSE vector system 
developed in Chapter 7 was not utilised so as to obtain a direct readout of the relative 
effect of functional genes or chemicals without interference from promoter transactivation. 
Cell viabilities measured 2 h post-transfection were 84.5%–89.9% (mean 87.9%).  
Molecular chaperones, foldases and UPR transactivators exerted molecule-specific 
effects on either Sp35:Fc productivity and/or cell growth (Figure  8.1A). Overexpression of 
BiP significantly improved the volumetric titre, mediated via an increase in qP, where 
higher quantities of chaperone having a proportionately higher effect (up to 1.6-fold 
increase). PDI also improved the production in a similar fashion but to a limited extend, 
and further improvement was obtained when it was co-expressed with ERO1Lβ. At the 
optimal amount of 20‒40% w/w rDNA, CypB substantially increased the volumetric titre 
(1.4-fold increase), however this was mediated via an increase in IVCD. Expression of 
either UPR transactivator gave similar effect to BiP expression, with maximum specific 
productivity observed at 80% w/w rDNA. However, both transactivators functioned to 
suppress cell growth rate, leading to a considerably lower IVCD (with no effect on cell 
viability) that in turn resulted in no significant improvement in volumetric titre. On contrast, 
PERK inhibitor functioned in the way of CypB, where increased in cell growth was 
observed (dependent upon inhibition level) although this did not lead to an improvement in 
product titre due to substantial reduction in qP. 
Additionally, we utilised chemical chaperones and mild hypothermic condition (32°C) 
to induce protein folding and stabilisation. Whilst this intervention may not be considered 
directly specific to cellular processes that govern difficult-to-express recombinant protein 
production rate, we chose to investigate the relative potency of chemical chaperones that 
may improve the Sp35:Fc folding and assembly interaction and/or offset the consequence 
of Sp35:Fc induction of the UPR (de Almeida et al., 2007; Roth et al., 2012). We tested 4-
phenylbutyrate (PBA), dimethyl sulfoxide (DMSO), glycerol, betaine and trimethylamine N-  
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Figure ‎8.1: Co-expression of molecular chaperones, foldases or UPR transactivators and 
use of chemical chaperones or hypothermic condition can improve difficult-to-express 
Sp35:Fc production via two distinct modes. (A) Molecular chaperones, foldases or active 
form of UPR transactivator gene was co-transfected at 10‒80% (w/w) of Sp35:Fc plasmid, while 
PERK inhibitor (IC50 = 0.4 nM) was added 3 h post-transfection. An empty vector was used to 
equalise total DNA load in all cases. (B) Each chemical chaperone was titrated at its active 
concentration, added 3 h post-transfection. For hypothermic condition, the cells were shifted to 
32°C 3 h post-transfection. Data are normalised with respect to control transfection of Sp35:Fc 
gene alone with equalised total DNA load and cultured under normal condition. Cell culture 
supernatant was harvested 96 h post-transfection and analysed by ELISA. Error bars represent 
the standard error of two biological replicates and two technical replicates. 
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oxide (TMAO) at different concentrations where purified water was used as a solvent and 
diluent and added at 2% v/v of total culture volume. Concentrations above 2 mM PBA, 3% 
v/v DMSO, 3% v/v glycerol, 200 mM betaine and 200 mM TMAO resulted in severe growth 
cessation and cytotoxicity and thus the chemicals were titrated below these 
concentrations. These data are illustrated in Figure  8.1B. 
As shown in Figure  8.1B, the IVCDs of PBA, DMSO and glycerol treated cultures 
were significantly lower than that of control culture due to depressed cell growth depending 
on the chemical dosage. The volumetric titres however were largely the same or higher, 
which imply that the improved Sp35:Fc production in these chemical chaperone-treated 
cultures were attributed to improved qP. In all cases, the productivity appeared to be 
strongly induced by the chemical concentration, where the highest increase in qP was 
observed at the highest concentration, with up to 3.7-fold increase using 2% v/v glycerol. 
However, taking the effect of reduction in IVCD, improvement in volumetric titre of product 
was observed only at a specific (mid) concentration of each chemical. Similar effect was 
observed with hypothermic condition, although the increase in qP was not sufficiently high 
to counteract the effect of depressed cell growth resulting in a net decrease in volumetric 
titre. In contrast, the methylamines (betaine and TMAO) appeared to improve cell growth, 
possibly by protecting host cells from ER stress although at the expense of recombinant 
protein productivity. This cell growth benefit however was suppressed at 100 mM betaine 
and 50 mM TMAO concentrations, likely due to high osmolality. Interestingly, the 
improvement in volumetric titre for betaine was observed at 50 mM with increase in IVCD 
and sub-optimal qP, whereas the improvement for TMAO was observed at 50 mM TMAO 
which was due to increase in qP.  
To verify that the effect of CypB, PERK inhibitor, betaine and TMAO on cell growth 
was due to the recombinant protein production, cells were ―mock-transfected‖ with empty 
vector and either with CypB gene or addition of PERK inhibitor, betaine or TMAO into 
culture medium. Results show that the IVCDs were similar in all cases compared to the 
mock-transfected control culture (data not shown). It is important to note that the increase 
in volumetric titre for slow growing cells could not be attributed to the effect of slower 
dilution of plasmid (i.e. higher rDNA copies per cell; discussed briefly in Chapter 7). Higher 
Sp35:Fc DNA copy number will not increase qP due to the expression saturation (Chapter 
4; Figure  4.4), and this saturation theoretically allows some dilution of the plasmids without 
affecting the qP. Additionally, without a significant increase in qP to counteract the lower 
IVCD, this would actually result in a net decrease in volumetric titre as observed in the 
32°C culture. Further analysis of the engineering strategies in Figure 8.1 showed that there 
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was a strong negative correlation between their impact on qP and on cell growth (Figure 
 8.2). This data highlights the importance of identifying genes and/or chemicals that can 
work synergistically to provide an optimal solution, i.e. enable the host cell to achieve both 
high qP and IVCD.  
 
 
Figure ‎8.2: Improvement in qP using cell and process engineering strategies correlates 
to repression of cell growth and vice versa. The stimulation of Sp35:Fc productivity is 
achieved at the expense of cell growth, whilst the stimulation of cell growth would result in a 
reduction in productivity.  
 
Having understood the effect of single molecular gene or chemical chaperone, we studied 
the effect of combining two cell/process strategies on Sp35:Fc production. These 
combined engineering strategies resulted in mixed outcomes (Figure  8.3). Firstly, whilst no 
further improvement was observed in single co-expression of PDI above 20% w/w 
(Figure  8.1A), further increases of 14% and 29% in volumetric titre were observed when 
20% w/w BiP was co-expressed with 20% and 40% w/w PDI, respectively (Figure  8.3). 
Simultaneous co-expressions of CypB and BiP, where the two proteins acted via different 
mode of actions, also further enhanced the volumetric titre where a 1.6-fold increase 
compared to control culture obtained using 20% w/w CypB and 20% w/w BiP.  
On the contrary, attempts to re-programme the UPR by co-expressing 40% w/w 
ATF6c or 40% w/w XBP1s while inhibiting PERK did not significantly enhance the  
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Figure ‎8.3: Combinations of cell and/or process engineering strategies yielded mixed 
results. Functional protein plasmids (BiP, PDI, CypB, ATF6c and XBP1s) were co-transfected 
with Sp35:Fc plasmid at specific functional protein to Sp35:Fc plasmids w/w percentage. 
Chemicals were added 3 h post-transfection. For hypothermic condition, the cells were shifted 
to 32°C 3 h post-transfection. Data are normalised with respect to control transfection of 
Sp35:Fc plasmid alone with equalised total DNA load and cultured under normal condition. Cell 
culture supernatant was harvested 96 h post-transfection and analysed by ELISA. Error bars 
represent the standard error of two biological replicates and two technical replicates. 
volumetric titre—whilst the IVCD was improved by PERK inhibitor (i.e. by avoiding the 
translational attenuation mechanism), the improvement in qP was not sufficiently high to 
confer benefit on the production titre (Figure  8.3). Similar results were obtained using 80% 
w/w ATF6c or 80% w/w XBP1s and 40 nM PERK inhibitor in which the IVCD benefit was 
offset by a relatively lower qP level (data not shown). Moreover, we found out that 
combining PERK inhibitor and CypB or betaine did not further improve the IVCD, whereas 
the use of PBA, even at a moderate concentration of 0.5 mM, fully inhibited CypB and 
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betaine's cell growth benefit (Figure  8.3). In fact, the use of 0.5 mM PBA and 50 mM 
betaine resulted in lower IVCD compared to 0.5 mM PBA alone although the reason 
behind this is unclear. 
We found that simultaneous utilisation of moderate concentrations of PBA (0.5 mM) 
and glycerol (1% v/v) in culture substantially increased the qP to 7.2-fold compared to 
control culture, implying that there was a synergistic effect between the two chemicals on 
Sp35:Fc production (Figure  8.3). This synergistic effect yielded a far higher cell productivity 
compared to individual and other combined cell/process engineering strategies (Figure 
 8.4). However, at this combined concentration the cell growth was reduced dramatically 
(with no effect on cell viability) resulting in only a 1.2-fold increase in volumetric titre. 
Utilising both 1 mM PBA and 32°C strategies resulted in 5.2-fold increase in qP (Figure 
 8.3) compared to the respective 2.7-fold and 2.4-fold increases when used individually 
(Figure  8.1B), indicating that both strategies are only additive. Despite having a lower 
combined specific productivity compared to the dual chemical chaperones strategy, 
employing this strategy in fed-batch culture may yield better result due to the extended 
culture duration associated with hypothermic condition. 
 
 
Figure ‎8.4: Combined engineering strategies can profoundly impact Sp35:Fc production. 
The combination of PBA and glycerol (open circle) is identified as an outlier that deviates from 
the general correlation between qP and IVCD of individual and combined cell/process 
engineering strategies (black and grey circles, respectively). 
Furthermore, to assess whether the cell and process engineering strategies are cell 
line-and protein-specific, we tested a number of strategies on two best-performing clones 
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isolated from the parental population that have distinct characteristics (C13 and C69; 
Chapter 6), as well as on SEAP-producing cells. These data are shown in Figure  8.5. With 
respect to the clones, C13 exhibited improved Sp35:Fc production via rapid cell growth 
without compromising productivity whereas C69 displayed inherently high qP with similar 
growth rate compared to the parental population (Chapter 6, Figure  6.7). Engineering 
strategies on C13 using CypB, betaine and PBA further enhanced the IVCD or qP (Figure 
 8.5), comparable to the results obtained in the parental population shown in Figure  8.1B.  
 
 
Figure ‎8.5: Cell and process engineering strategies can be clone and protein specific. In 
addition to Sp35:Fc, several engineering strategies were tested on Clones 13 and 69 and SEAP 
production. The C13 and C69 data including the no treatment (NT) controls were normalised to 
the parental population control culture, whereas SEAP data was normalised to SEAP control 
culture. Cell culture supernatant was harvested 96 h post-transfection and analysed by ELISA. 
Error bars represent the standard error of two biological replicates and two technical replicates. 
CypB and betaine made less appreciable impact on C69 in which only slight 
improvements in IVCD were observed (1.2-fold increase; Figure  8.5). We hypothesise that 
C69 had an innate cellular capability in producing Sp35:Fc (reflected in its higher qP) with 
lower ER stress and therefore was less responsive to CypB and betaine. This is 
corroborated by the results obtained with easy-to-express (ETE) SEAP where no effects 
were observed using CypB and betaine as well as the more limited improvement in SEAP 
specific productivity using PBA. However, treatment with PBA on both C13 and C69 
Cell and Process Engineering for Improved Transient Production of a DTE Fusion Protein 
 
139 
significantly increased their qP regardless of their initial level, illustrating that the chemical 
could affect Sp35:Fc production in a more universal way. Overall, these data illustrated 
that the effect of molecular and chemical chaperones can be cell line and protein-specific 
depending on the cell's cellular capability to produce a particular protein. 
 
 
In an attempt to reduce Sp35:Fc aggregation, the culture supernatants from the individual 
engineering study were analysed as described in Chapter 4 (Figure 4.5). Western blot 
analysis of the secreted Sp35:Fc revealed that the molecular chaperones, foldases, 
chemical chaperones and culture temperature greatly influenced the amount of aggregates 
produced (Figure  8.6). Whilst chemical chaperones generally suppressed aggregate 
formation, the increase in folding and assembly rate through overexpression of PDI 
(particularly in combination with ERO1Lβ) appeared to increase the amount of aggregates. 
Higher oligomer, likely to be octamer (800 kDa), also became apparent as shown in the 
Western blot image of Figure  8.6A.  
At the extreme, the total amount of Sp35:Fc aggregates increased from 4.8% w/w in 
the control culture to 10.5% w/w when the recombinant protein was co-expressed with PDI 
and ERO1Lβ (Figure  8.6B). We hypothesise that whilst ER induction in disulphide bond 
formation accelerated the Sp35:Fc folding and the overexpression of ERO1Lβ created an 
altered oxidising environment that was favourable for this reaction, they did not resolve 
the limiting ER-to-Golgi transport rate in the cells (Chapter 4, Figure  4.6C). Indeed, 
addressing a limitation in the early secretory pathway without solving the downstream 
bottleneck may not lead to desired results (Delic et al., 2014) and in the case of Sp35:Fc it 
would amplify the ER stress and further deteriorate product quality control. In contrast, 
CypB appeared to have the ability to partially suppress aggregates formation with a 41% 
reduction from the control (Figure  8.6B). This effect might owe to the dual function of the 
lumenal protein where it has been implicated both in protein folding (Feige et al., 2009; 
Kim et al., 2008) and in ERAD of soluble lumenal substrates (Bernasconi et al., 2010). On 
the other hand, the UPR transactivators and PERK inhibitor did not effectively reduce the 
amount of aggregates (P > 0.05) even though the former is known to regulate the secretory 
machinery in a global fashion (Schröder, 2008).  
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Figure ‎8.6: Quantitative Western blot of Sp35:Fc from cell culture supernatant revealed 
the varying amount of aggregates produced under different systems. (A) Representative 
Western blot image. Culture supernatant was harvested 96 h post-transfection and separated 
by non-reducing SDS-PAGE in the presence of the alkylating agent NEM to suppress 
disulphide bond reduction and scrambling. Under reducing condition, all bands were reduced to 
100 kDa (data not shown). (B) Relative amount of aggregates were quantified using image 
analysis software. The bar number in the chart corresponds to lane number of the 
representative Western blot image. Data shown is mean value of two biological and two 
technical replicates. Error bars represent the standard deviation. 
The use of chemical chaperones particularly PBA, as well as hypothermic condition, 
effectively suppressed aggregates formation (between 52% and 96% reduction; Figure 
 8.6B). Indeed, several previous studies have shown that chemical chaperones and low 
culture temperature can reduce the aggregation of recombinant proteins such as β-
interferon (Rodriguez et al., 2005; Tharmalingam et al., 2008) and cartilage oligomeric 
matrix protein angiopoietin-1 (Hwang et al., 2011a,b). As Sp35:Fc aggregates formed 
intracellularly, we propose that CypB and the chemicals efficiently mediated intracellular 
folding and target misfolded proteins for further refolding or degradation process, whereas 
the hypothermic condition shifted the cellular energy used on cell growth/maintenance to 
the energy extensive recombinant protein folding (discussed in Chapter 4). 
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We employed a design of experiment–response surface modelling (DOE-RSM) approach 
to further study the effect of combining two molecules with distinct modes of action, namely 
BiP and CypB, and a chemical chaperone (PBA) on Sp35:Fc production. Only two 
functional genes were utilised in order to minimise the transfection cytotoxicity effect. We 
defined DOE design space boundaries (rDNA amount and chemical concentration ranges) 
for the three Sp35:Fc production effectors based on the individual study. The Box-Behnken 
design was chosen due to its minimal number of experiments required while still providing 
sufficient information to identify key interactions and generate model predictions. Each 
effector was deployed at a notional low, medium, or high amount/concentration within its 
design space, yielding 12 discrete coordinates. The mid-point coordinate was replicated 
five times to determine pure error. Three response variable outputs were measured at 
each coordinate, specifically the volumetric titre, IVCD and qP. All outputs were normalised 
against control culture that contained neither functional genes nor chemical chaperone.  
Quadratic response surface models were used to compare the relationship between 
CypB, BiP and PBA effectors on titre and IVCD output variables, while two-factor 
interaction (2FI) response surface model was used on qP. The quadratic model derived 
from the relative titre analysis is as follows: 
Titre = 1.9 + 0.13 CypB + 0.18 BiP + 0.22 PBA − 0.004 CypB  BiP −
           0.098 PBA  BiP − 0.045 CypB  PBA − 0.12(CypB)2 − 0.092(BiP)2 −
           0.27(PBA)2                                                                                                                               (8.3)  
Based on the ANOVA, it was found that there were a number of insignificant model terms 
for IVCD and qP outputs, thereby reducing model fit (goodness of fit). CypB for instance 
was an insignificant effector on qP, both individually and in combination with other 
effectors, where the interaction term was eventually removed from the model equation. 
The reduced quadratic model for relative IVCD and the linear 2FI model for relative qP are 
described in Equations 8.4 and 8.5, respectively. 
IVCD = 1.04 + 0.064 CypB − 0.069 BiP + 0.17 PBA − 0.034 PBA  BiP −
           0.036 CypB  PBA − 0.045 BiP 2 − 0.71 PBA 2                                                         8.4   
𝑞P = 1.76 + 0.024 CypB + 0.33 BiP + 0.55 PBA + 0.085 PBA  BiP              8.5   
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Table  8.1 summarises the response surface models employed. Highly significant 
models were obtained (P < 0.05) for each response and all models displayed an 
insignificant ―lack of fit‖ indicating comparable variance of modelled and empirical data. 
Additionally, all models achieved a good agreement between the predicted and adjusted 
R
2
 values (< 0.2 difference) signifying the reliability of the models in predicting the output 
response to the combination of effectors (Mandenius and Brundin, 2008). The response 
surface models for relative titre, IVCD and qP are graphically represented in Figure  8.7, 
8.8 and 8.9, respectively, illustrating the modelled response surfaces for the interaction of 
two parameters at a constant, mid amount of the third parameter. 
 
Table ‎8.1: Summary of DOE-RSM analysis of parameters and parameter interactions 
controlling Sp35:Fc production and CHO cell proliferation. 
Response Factor 
Goodness 
of fit 
Probability data > 
random error 
Significant? 
(P < 0.05) 
Model predictability 
(Pred/Adj R
2
) 
Titre Model 1.23 0.0001 Yes 0.90/0.94 
 CypB 0.13 0.0013 Yes  
 BiP 0.25 0.0002 Yes  
 PBA 0.37 < 0.0001 Yes  
 (CypB)(BiP) 0.00 0.9117 No  
 (PBA)(BiP) 0.04 0.0265 Yes  
 (CypB)(PBA) 0.00 0.2371 No  
 (CypB)
2
 0.06 0.0097 Yes  
 (BiP)
2
 0.04 0.0308 Yes  
 (PBA)
2
 0.31 < 0.0001 Yes  
IVCD Model 0.34 < 0.0001 Yes 0.72/0.90 
 CypB 0.04 0.0041 Yes  
 BiP 0.03 0.0027 Yes  
 PBA 0.23 < 0.0001 Yes  
 (PBA)(BiP) 0.00 0.1893 No  
 (CypB)(PBA) 0.00 0.1642 No  
 (BiP)
2
 0.00 0.0839 No  
 (PBA)
2
 0.02 0.0137 Yes  
qP Model 3.35 < 0.0001 Yes 0.88/0.93 
 CypB 0.00 0.5922 No  
 BiP 0.89 < 0.0001 Yes  
 PBA 2.43 < 0.0001 Yes  
 (PBA)(BiP) 0.03 0.1967 No  
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Figure ‎8.7: DOE response surface models predict Sp35:Fc volumetric titre as a function 
of CypB and BiP co-expressions and PBA treatment. Modelled response surfaces (96 h 
culture) are illustrated for the CypB/BiP interaction at fixed 0.3 mM PBA concentration (A), the 
PBA/BiP interaction at fixed 25% CypB gene load (B), and the PBA/CypB interaction at fixed 
50% BiP gene load (C).  
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Figure ‎8.8: DOE response surface models predict CHO cell IVCD as a function of CypB 
and BiP co-expressions and PBA treatment. Modelled response surfaces (96 h culture) for 
IVCD are illustrated for the PBA/BiP interaction at fixed 25% w/w CypB gene load (A) and the 
PBA/CypB interaction at fixed 50% w/w BiP gene load (B). The CypB/BiP interaction was 
insignificant and was removed from the model to improve model fit. 
Statistical analysis revealed that all parameters significantly influenced titre 
individually (P < 0.01; Table  8.1) which is reflected in Figure  8.7. High amount of BiP and 
PBA was particularly favourable on product titre, and there was a significant synergistic 
effect between the two parameters (P < 0.05; Table  8.1). However, the titre appeared to 
decrease when the concentration of PBA was increased above 0.4 mM (Figure  8.7B and 
C)―the point at which the inhibition of cell growth by PBA outweighed the increase in qP. 
All parameters were also found to have strong individual influence on IVCD (P < 0.01) 
where the response surface models are presented in Figure  8.8. However, CypB did not 
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Figure ‎8.9: DOE response surface models predict CHO cell specific productivity as a 
function of BiP co-expression and PBA treatment. Modelled response surfaces (96 h 
culture) for qP is illustrated for the PBA/BiP interaction at fixed 25% w/w CypB gene load.  
exhibit any interaction with BiP as analysed at fixed 0.3 mM PBA and was removed from 
the quadratic model in order to improve the model predictability (Pred/Adj R
2
; Table  8.1). 
The deleterious effect of PBA on CypB is also evident in Figure  8.8A and B, where it is 
clear that CypB's cell growth benefit was completely suppressed at 0.5 mM PBA. 
Additionally, as the specific productivity is dependent on BiP and PBA (Figure  8.9) and not 
on CypB (P > 0.05; Table  8.1), it can be concluded that the use of CypB alongside such 
chemical chaperone is incompatible and of limited advantage. The combination of BiP and 
PBA was able to enhance the qP by up to 2.9-fold (Figure  8.9) although there was no 
interaction between the two strategies (P > 0.05; Table  8.1). 
Using the response surface models (Equations 8.3‒8.5), it is theoretically possible to 
predict a desired combination of effectors to achieve a specific objective. For example, the 
models predict that a maximal 2.0-fold increase in volumetric titre with 1.0-fold change in 
IVCD can be achieved by using the combination of 32% w/w CypB, 70% w/w BiP and 0.32 
mM PBA. Moreover, even though our models did not take into account the cell 
growth/death and protein production during stationary and decline phases, it is still 
possible to utilise the short-term batch culture data presented here for improved fed-batch 
culture. Specifically, the combination of 37% w/w CypB, 45% w/w BiP and 0.21 mM PBA is 
predicted to yield an optimal titre and IVCD (equal weight) of 1.9-fold and 1.1-fold 
increases, respectively, that could be more advantageous in longer culture duration (i.e., 
fed-batch culture). 
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Derived from our cell and process engineering data on short-term Sp35:Fc production, we 
designed two different biphasic culture strategies for transient fed-batch production. For 
both biphasic culture strategies, the first phase was centred on cell growth in which we 
employed co-expression of 20% w/w CypB to enable rapid proliferation of cells. The 
second phase began once the cells reached the peak VCD (approximately 24×10
6
 cells 
mL
-1
) on Day 6 where we utilised two different process combinations; (i) 1 mM PBA and 
temperature shift to 32°C, and (ii) 0.5 mM PBA and 1% v/v glycerol. Additionally, we 
employed a biphasic culture with only a shift in culture temperature (i.e. without CypB co-
expression and chemical addition) to mimic the commonly used biphasic process strategy. 
This culture was shifted to 32°C on Day 7. 
 As shown in Figure  8.10A, CypB co-expression facilitated the growth of Sp35:Fc-
producing cells, allowing the cultures to reach peak VCD one day earlier compared to 
the control as well as the "pure" 32°C biphasic culture. With regard to the second phase 
culture, the combination of 1 mM PBA and 32°C extended the stationary phase 
substantially, leading to a 24% increase in IVCD compared to the 0.5 mM PBA and 1% v/v 
glycerol strategy, and a 70% increase over the control (Figure  8.10B). Nevertheless, 
despite the lower IVCD (Figure  8.10B), the synergistic effect of the latter process strategy 
outperformed the former in terms of volumetric titre (Figure  8.10C). Specifically, 20% w/w 
CypB, 0.5 mM PBA and 1% v/v glycerol resulted in a 5.9-fold increase in volumetric titre 
compared to the control culture of 6.6 µg mL
-1
 while 20% w/w CypB, 1 mM PBA and 32°C 
gave a 4.4-fold increase. In both cases, the combinations of cell and process engineering 
strategies are far better than the typical process strategy of shift in culture temperature 
only (which gave only 1.9-fold increase compared to control).  
Furthermore, we tested the optimised strategy (20% w/w CypB, 0.5 mM PBA and 1% 
v/v glycerol) on the C13 (improved production via rapid cell growth) and C69 (inherently 
high DTE Sp35:Fc productivity). Results show that C13 displayed significantly improved 
cell growth and peak VCD during fed-batch culture (Figure  8.11A) which in turn resulted in 
a 47% increase in IVCD compared to the parental cell line control culture (Figure  8.11B). 
However, the volumetric titres of both C13 and C69 were limited to about 12 µg mL
-1 
(1.9-
fold increase; Figure  8.11C), illustrating the natural "productivity boundary" of the host cell 
background. Using the optimised, biphasic culture strategy, the volumetric titres were 
increased to about 41 µg mL
-1
 (Figure  8.11C) hence demonstrating that the use of cell and 
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Figure ‎8.10: Integrated engineering strategies for transient Sp35:Fc productions. 2.5×107 
cells were transfected with 16.67 µg Sp35:Fc plasmid and subjected to different strategies; a 
shift to hypothermic condition (   ), co-transfection with 20% w/w CypB and addition of 1 mM 
PBA and shift to hypothermic condition (  ), or co-transfection with 20% w/w CypB and 
treatment with 0.5 mM PBA and 1% v/v glycerol (   ). The cells were cultured alongside a 
control that contained neither CypB gene nor chemical chaperones and maintained at 37°C       
(   ). Arrows indicate the timing of chemical addition and/or temperature shift. (A) Viable cell 
density (VCD) profile. (B) Integral of viable cell density (IVCD) profile. (C) Sp35:Fc titre profile. 
Error bars represent the standard deviation of two biological and two technical replicates. 
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Figure ‎8.11: Integrated engineering strategies for transient Sp35:Fc productions using 
two clonally derived cell lines. 2.5×10
7
 cells were co-transfected with 16.67 µg Sp35:Fc 
plasmid and 20% w/w CypB, and treated with 0.5 mM PBA and 1% v/v glycerol using either 
C13 (   ) or C69 (   ) cell lines. The cells were cultured alongside a C13 control (   ), a C69 
control (   ) and the parental cell line control (   ) that contained neither CypB gene nor chemical 
chaperones. All cells were maintained at 37°C. Arrow indicates the timing of chemical addition. 
(A) Viable cell density (VCD) profile. (B) Integral of viable cell density (IVCD) profile. (C) 
Sp35:Fc titre profile. Error bars represent the standard deviation of two biological and two 
technical replicates. 
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Figure ‎8.12: Integrated engineering strategies for transient SEAP productions and using 
two clonal cell lines. 2.5×10
7
 cells were transfected with 16.67 µg SEAP plasmid using C13    
(   ) and C69 (   ) cell lines, or co-transfected with 20% w/w CypB and treated with 0.5 mM PBA 
and 1% v/v glycerol using the parental cell line (   ). The cells were cultured alongside a SEAP-
producing parental cell line control (  ) that contained neither CypB gene nor chemical 
chaperones. Arrows indicate the timing of chemical addition. (A) Viable cell density (VCD) 
profile. (B) Integral of viable cell density (IVCD) profile. (C) SEAP titre profile. Error bars 
represent the standard deviation of two biological and two technical replicates. 
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process engineering was a much more effectual strategy in controlling the production of 
DTE protein than exploiting the inherent heterogeneity in the host cell population for 
improved production. 
Conversely, the implementation of the optimised strategy (20% w/w CypB, 0.5 mM 
PBA and 1% v/v glycerol) on ETE SEAP showed that CypB had no effect on the cell 
growth (Figure  8.12A) resulting in no improvement in IVCD (Figure  8.12B). Moreover, the 
additions of PBA and glycerol into the SEAP culture increased the volumetric titre by only 
1.9-fold which was comparable to the volumetric titre achieved by C13 without any 
engineering strategies (Figure  8.12C). Together, these data indicate that the designed 
engineering strategies employed were more valuable for DTE protein productions. 
However, as we still observed some improvement on the SEAP titre using PBA and 
glycerol, this suggests that the treatment of cell culture with chemical chaperones could be 
an easy-to-implement, generic tool (owing to their versatility of general and specific effects) 
in improving transient expression compared to the cell engineering strategy. 
 
 
To assess the aggregate contents and whether the improvements in Sp35:Fc productivity 
were due to improvement in cellular activities, cell culture supernatant of the final harvest 
and equal amount of cells on Day 8 of the fed-batch culture were lysed. The extra and 
intracellular Sp35:Fc polypeptides were immunoblotted as shown in Figure  8.13A. In both 
cases, no Sp35:Fc aggregates were detected for culture employing chemical(s) treatment, 
hence proving that the combinations of the molecular/chemical chaperones were effective 
in inhibiting intracellular aggregate formation during fed-batch culture. Additionally, the 
amount of aggregates were considerably reduced (67% reduction compared to control) in 
cells subjected to hypothermic condition alone. A slight decrease (29% reduction 
compared to control) was also observed with C69 employing no engineering strategies 
which was consistent with the previous data obtained in Chapter 6 (Figure  6.9). 
Further quantitative image analysis of the intracellular samples (Figure  8.13B) 
revealed that the engineering strategies resulted in increases in the amount of nascent 
monomer by up to 2.4-fold, likely through an increase in transcriptional rate and/or mRNA 
stability (Hwang et al., 2011a; Jiang and Sharfstein, 2008). Importantly, we observed that 
the engineering strategies resulted in increases in dimer to monomer ratio (indicated by 
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Figure ‎8.13: Western blot analysis revealed that the improvements in Sp35:Fc production 
were due to improvement in cellular activities. (A) Representative Western blots of Sp35:Fc 
polypeptide species in extracellular culture supernatant (final harvest) and intracellular species 
of equal amount of cells (2×10
4
 cells) on Day 8 of fed-batch culture of different culture 
strategies and clones. The lane number corresponds to the bar chart number for different 
engineering strategy and/or clone used. (B) Intracellular Sp35:Fc unfolded monomer and 
assembled dimer per cell determined by quantitative Western blot. Error bars represent the 
standard deviation of two biological and two technical replicates. The dimer to monomer ratio 
per cell for each engineering strategy and/or clone is indicated above the bars. 
the number on respective bars) which imply that the molecular/chemical chaperones, and 
to a lesser extent the hypothermic condition, restored the cells' cellular function. It is also 
interesting to point out that C69 which had a relatively high qP and low aggregates 
(Chapter 6, Figures 6.7 and 6.9), had an intrinsically high dimer to monomer ratio (Figure 
 8.13B) that indicate an inherent efficient folding/assembly processes. We conclude that the 
integrated cell and process engineering effectively improved the DTE protein production 
and product quality. 
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TGE systems are an attractive method for rapid production of research-grade biologics but 
suffer from relatively low product titres. Whilst improvements through optimisation of large-
scale transfection protocols and/or culture media during transient expression are well 
established (Cain et al., 2013; Daramola et al., 2014; Rajendra et al., 2011; Raymond et 
al., 2011), for DTE proteins it is imperative to study the effects of engineering the secretory 
pathway and exocytosis to relieve the posttranslational bottlenecks. Therefore, in this 
study we investigated the effect of a range of molecular and chemical chaperones and 
UPR re-programming on CHO cell growth and Sp35:Fc production. Fundamentally, we 
observed that Sp35:Fc production could be improved via two distinct routes albeit at 
varying degrees; (i) stimulation of qP with general suppression in cell growth (BiP, PDI, 
ATF6, XBP1, PBA, DMSO, glycerol and hypothermic condition), and (ii) stimulation of cell 
growth correlated to repression of qP (CypB, PERK inhibitor, betaine and TMAO).  
The effects of molecular chaperones and foldases are likely to be protein specific and 
often do not result in the desirable outcomes in the host cells (Borth et al., 2005; Davis et 
al., 2000; Dorner and Kaufman, 1994; Grubb et al., 2012). In this study, the 
overexpression protein folding catalyst PDI in CHO cells resulted in increase in aggregates 
formation, which is in contrast to report by van den Berg et al. (1999) demonstrating that 
PDI was particularly effective in preventing lysozyme aggregation under crowded 
conditions in vitro. In this context, cell engineering with UPR-related genes is a more useful 
strategy for enhancing the secretion of recombinant proteins by increasing concentrations 
of several chaperones in a functionally meaningful ratio (Delic et al., 2014). However, the 
overexpression of UPR-related genes leads to a general survival disadvantage via 
increased apoptosis where the effects had been observed in both stable cell lines (Becker 
et al., 2008) and transient expression of DTE MAbs (Pybus et al., 2014a) which was 
consistent with our data on Sp35:Fc production. Even though the combination with anti-
apoptotic engineering may rescue the cells (e.g., co-expression of x-linked inhibitor of 
apoptosis; Becker et al., 2010), we also did not observe any benefit of UPR transactivators 
in preventing Sp35:Fc aggregation, thus rendering them a less attractive strategy.  
For DTE Sp35:Fc, our data show that CypB and PERK inhibitor had positive impacts 
on cell proliferation where the former corroborates recent work in this laboratory on CHO 
cells expressing DTE MAbs (Pybus et al., 2014). While we may infer that the basic function 
of the PERK inhibitor is to restrain eIF1α phosphorylation and hence retain global mRNA 
translation rates, it was interesting to note that CypB was able to partially suppressed 
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Sp35:Fc aggregation, as well as act in concert with BiP to simultaneously increase both µ 
and qP. These effects might owe to the dual function of the lumenal protein where it has 
been implicated both in protein folding (Feige et al., 2009; Kim et al., 2008) and in ERAD of 
soluble lumenal substrates (Bernasconi et al., 2010). However, the impacts of the 
functional proteins were generally lower compared to the use of chemical additives. As we 
did not measure the amounts of the functional proteins expressed nor their mRNA levels, 
further work is required to verify that the limited effects of the cell engineering strategy 
were not actually due to the inability of the cell hosts to overexpress the functional genes. 
On a different note, in order to achieve high transfection efficiency with low toxicity, we 
found that the cell engineering strategy for our fed-batch system was limited to co-
expression of a single functional protein, hence necessitating additional process 
engineering approaches to effectively improve the production titre.  
Chemical chaperones, despite have been intensively studied/used for clinical 
applications (reviewed in Papp and Csermely (2006) and Perlmutter (2002)), are still 
under-utilised in the therapeutic protein production industry. With the exception of sodium 
butyrate (and its HDAC inhibitor counterparts), there are limited reports on how these small 
molecules can benefit the biomanufacturing process, especially for DTE proteins. Another 
interesting finding of our work is that a moderate concentration of methylamines (betaine 
and TMAO) in CHO cell culture facilitated cell growth, possibly by alleviating ER stress via 
improved intracellular Sp35:Fc trafficking (Roth et al., 2012). Even though qP was 
compromised, we speculate that the chemicals could potentially be used in cell line 
development for DTE protein production. Obviously, sustained UPR activation due to DTE 
protein overexpression is incompatible with high cell specific growth rate, and stable 
transfectants whose proliferation is compromised by induction of a UPR do not persist (the 
main selective pressure within functionally heterogeneous cell populations; Davies et al., 
2013). Therefore, by treating a stable clone (or transfectant pool) with a methylamine (or 
PERK inhibitor) at the beginning of cell line development stage, we may be able to 
sustain/enrich the cell populations with high producing cells. The UPR-suppressing 
chemical can then be withdrawn during the manufacturing process and replaced with other 
chemicals aiming at optimising productivity such as PBA. 
Consistent to previous reports, we observed that the addition of PBA, DMSO and 
glycerol to culture medium significantly increased qP and at the same time restrained CHO 
cell growth in a dose-dependent manner (Hwang et al., 2011a). Importantly, we found that 
there could be a synergistic effect between two chemicals, where a 7.2-fold increase in qP 
was obtained by combining PBA with glycerol. Different chemical chaperones are known to 
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act in different ways on recombinant proteins. For example, tauroursodeoxycholic acid has 
been shown to block the UPR activation in HFE C282Y-producing cells by acting directly 
on its signal transduction pathway, whereas PBA suppresses the ER stress by enhancing 
the ER capacity to degrade misfolded HFE C282Y protein therefore preventing the 
formation of intracellular aggregates (de Almeida et al., 2007). In this study, we 
hypothesise that PBA and glycerol complemented each other's function in facilitating 
Sp35:Fc expression, yielding a far higher cell productivity compared to when used alone. 
However, as the combination of "protective" betaine (Chapter 2, Table  2.1) with PBA did 
not avert the cytotoxic effect of the latter (Figure  8.3A) we consider that overexpression of 
antiapoptotic proteins Bcl-2 (Kim and Lee, 2000; Sung and Lee, 2005) and Bcl-xL (Kim et 
al., 2011b) or antisense RNA of caspase-3 (Kim and Lee, 2002) may be the effectual way 
to inhibit chemical chaperone-induced apoptosis. Additionally, our data show that the 
chemical chaperones were extremely effective in suppressing Sp35:Fc aggregates 
formation. However, the exact mechanisms underlying the ability of chemical chaperones 
to inhibit aggregate formation are less clear, and although a number of studies have 
provided some detailed understanding on this subject (e.g. by shifting the native protein 
toward more compact confirmation via preferential hydration; Vagenende et al., 2009), the 
mechanisms are likely to differ from one chemical to another.  
Besides chemical additives, it has been reported that the formation of aggregates of 
recombinant proteins may be reduced by hypothermic culture temperatures (Estes et al., 
2015; Hwang et al., 2011b), which was also observed in this study. This is in general 
agreement with our previous hypothesis (Chapter 4) that Sp35:Fc misfolding/aggregation 
was due to improper N-glycosylation. The distribution of N-glycan structures 
(microheterogeneity) and the levels of site occupancy (macroheterogeneity) may be 
regulated via culture conditions (including low culture temperature and addition of butyrate; 
Butler, 2006), which in turn lead to proper functioning of the quality control mechanism to 
ensure that only correctly folded proteins are transported to the Golgi complex. 
Additionally, the physical effects of low culture temperature can described by the second 
law of thermodynamics, where stable systems occupy the states with lowest Gibbs free 
energy (ΔG = ΔH – TΔS). The rate-limiting step in the folding process is the formation of 
the folding intermediate, i.e. the conformation that has the highest Gibbs free energy. 
Lowering the system‘s temperature (T) would minimise this rate-limiting step, as well as 
further reduces the enthalpy (ΔH) by lowering the reaction rates of non-bonding 
interactions, therefore promoting protein folding and stability (Szilágyi et al., 2007). 
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In addition to their advantages in cell culture processes as presented in this study, 
chemical chaperones also hold the prospect for utilisation in the downstream formulation 
process to improve product stability. Likewise, chemicals that have been used in product 
formulations hold promise to improve the production process. For example, trehalose, 
which is used as a protectant for several commercially available therapeutic antibodies and 
proteins, has recently been demonstrated to significantly effective in minimising antibody 
aggregates as well as in improving the specific and volumetric antibody production titre 
(Onitsuka et al., 2014). This is highly relevant considering that chemical chaperones are 
protein and cell line specific. For example, whilst treatment of CHO cell lines with butyrate 
stimulated up to 15-fold enhancement of yellow fluorescent protein (YFP) production, only 
up to a 2-fold increase was observed in MAb production (Hunt et al., 2002). Additionally, 
HDAC inhibitor valproic acid (VPA) had been shown to be more effective in HEK293 cells 
with 4-fold increase in MAb titres compared to in CHO cells (1.5-fold increase; Backliwal et 
al., 2008). The data from this study also corroborate those observations in which PBA 
appeared to have less impact on SEAP production while betaine did not confer any growth 
benefit onto the SEAP-producing cells. 
We have shown that Sp35:Fc production can be controlled through the DOE 
methodology or biphasic culture strategy. With respect to the former, it was possible to 
pinpoint the exact functional genes and chemical chaperone concentration required to 
produce Sp35:Fc with defined levels of cell growth. Desirability analysis identified the 
combination of CypB, BiP and PBA predicted to yield the highest volumetric titre, without 
compromising cell growth (i.e., similar IVCD to control). However, the PBA effectively 
suppressed the CypB's growth benefit. Instead of attempting to reverse the apoptotic effect 
of the chemical chaperones by transfecting in Bcl-2 or Bcl-xL (Kim and Lee, 2000; Sung 
and Lee, 2005), we used a simple biphasic culture that allowed high productivity without 
compromising cell growth―enabling up to 6-fold increase in volumetric titre. Interestingly, 
the same strategies were also able to increase SEAP production, although the fact that the 
impact was less profound (1.9-fold increase) suggested that engineering strategies still 
need to be protein specific. 
Overall, from a functional perspective, for a host cell with a product induced UPR it is 
feasible to closely control the negative relationship between qP and µ (Figure 8.4). Our 
data imply that inducing cellular folding/assembly capacity or the UPR components are 
effective for short-term specific productivity enhancement but incompatible with the 
creation of productive biomass over the longer term. This is consistent with our preceding 
observation (Chapter 4, Figure 4,7) where the activation of the UPR to promote protein 
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folding would prevent cell growth, and it was unlikely that overexpression of ER 
chaperones actually served to directly ―switch-off‖ the UPR-mediated growth arrest. In 
contrast, using specific functional genes or chemicals it is possible to either inhibit or 
offset, via different mechanisms, the effects of the UPR to either permit cell proliferation 
(e.g. using CypB) or DTE protein expression (e.g. using PBA). Therefore, whilst the 
optimal combination of functional genes and/or chemicals tends to be protein-specific, from 
the recognised function(s) of the ER functional effectors we utilised, we can deduce that 
direct inhibition or alleviation of ER load/stress may be preferable to attempts to indirectly 
reduce ER load by a general increase in secretory pathway capacity or the rate of forward 
folding/assembly reaction within the ER. This is also consistent with our in silico analysis 
(Chapter 5, Figures 5.5 and 5.6) which suggests that the translational attenuation 
mechanism of the UPR (i.e. direct reduction of ER load) is required and sufficient in 
maintaining cellular homeostasis, whereas engineering the rate of folding/assembly 
reaction has no apparent benefits, nor it could solve the secondary trafficking bottleneck 
(rate of ER to cis-Golgi) to reduce UPR severity and permit cell biomass accumulation. 
Finally, our study illustrates that the optimal engineering strategy for a given 
recombinant protein requires synergistic combination of genes, chemicals and/or process 
conditions designed to overcome cellular rate limiting steps simultaneously, enabling the 
host cell to attain both high qP and IVCD. Indeed, the highest TGE titre of 2 g/L reported 
by Daramola et al. (2014) in CHO cells was obtained by combining powerful expression 
vector technologies with optimised polyethyleneimine (PEI)-based transfection condition 
and fed-batch cell culture process. Comparatively, Backliwal et al. (2008) achieved 1.1 g/L 
titre in HEK293 cells with a combination of optimised expression vector, highly efficient PEI 
transfection, use of specific growth factor and cell cycle regulators, as well as treatment of 
cells with VPA. We envisage that the increasingly complex, difficult to produce biologics in 
the biopharmaceutical industry will necessitate a multi-component cell/process design and 
engineering platform to create attuned cell phenotype and process condition. Such an 
approach would require an appropriate multi-gene expression technology (Chatellard et 
al., 2007; Kriz et al., 2010) and rapid high-throughput statistical assessment of the optimal 
combination of multiple genetic and chemical components. 
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This chapter summarises the data presented in this thesis by highlighting the important findings 
and outcomes, specifically for the production of Sp35:Fc fusion protein and difficult-to-express 
proteins in general. The prospect of continuation work is also briefly described. 
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In biologics development, it can be said that the low-hanging fruits have been harvested. 
Today, the bioindustry invests far more on R&D and produces fewer new molecules than it 
did two decades ago. Indeed, while the approval of 112 biopharmaceuticals in the period 
of 2006–2014 suggests a vibrant sector, only half (51%) were genuinely new 
biopharmaceutical entities whilst the rest of the products approved were biosimilars, 
reformulated or me-too versions of previously approved substances (Walsh, 2010, 2014). 
As the market moves towards treatment for uncommon diseases and more effective drugs, 
more complex, difficult to express proteins such as bispecific antibodies and fusion 
proteins are being developed. Consequently, the industry is likely to be impeded by an 
imposing and growing obstacle resulting from the inability to rapidly and efficiently produce 
large quantities of recombinant protein at low cost.  
The TGE technology platform has the advantage of short development times and low 
overall cost, and hence is actively pursued to produce a broad range of therapeutic MAbs, 
proteins and vaccines for preclinical studies. However, transient expression processes 
employ genetically/functionally diverse parental cell populations, whose intrinsic functional 
heterogeneity has not been utilised to generate a host cell clone intrinsically suited to the 
production of the recombinant product. As a result, transient production processes are 
generally low yielding, and the problems are exacerbated in the case of DTE recombinant 
proteins. Therefore, several strategies had been developed in this study to improve the 
transient production of DTE proteins in mammalian systems. The cellular production of  
model Sp35:Fc fusion protein was first systematically studied through a simple, rapid TGE 
assay and a mathematical model (Chapters 4 and 5), followed by various mitigation 
strategies, i.e. clone screening, controllable expression vector, and cell/process 
engineering (Chapters 6‒8). 
Data presented in this study support the notion that mammalian cells have limited 
secretory capacity, and that post-translational mechanisms are often limiting in transient 
systems (Mason et al., 2012) especially for DTE proteins (Pybus et al., 2014a). The simple 
and rapid TGE assay system enabled comparable measurement of the basic parameters 
that underpin product manufacturability, i.e. the relative ability of the host cell to synthesise 
and secrete a given recombinant product and to proliferate during the production process. 
In the case of DTE Sp35:Fc, it appears that a sweet-spot exists between the protein 
folding and aggregates formation to achieve a sub-optimal transgene expression. Even 
though we tested only two recombinant products in this work (i.e. Sp35:Fc vs. SEAP), the 
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assay is amenable to medium-high throughput operation and compatible with subsequent 
analyses of protein molecular variations such as aggregation or glycosylation. Similarly, 
whilst the intracellular behaviour modelled in this study was specific to Sp35:Fc produced 
in CHO cells, the model does offer a practical adjunct to other experimental studies. The 
iterative in silico engineering approach can be implemented as a generic framework for Fc-
fusion protein productions, with the aim of using it as a platform to better understand the 
factors underlying cell factory processes, and subsequently propose predictive, rational 
strategies to overcome the limiting production factors in mammalian production systems.  
The data of subclones of the parental CHO-S cell line showed the wide diversity and 
flexibility of metabolic capacities of CHO cells―a fact known for decades. Indeed, this 
know-how is used, intuitively, in the bioindustry by evaluating productivities and qualities of 
product in clonally derived cell populations. Our results provide a fundamental 
understanding for CHO host cell choice to express difficult to produce recombinant 
proteins, where the improvement in titre could be achieved either via increase in µ or qP, 
indicating variations in cellular machinery. However, analysis of the clones revealed that, 
unlike the production of characteristically easy-to-express GFP, Sp35:Fc productivity was 
negatively correlated to cell growth, which indicates that it is relatively difficult to obtain 
clones with improved DTE protein titres. Additionally, the fed-batch data in Chapter 8 
demonstrate that the two best-performing clones responded in the same way to the 
cell/process engineering strategies applied to the parental cell population. Together, these 
data suggest clone selection is more appropriate for ETE proteins, whereas for DTE 
proteins cell/process engineering strategy is likely to be far more effective than a reliance 
on intrinsic clonal heterogeneity. Nevertheless, transcriptomics and proteomics (Charaniya 
et al., 2009; Dinnis et al., 2006) of the clones that displayed superior DTE protein 
production functionality could facilitate future employment of direct cell line engineering 
strategies (reverse engineering). 
DTE proteins have mis-matched kinetics of transcription, translation and folding 
reactions, where overexpression of such proteins using strong promoters generally results 
in the induction of the UPR (and therefore reduced µ). Cell line engineering for enhanced 
DTE protein expression to improve cellular machinery is likely to require multi-gene 
modulation. Therefore, at the initial stage a vector engineering strategy might be more 
appropriate to achieve both high qP and IVCD, than gene by gene cell line engineering 
methods. The novel ERSE vectors employed in this study enabled a positive feedback 
loop within the system, thus enabling a shift from fast-growing cells to high-producing cells 
during the transient production of DTE Sp35:Fc in fed-batch culture. Although the ERSE-
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SV40 vector achieved less than 2-fold increase in Sp35:Fc volumetric titre (and thus 
required a more effective engineering approach), this study was only the first step towards 
developing a mammalian controlled/dynamic expression system for DTE proteins and the 
system has various potential applications. Additionally, as cell/process engineering 
approach requires identification of a bespoke, protein-product specific strategy, we 
speculate that this system could be a more generic strategy to mitigate the UPR induction 
(low µ) associated with DTE recombinant proteins while having control over qP. 
The results from cell and process engineering strategies demonstrate that it is 
possible to closely control the inverse relationship between µ and qP using either 
functional genes or chemicals. However, given the complexity of mammalian cellular 
regulation, targeting individual components of the secretory pathway discretely by 
overexpressing specific functional proteins may not always lead to the desired result (e.g. 
increase in Sp35:Fc aggregates), and as we have shown for Sp35:Fc, resulted in only 
modest improvements in µ or qP (<1.5-fold change). These results, however, are not 
entirely unexpected as our modelling work (Chapter 5, Figure  5.5) suggests that the 
translational attenuation mechanism played a vital role in maintaining cellular homeostasis, 
and with this mechanism in place, engineering the folding processes would yield no 
effects. Moreover, as our early diagnostic assay (Chapter 4, Figure  4.7) detected high 
levels of endogenous UPR-related proteins, it is also unsurprising that overexpression of 
these proteins did not lead to significant improvements in qP. This is in contrast to 
overexpression of ATF6c in SEAP producing cells (Chapter 7, Figure  7.3) which led to a 
1.5-fold in SEAP titre. 
On the other hand, chemical additives appeared to be very versatile where they were 
able to both significantly improve cell productivity and growth as well as suppress 
aggregates formation. Moreover, our work suggests that the use of small molecules should 
precede other development or engineering strategies for DTE proteins, especially when 
resources (i.e. time and money) are limited. In addition to having profound effects (Chapter 
8, Figure 8.1) and easy implementation (less preparation/validation, easy to titrate, etc), 
chemical additives appeared to be largely cost-effective. With the exception of TMAO, the 
costs of chemicals at the highest concentrations used in this study were highly 
affordable―approximately between 0.2‒18% of the cost of CD CHO culture medium 
($104/L; Table  9.1). This would enable cost-effective manufacturing should the chemicals 
be used in large-scale transient/stable productions. 
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Table ‎9.1: Cost of different chemical additives per litre culture. 
Chemical Concentration Cost/L culture ($) 
PBA 1 mM 0.2 
PERK inhibitor 40 nM 0.6 
Glycerol 2% v/v 2.6 
DMSO 2% v/v 7.7 
Betaine 100 mM 19 
TMAO 50 mM 113 
 
 
Due to protein-product specificity, there is unlikely to be a generic solution which can 
be utilised for all recombinant proteins and cell lines. Our data also demonstrated that the 
optimal engineering intervention for a given DTE recombinant protein requires synergistic 
interaction between cell engineering and modulation of culture environment to alleviate 
cellular bottlenecks (and the associated poor expression) without compromising productive 
cell biomass accumulation. Nevertheless, the number of potentially useful 
product/process-specific effectors is likely to be very large. For this reason, a high-
throughput, standardised platform to determine the optimal balance of functional effectors 
is highly desirable. Yet, it has to be based on combinatorial, context-dependent empirical 
modelling approaches to identify the optimal solution. In this regards, our study serves as a 
paradigm for multivariate optimisation in enabling host cells to achieve both high qP and 
IVCD, and therefore improved DTE protein production titres. We need to replace the 
current notion that some products are ―difficult-to-express‖ with the concept that a 
―designer product‖ requires a ―designer cell factory‖ that does not solely rely on screening 
natural biological variation for functionality. 
 
 
Based on work presented in this thesis, the direction of future work could follow several 
branches. One avenue to explore would be the transient production using a bioreactor 
under fully optimised conditions. The highest 40 mg/L yield of Sp35:Fc protein in this study 
was obtained in a small-scale, non-optimised feeding strategy and is still relatively low 
compared to characteristically easy-to-express protein productions. Large scale transient 
transfections can be carried out using polyplex-based methods where the detailed 
underlying mechanisms (Mozley et al., 2014), optimisation technique (Thompson et al., 
2012) and large-scale protocols (Daramola et al., 2014) have been described in the 
literature. Moreover, one major limitation in this study was the progressive loss 
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recombinant plasmid over long-term culture. Therefore, it would also be useful to include 
the ERSE-SV40 vectors or other episomal-based expression system in the optimised 
system. With regard to the former, it could be worth studying whether co-expression of 
XBP1s (as a replacement or complement to ATF6c) could further improve the yield of the 
ERSE system. Although our data indicate that the production of Sp35:Fc is limited at post-
translational processes, it may also be worthwhile to perform codon optimisation (Chung et 
al., 2013) on the Sp35:Fc gene to further enhance the expression. Larger volume and/or 
higher titre would eventually enable comprehensive analysis of product quality especially 
the N- and O-glycosylation patterns that presently cannot be tested using our methods due 
to insufficient quantities. 
Building on data presented in Chapter 8 highlighting the various effects of functional 
gene co-expressions and chemical chaperone treatments, a future line of experimentation 
could employ a rapid, high-throughput DOE platform to assess various cell lines and 
recombinant proteins by testing for the optimal combination of multiple genetic/chemical 
components for a desired synthetic phenotype and appropriate culture processes. While 
the use of multiple plasmid vectors (i.e. high DNA loads) could result in high transfection 
toxicity, an alternate strategy for the expression of multiple genes could be through the use 
of multi-gene engineering technology (Kriz et al., 2010) or a bi-directional promoter system 
(Chatellard et al., 2007). Factorial designs can be employed to screen the factors affecting 
the responses and identify the basic interactions between the factors. Alternatively, if some 
of the factors are known to have little/no interactions or applied during different process  
 
 
Figure ‎9.1: Parallel Box-Behnken designs can be used to obtain the optimal responses of 
5 factors at a reduced number of experiments (21 design points). Factors A, B and C may 
represent co-expressions of CypB, XBP1s and BiP, while Factors D and E may represent 
additions of PBA and glycerol during stationary phase, respectively. The interaction among 
XBP1s (B), PBA (D) and glycerol (E) is also studied (but not among all 5 factors) as these 3 
factors can induce apoptosis. A normal 3-level, 5-factor design would have 46 design points. 
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condition (e.g. during a biphasic culture), parallel response surface designs (Figure  9.1) 
can also be utilised. Such parallel technique could significantly reduce the number of 
experiments required and has been successfully applied to optimise the transient 
production of MAbs (Daramola et al., 2014) by studying the effects of PEI and DNA 
concentrations, cell density, culture media, and nutrient supplements. It is also useful to 
further explore the general and specific effects of different chemical chaperones on the 
cellular processes such as rDNA/mRNA stability, transcription, secretion and the UPR. 
Promising drug candidates in preclinical studies will eventually require stable 
production of kilogram quantities for the subsequent testing phases and commercialisation. 
The mathematical model presented in Chapter 5 can potentially be developed as a 
predictive tool for stable performance from a transient expression platform (i.e., to aid cell 
line selection), especially for DTE proteins (Figure  9.2). Obviously, the selection of stable 
cell lines (or the transfectant pool) requires the host cell to combine both reasonable cell 
growth and recombinant protein expression. For DTE proteins, it seems likely that stable 
production cell lines would utilise cellular strategies to minimise/avoid UPR induction by 
decreasing recombinant protein synthesis. As transient production with increasing rDNA 
dose can determine the specific expression saturation point, further development of the 
existing model by coupling it to a measurement of cell proliferation and UPR induction may 
give it the capability to predict the likely specific production range of stable transfectants, 
and in the case of Sp35:Fc, whether the transfectants will produce aggregates. 
 
 
Figure ‎9.2: Prediction of stable performance from a transient expression platform. UPR 
induction inhibits cell growth, and stable cell lines effectively avoid UPR induction by decreasing 
recombinant protein synthesis. This leads to lower stable transcriptional output of DTE proteins 
compared to ETE proteins (A). A linkage between cell proliferation and UPR induction 
measurements may grant the existing model a capability to predict the likely specific production 
range and distribution of stable transfectants (B). 
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Figure A1: Plasmids constructed/provided by other people for use in this study. (A) The 
CMV SEAP vector encoding SEAP. The plasmid was modified from pSEAP2-Control vector 
(Clontech) by replacing the original SV40 promoter with a CMV promoter and removing the 
SV40 enhancer. (B) The 9xERSE-SV40 vector encoding SEAP. 9 units of ERSE sequence 
were inserted upstream of the SV40 promoter of pSEAP2-Control vector. Similar 9xERSE-
SV40 vectors encoding Sp35:Fc or ATF6c were also constructed (not shown). (C) The SV40 
Sp35:Fc vector encoding Sp35:Fc was constructed by replacing the SEAP gene in pSEAP2-
Control with an Sp35:Fc gene. (D) The pcDNA3.1(+) vector (Life Technologies) driven by a 
CMV promoter with ATF6c gene insert. A pcDNA3.1(+) vector encoding XBP1s was also 
constructed (not shown). 
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********** MODEL NAME 
Sp35:Fc fusion protein production in CHO cells 
 
********** MODEL NOTES 
Aggregation is assumed to be irreversible and occur in the ER 
Parameter values shown are for 3 ug rDNA load 
 
********** MODEL STATES 
%Define mass balance equations 
d/dt(mRNA) = Ngene*Sm-kdeg*mRNA-u*mRNA %mRNA 
d/dt(P) = TP*mRNA-2*RP2-u*P %Monomer 
d/dt(P2ER) = RP2-2*RP4-RP6-kERP2*P2ER-kuP2*P2ER-u*P2ER %Dimer in ER 
d/dt(P4ER) = RP4-RP6-kERP4*P4ER-kuP2*P4ER-u*P4ER %Tetramer in ER 
d/dt(P6ER) = RP6-kERP6*P6ER-kuP2*P6ER-u*P6ER %Hexamer in ER 
d/dt(Pu) = kuP*P-u*Pu %Ubiquitinated monomer 
d/dt(P2u) = kuP2*P2ER-u*P2u %Ubiquitinated dimer 
d/dt(P2G) = kERP2*P2ER-kGP2*P2G-u*P2G %Dimer in Golgi complex 
d/dt(P4G) = kERP4*P4ER-kGP4*P4G-u*P4G %Tetramer in Golgi complex 
d/dt(P6G) = kERP6*P6ER-kGP6*P6G-u*P6G %Hexamer in Golgi complex 
 
%Define initial conditions 
mRNA(0) = 1e3 
P(0) = 7e3 
P2ER(0) = 9e4 
P4ER(0) = 400 
P6ER(0) = 50 
Pu(0) = 300 
P2u(0) = 300 
P2G(0) = 300 
P4G(0) = 1 
P6G(0) = 0.1 
 
********** MODEL PARAMETERS 
%Define parameters (fitted values) 
u = 0.0225714 
Ngene = 72000 
Sm = 0.001333 
tdeg = 11.9463 
TP = 42.0174 
kfa = 0.000406347  
kaggP4 = 6.01546e-8 
kaggP6 = 8.04124e-8  
kuP = 0.000917286  
kuP2 = 7.91967e-5 
thERP2 = 3.1003 
thERP4 = 5.04359  
thERP6 = 5.41146 
thGP2 = 0.0104184   
thGP4 = 0.0155464    
thGP6 = 0.0173787 
 
********** MODEL VARIABLES 
%Define mRNA degradation and Sp35:Fc transport rates 
kdeg = 0.6931/tdeg 
kERP2 = 0.6931/thERP2 
kERP4 = 0.6931/thERP4 
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kERP6 = 0.6931/thERP6 
kGP2 = 0.6931/thGP2 
kGP4 = 0.6931/thGP4 
kGP6 = 0.6931/thGP6 
 
%Define folding/assembly and aggregation reactions 
RP2 = kfa*P*P 
RP4 = kaggP4*P2ER*P2ER 
RP6 = kaggP6*P2ER*P4ER 
 
%Define specific productivity rate of Sp35:Fc species 
qP = 3.32e-7*(kGP2*P2G)*24 %qP for dimer 
qPaggP4 = 6.64e-7*(kGP4*P4G)*24 %qP for tetramer 
qPaggP6 = 9.96e-7*(kGP6*P6G)*24 %qP for hexamer 
 
********** MODEL REACTIONS 
 
 
********** MODEL FUNCTIONS 
 
 
********** MODEL EVENTS 
 
 
********** MODEL MATLAB FUNCTIONS 
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%%This m file calculates local sensitivity analysis for Sp35:Fc model for 
3 ug rDNA load 
  
%Initialise global parameters  
global u Ngene Sm kdeg TP kfa kaggP4 kaggP6 kuP kuP2 kERP2 kERP4 kERP6 
kGP2 kGP4 kGP6  
  
%Define fixed parameters  
u = 0.0226; 
Ngene = 72000; 
lamda = 3.32e-7; 
 
%Define perturbable parameters to their initial value 
Smi = 0.001333; 
tdegi = 11.95;    
TPi = 42.02;  
kfai = 0.0004063;    
kaggP4i = 6.015e-008;    
kaggP6i = 8.041e-008;    
kuPi = 0.0009173;    
kuP2i = 7.920e-005;  
thERP2i = 3.100;  
thERP4i = 5.044;    
thERP6i = 5.411;      
thGP2i = 0.01042;  
thGP4i = 0.01555;    
thGP6i = 0.01738;     
 
%Define variables 
kdegi = log(2)/tdegi; 
kERP2i = log(2)/thERP2i;    
kERP4i = log(2)/thERP4i;    
kERP6i = log(2)/thERP6i;    
kGP2i = log(2)/thGP2i;    
kGP4i = log(2)/thGP4i;    
kGP6i = log(2)/thGP6i;  
   
%Perform local sensitivity analysis on the parameters 
for parameterchange = 1:8  
       
    %Define/reset parameters to their initial value 
    Sm = Smi; 
    kdeg = kdegi;    
    TP = TPi; 
    kfa = kfai;    
    kaggP4 = kaggP4i;    
    kaggP6 = kaggP6i;    
    kuP = kuPi;    
    kuP2 = kuP2i;   
    kERP2 = kERP2i;    
    kGP2 = kGP2i;    
          
    x0 = [1e3 7e3 9e4 400 50 300 1 0.1 300 300]; %Initial conditions 
    tspan = [0 700]; 
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    if parameterchange == 1 %Perturb Sm 
        %Run mass balance equations with +1% perturbation 
        Sm = Smi*1.01; 
        [t,x] = ode45(@Sp35Fc,tspan,x0); %Call ODE function 
        qPupper = lamda*kGP2*x(:,8)*24; 
        matsize = size(x); 
        qPupperf = qPupper(matsize(1)); 
        %Run mass balance equations with -1% perturbation 
        Sm = Smi*0.99;  
        [t,x] = ode45(@Sp35Fc,tspan,x0); %Call ODE function 
        qPlower = lamda*kGP2*x(:,8)*24;  
        matsize = size(x); 
        qPlowerf = qPlower(matsize(1)); 
        %Calculate response coefficient on qP 
        RCSm = (qPupperf - qPlowerf)/(qPupperf + qPlowerf)/0.01  
     
    elseif parameterchange == 2 %Perturb kdeg 
        kdeg = kdegi*0.99; 
        [t,x] = ode45(@Sp35Fc,tspan,x0);  
        qPupper = lamda*kGP2*x(:,8)*24;    
        matsize = size(x); 
        qPupperf = qPupper(matsize(1)); 
        kdeg = kdegi*1.01; 
        [t,x] = ode45(@Sp35Fc,tspan,x0);  
        qPlower = lamda*kGP2*x(:,8)*24;  
        matsize = size(x); 
        qPlowerf = qPlower(matsize(1)); 
        RCkdeg = (qPupperf - qPlowerf)/(qPupperf + qPlowerf)/0.01 
         
   elseif parameterchange == 3 %Perturb TP 
        TP = TPi*1.01; 
        [t,x] = ode45(@Sp35Fc,tspan,x0);  
        qPupper = lamda*kGP2*x(:,8)*24;    
        matsize = size(x); 
        qPupperf = qPupper(matsize(1)); 
        TP = TPi*0.99; 
        [t,x] = ode45(@Sp35Fc,tspan,x0);  
        qPlower = lamda*kGP2*x(:,8)*24; 
        matsize = size(x); 
        qPlowerf = qPlower(matsize(1)); 
        RCTP = (qPupperf - qPlowerf)/(qPupperf + qPlowerf)/0.01 
     
    elseif parameterchange == 4 %Perturb kfa 
        kfa = kfai*1.01; 
        [t,x] = ode45(@Sp35Fc,tspan,x0);  
        qPupper = lamda*kGP2*x(:,8)*24;   
        matsize = size(x); 
        qPupperf = qPupper(matsize(1)); 
        kfa = kfai*0.99; 
        [t,x] = ode45(@Sp35Fc,tspan,x0);  
        qPlower = lamda*kGP2*x(:,8)*24;  
        matsize = size(x); 
        qPlowerf = qPlower(matsize(1)); 
        RCkfa = (qPupperf - qPlowerf)/(qPupperf + qPlowerf)/0.01 
                 
     elseif parameterchange == 5 %Perturb kagg 
        kaggP4 = kaggP4i*0.99; 
        kaggP6 = kaggP6i*0.99; 
        [t,x] = ode45(@Sp35Fc,tspan,x0);  
        qPupper = lamda*kGP2*x(:,8)*24; 
        matsize = size(x); 
        qPupperf = qPupper(matsize(1)); 
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        kaggP4 = kaggP4i*1.01; 
        kaggP6 = kaggP6i*1.01; 
        [t,x] = ode45(@Sp35Fc,tspan,x0);  
        qPlower = lamda*kGP2*x(:,8)*24; 
        matsize = size(x); 
        qPlowerf = qPlower(matsize(1)); 
        RCkagg = (qPupperf - qPlowerf)/(qPupperf + qPlowerf)/0.01 
         
     elseif parameterchange == 6 %Perturb kuP 
        kuP = kuPi*0.99; 
        kuP2 = kuP2i*0.99; 
        [t,x] = ode45(@Sp35Fc,tspan,x0);  
        qPupper = lamda*kGP2*x(:,8)*24;   
        matsize = size(x); 
        qPupperf = qPupper(matsize(1)); 
        kuP = kuPi*1.01; 
        kuP2 = kuP2i*1.01; 
        [t,x] = ode45(@Sp35Fc,tspan,x0);  
        qPlower = lamda*kGP2*x(:,8)*24;  
        matsize = size(x); 
        qPlowerf = qPlower(matsize(1)); 
        RCku = (qPupperf - qPlowerf)/(qPupperf + qPlowerf)/0.01 
  
    elseif parameterchange == 7 %Perturb kERP2 
        kERP2 = kERP2i*1.01; 
        [t,x] = ode45(@Sp35Fc,tspan,x0);  
        qPupper = lamda*kGP2*x(:,8)*24;  
        matsize = size(x); 
        qPupperf = qPupper(matsize(1)); 
        kERP2 = kERP2i*0.99; 
        [t,x] = ode45(@Sp35Fc,tspan,x0);  
        qPlower = lamda*kGP2*x(:,8)*24; 
        matsize = size(x); 
        qPlowerf = qPlower(matsize(1)); 
        RCkERP2 = (qPupperf - qPlowerf)/(qPupperf + qPlowerf)/0.01 
        
    else %Perturb kGP2 
        kGP2 = kGP2i*1.01; 
        [t,x] = ode45(@Sp35Fc,tspan,x0);  
        qPupper = lamda*kGP2*x(:,8)*24; 
        matsize = size(x); 
        qPupperf = qPupper(matsize(1)); 
        kGP2 = kGP2i*0.99; 
        [t,x] = ode45(@Sp35Fc,tspan,x0);  
        qPlower = lamda*kGP2*x(:,8)*24;  
        matsize = size(x); 
        qPlowerf = qPlower(matsize(1)); 
        RCkGP2 = (qPupperf - qPlowerf)/(qPupperf + qPlowerf)/0.01           
    end 
end    
 
_______________________________________________________________________ 
 
 
 
%%This ODE function is called for to simulate mass balance equations 
function [massbalance] = Sp35Fc(t,x) 
 
  %Initialise global parameters 
  global Ngene u Sm kdeg TP kfa kaggP4 kaggP6 kuP kuP2 kERP2 kERP4 
kERP6   
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  kGP2 kGP4 kGP6  
  
  %Define folding/assembly and aggregation reactions 
  RP2 = kfa*x(2)^2; 
  RP4 = kaggP4*x(3)^2; 
  RP6 = kaggP6*x(3)*x(4); 
 
  % x(1): mRNA = Ngene*Sm-kdeg*mRNA-u*mRNA 
  % x(2): [P] = TP*mRNA-2*RP2-kuP*[P]-u*[P] 
  % x(3): [P2]ER = RP2-2*RP4-RP6-kERP2*[P2]ER-kuP2*[P2]ER-u*[P2]ER 
  % x(4): [P4]ER = RP4-RP6-kERP4*[P4]ER-kuP2*[P4]ER-u*[P4]ER 
  % x(5): [P6]ER = RP6-kERP6*[P6]ER-kuP2*[P6]ER-u*[P6]ER 
  % x(6): [Pu] = kuP*[P]-u*[Pu] 
  % x(7): [P2u] = kuP2*[P2]ER-u*[P2u] 
  % x(8): [P2]G = kERP2*[P2]ER-kGP2*[P2]G-u*[P2]G 
  % x(9): [P4]G = kERP4*[P4]ER-kGP4*[P4]G-u*[P4]G 
  % x(10): [P6]G = kERP6*[P6]ER-kGP6*[P6]G-u*[P6]G 
 
  %Run mass balance equations 
  massbalance =  
      [Ngene*Sm-kdeg*x(1)-u*x(1);  
      TP*x(1)-2*RP2-kuP*x(2)-u*x(2);  
      RP2-2*RP4-RP6-kERP2*x(3)-kuP2*x(3)-u*x(3);  
      RP4-RP6-kERP4*x(4)-kuP2*x(4)-u*x(4);  
      RP6-kERP6*x(5)-kuP2*x(5)-u*x(5); 
      kuP*x(2)-u*x(6); 
      kuP2*x(3)-u*x(7);  
      kERP2*x(3)-kGP2*x(8)-u*x(8);  
      kERP4*x(4)-kGP4*x(9)-u*x(9);  
      kERP6*x(5)-kGP6*x(10)-u*x(10)]; 
end 
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Figure D1: The effect of ATF6(90), ATF6(50), XBP1μ and XBP1 on SEAP protein 
expression from three different SEAP DNA vectors. SEAP protein expression for 0.5 μg of 
SV40-SEAP, 9xERSESV40-SEAP and CMV-SEAP vector DNA co-transfected with the 0.5 μg 
of UPR activator vectors (ATF6(90), ATF6(50), XBP1u and XBP1s) in CHOK1SV cells. The 
total amount of transfected DNA was kept constant using the –ve control DNA vector. Cell 
media was collected 48 hours post-transfection and analysed for SEAP protein expression. For 
each SEAP vector, mean values significantly different (Dunnett‘s test) from their control are 
indicated by asterisks (*p < 0.05, **p < 0.01, ***p < 0.001). N = 3, error bars represent + 1 S.D. 
Figure and text are reproduced with permission form West (2014). 
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Figure D2: The effect of different numbers of the ERSE sequence on SEAP protein and 
mRNA copy number when co-transfected with the ATF6(50) DNA vector. (A) SEAP protein 
expression for 0.5 μg of SV40-SEAP, 1xERSE-SV40-SEAP, 3xERSE-SV40-SEAP, 6xERSE-
SV40-SEAP, 9xERSE-SV40-SEAP and CMV-SEAP vectors when co-transfected with 0.125 μg 
ATF6(50) vector DNA in CHOK1SV cells. (B) SEAP mRNA copy numbers for the different 
SEAP vectors taken form samples as used in A. Cell media was collected 48 hours post-
transfection and analysed for SEAP protein expression. For each SEAP vector, values with 
different letters differ significantly from each other (Tukey‘s test, p < 0.05). N = 3, Error bars 
represent + 1 S.D. Figure and text are reproduced with permission form West (2014). 
